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Abstract 
 
  The heat shock protein 90 (Hsp90) family of molecular chaperones is responsible for the 
conformational maturation of nascent polypeptides and refolding of denatured proteins. Hsp90 is 
known to play an important role in the regulation of cell signaling, survival and proliferation, 
transforming it into a promising target for the  treatment of several diseases, including cancer. 
Proteins associated with all six hallmarks of cancer, as described by Weinberg, are Hsp90 
clients. Since these proteins depend upon Hsp90, its inhibition has the potential to 
simultaneously disrupt all six and halt the malignant progression using a single small molecule. 
Hsp90 is abundantly expressed in the cell and accounts for 1-2% of the total cellular protein, 
making itone of the most prevalent proteins in eukaryotic cells. The Hsp90 isoforms are 
responsible for the conformational maintenance of greater than 150 proteins. There are four 
distinct isoforms, including Hsp90α, Hsp90β, GRP94 and TRAP1. Hsp90α and β are located in 
the cytoplasm; Hsp90α is the major inducible form, while Hsp90β is the constitutively active 
form. In contrast, GRP94 is found in the endoplasmic reticulum and TRAP1 is located in the 
mitochondrial matrix. 
Hsp90 exists as a homodimer consisting of an N- and C-terminal domain, connected by a 
middle domain. The Hsp90 N-terminus contains an ATP binding site, responsible for the ATPase 
activity of the chaperone associated with folding of clients. Small molecules that preferentially 
bind to this nucleotide binding site inhibit the ability of Hsp90 to properly fold polypeptides, 
ultimately tagging them for degradation through the ubiquitin-proteasome pathway. Natural 
product inhibitors of the N-terminal ATP binding site include the ansamycin antibiotic 
geldanamycin (GDA) and the macrocyclic lactone radicicol (RDC). Blagg and co-workers have 
previously reported the chimeric N-terminal inhibitor radamide, which combines the resorcinol 
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portion of RDC and the quinone portion of GDA through a flexible linker. Radamide manifests a 
slightly greater binding affinity for GRP94 (Kd = 0.52 μM) versus cytosolic Hsp90 (Kd = 0.87 
μM). This phenomenon is elucidated by examining the unique binding conformations adopted by 
radamide when crystal structures of were obtained using each isoform. When bound to Hsp90, 
radamide exhibits a linear conformation, while when bound to GRP94 the quinone portion is 
bent towards a pocket that is not accessible in Hsp90α or β. By employing conformational 
constraint, it was proposed that the quinone portion of radamide could exhibit the bent 
conformation seen in the natural products and result in increased affinity for Hsp90 as well as 
selective binding to the cytosolic isoforms. 
In contrast to radamide, a recent paper by Gasiewicz and co-workers examined the effects 
of flavones and (-)-Epigallocatechin-3-Gallate (EGCG), the major polyphenolic catechin found 
in green tea, on the aryl hydrocarbon receptor (AHR). Due to its diverse medicinal properties, 
EGCG has been proposed as a potential treatment for several diseases. The study by Gasiewicz 
revealed that EGCG functions through a different mechanism of action than the known flavone 
antagonists, interacting with the Hsp90 C-terminus rather than the AHR. It was confirmed that 
EGCG binds specifically to the C-terminal nucleotide binding site, either within or proximal to 
the site where the natural product novobiocin is thought to bind. Previous studies have 
determined that EGCG manifests an IC50 of ~150 μM against MCF-7 cells. Upon examination 
of an overlay of EGCG and novobiocin, the structural similarities of the coumarin and the 
catechin cores become apparent. It was proposed that design of molecules based on the 
structure–activity relationships established for novobiocin may result in Hsp90-specific 
inhibitors based upon the EGCG scaffold.  
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Chapter 1 
Hsp90 Background 
I. Introduction 
 
The heat shock protein 90 (Hsp90) family of molecular chaperones is responsible for the 
maturation of nascent polypeptides and the refolding of denatured proteins. Hsp90 is known to 
play an essential role in regulation of cell signaling, proliferation and survival, which has 
transformed it into a promising target for the treatment of several diseases, including cancer.
1-3
 
Hanahan and Weinberg defined the six hallmarks of cancer as causative factors in developing 
malignancy. These hallmarks include: 1) self-sufficiency in growth signals, 2) insensitivity to 
antigrowth signals, 3) evasion of apoptosis, 4) limitless replicative potential, 5) sustained 
angiogenesis, and 6) tissue invasion/metastasis.
4
 Hsp90 inhibitors allow for a first-in-class 
approach toward cancer by enlisting a single agent to functionally disrupt all six of these 
hallmarks through the targeting of a single Hsp90 protein.
5
 Natural product inhibitors of Hsp90, 
including geldanamycin (GDA), radicicol (RDC), novobiocin, and epigallocatechin-3-gallate 
(EGCG), represent lead compound that are under investigation for drug development. 
II. Structure of Hsp90 
 
The Hsp90 monomer consists of three distinct domains; the 12kDa C-terminal binding 
domain, 35 kDa middle domain connected through a charged linker to a 25 kDa N-terminal 
binding domain. The crystal structure of the yeast Hsp90 homodimer is shown in Figure 1.
6
 In 
eukaryotic cells, Hsp90 is functional as a homodimer and each domain is responsible for distinct 
functions.
7-8
 The C-terminus is responsible for through a bundle of four α-helixes.
9-10
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Additionally, it was discovered that the C-terminus contains a nucleotide binding site that 
exhibits non-ATPase functions, such as coordinating the exchange of N-terminal nucleotides in 
an allosteric manner.  Novobiocin, EGCG, 
and taxol are natural products known to bind 
the C-terminal nucleotide binding site and 
prevent the binding of ATP to the N-terminus, 
resulting in inhibition of Hsp90. The C-
terminus is also responsible for the 
coordination of partner proteins, most notably 
the Hsp70-Hsp90 organizing protein (HOP).  
Additionally, several Hsp90-associated 
partner proteins contain a tetratricopeptide 
repeat (TPR), that bind the Hsp90 C-terminal 
motif, MVEED, and mediate protein–protein 
interactions during the protein folding process.
11-12
  
In contrast to the C-terminus, more is known about the Hsp90 N-terminus.  Unlike the C-
terminal nucleotide binding site, a co-crystal structure of the yeast Hsp90 N-terminus bound to 
ADP has been solved.
13
  Nucleotide binding to this site revealed a unique bent conformation, 
which is only found in related enzymes. Members of this family include DNA gyrase, histidine 
kinase and MutL, which are members of the GHKL superfamily of proteins. The N-terminal 
ATP/ADP binding pocket contains a Bergerat fold, characterized by four mixed β-sheets and 
three α-helices, aligned to sandwich a β-sheet between the α-helices. The ATP binding site is 
formed by the amino acids on the conserved loops connecting the helices and sheets.
14
 The 
Figure 1 - Crystal structure of Hsp90 
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natural products GDA and RDC have been shown to compete with ATP for binding to this 
pocket and have been studied extensively as Hsp90 inhibitors. 
Finally, the middle domain is a highly charged region that has been identified to associate 
with the majority of client proteins. This region is also the least conserved amongst species and 
isoforms.
15-16
 Consistent with other members of the GHKL superfamily, Hsp90 has catalytic 
loop, which contains a key arginine residue (Arg 380) located in the middle domain that is 
essential for the ATPase activity in vitro. This conserved arginine residue functions by polarizing 
the β-γ-phosphodiester bond of ATP bound to the N-terminus, facilitating the hydrolysis of ATP 
to ADP.
10
 
III. Hsp90 Functions as a Molecular Chaperone 
 
Molecular chaperones serve many important functions in eukaryotic cells. Chaperones 
prevent proteins from aggregating and can resolubilize aggregates as well. Moreover, they assist 
in the folding of nascent polypeptides and can also function in the refolding of damaged 
proteins.
17
 Chaperones utilize an ATP-driven cycle of conformational changes, which are used to 
fold their targets.
18
 Eukaryotic Hsp90 comprises approximately 1-2% of the total protein found 
in the cytoplasm during normal conditions, and can become significantly overexpressed during 
cellular stress.
5,19
 Cellular stress can be defined as conditions that result in the accumulation of 
midfolded proteins resulting from elevated temperature, variation in pH, or nutrient deprivation, 
leading to induction of the heat shock response to fold those misfolded proteins.
1
 
As the ribosome synthesizes single-stranded polypeptides, the amino acids have the 
propensity to spontaneously aggregate. Molecular chaperones are responsible for preventing this 
aggregation and folding these polypeptide strands into their tertiary and quaternary structures. 
4 
 
The folding process begins with Hsp70 in complex with ATP, and Hsp40 bound to the 
developing polypeptide. ATP is hydrolyzed to ADP, clamping Hsp70 to the polypeptide 
substrate to provide 
 
Figure 2 - Hsp90 folding process 
 
stability and prevent aggregation.
17
 Hsp70 interacting protein (HIP), binds to this complex and 
promotes interactions between Hsp70 and Hsp90 to facilitate peptide transfer to the Hsp90 
homodimer. Bcl2-associatied athanogene (BAG) can promote dissociation of Hsp70/client 
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protein complexes through the exchange of ATP for ADP, resulting in polypeptide release from 
the complex.
20-21
 Hsp90-Hsp70 organizing protein (HOP) recognizes Hsp90 through a TPR 
region and coordinates binding of the polypeptide-Hsp70 complex to Hsp90 forming a 
heteroprotein complex in the open conformation.
22
 This promotes transfer of the unfolded 
substrate to Hsp90 and the dissociation of Hsp70, HIP and HOP.
23-24
 Immunophilins and 
cochaperones bind to the binary complex, providing ATP the opportunity to occupy the N-
terminus, promoting Hsp90 into the closed-clamped conformation around the polypeptide 
substrate.
25
 Competitive inhibitors bind to the N-terminus and prevent Hsp90 from obtaining its 
closed conformation, ultimately destabilizing the protein complex, which leads to degradation 
via the ubiquitin-proteasome pathway. In the absence of an inhibitor and in the presence of ATP 
the protein folding cycle continues through binding of cochaperone p23 to the ATP bound 
complex, which stimulates the hydrolysis to ADP. The protein complex then folds the linear 
polypeptide into its intact three dimensional structure, through an uncharacterized process, which 
is ultimately released. Dissociation of the cochaperones and immunophilins allows the N-
terminus to open and allows the cycle to repeat. Figure 2 represents a simplified paradigm for the 
protein folding cycle, highlighting the central interactions described above. 
IV. Applications for Hsp90 Inhibitors 
 
Hsp90’s primary function as a molecular chaperone is to properly fold polypeptides or 
proteins that are misfolded and unable to function properly.  This mechanism can be exploited 
for development of drugs targeting multiple disease states.
26
 Hsp90 is responsible for folding 
nascent polypeptides, in addition to assisting in the solubilization and refolding of aggregated or 
denatured proteins. Through development of small molecules possessing a cytotoxic profile, a 
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blockage of the intact Hsp90-client protein complex ensues, preventing the maturation of bound 
polypeptides. This blockade disrupts the folding cycle and ultimately targets the protein complex 
for ubiquitin-proteasome degradation.
27-28
 A compound that exhibits a cytotoxic profile 
possesses the potential for the treatment of cancer through disruption of multiple signaling 
pathways.
29
 In contrast, non-toxic molecules that induce Hsp90 provide increased levels of 
chaperones, allowing for the refolding of aggregated and denatured proteins.
30-31
 Molecules 
possessing these non-toxic activities belong to a class of molecules that may be used for the 
treatment of neurodegenerative diseases. 
A. Cancer Therapeutics 
 
Traditional therapeutic strategies 
for cancer have focused on the 
inhibition of specific oncogenic 
receptors and enzymes. In 2000, 
Hanahan and Weinberg defined the 
six hallmarks that need to be 
manifested through cellular proteins, 
enzymes and receptors that can 
become hijacked by malignant cells to be classified as cancerous (Figure. 3).
4
 Many cancer 
therapeutics have been successfully developed to target a specific protein or enzyme associated 
with the hallmarks of cancer, however none have demonstrated the ability to inhibit all six 
simultaneously. The Hsp90 protein folding machinery has been shown to be critical for the 
manifestation of all six hallmarks (Table 1), which allows for a single Hsp90 inhibitor to 
simultaneously disrupt all six hallmarks.
5,32
 To date, no other cellular target has exhibited the 
Figure 3 - The six hallmarks of cancer 
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ability to inhibit all six hallmarks simultaneously, which has allowed Hsp90 to become one of 
the most sought after cancer targets yet identified.  
Table 1 - Hsp90 client proteins that are associated with the six hallmarks of cancer 
Hallmark Client Protein(s) 
Self-sufficiency in growth signals Raf-1, AKT, Her2, MEK, Bcr-Abl 
Insensitivity to anti-growth signals Plk, Wee1, Myt1, CDK4, CDK6 
Evasion of apoptosis RIP, AKT, mutant p53, c-MET, Apaf-1, survivin 
Limitless replicative potential Telomerase (h-Tert) 
Sustained angiogenesis FAK, AKT, Hif-1α, VEGFR, Flt-3 
Tissue invasion/metastasis c-MET 
 
Hsp90 inhibitors have shown significant differential selectivity toward malignant cells 
compared to normal cells at concentrations that are nontoxic to animals.
33-35
 There are currently 
three mechanisms that have been postulated to explain the selectivity of Hsp90 inhibitors for 
transformed cells. First, the over-expression of Hsp90 is directly related to malignant cells 
attempting to compensate for the upregulated amount of client proteins required for constant 
growth.
36-37
 The second mechanism is based on an idea by researchers at Conforma 
Therapeutics, wherein the intact Hsp90 homodimer’s affinity for ATP compared to the 
individual monomers. Malignant cells overproduce mutated and overexpressed proteins and 
force Hsp90 to maintain its intact homodimer form. In contrast, Hsp90 in normal cells shows a 
higher affinity to maintain the monomer form. Inhibitors are able to bind Hsp90 with greater 
affinity than ATP thus allowing for selective binding to malignant cells over normal cells.
2
 The 
final mechanism is based on a physiochemical explanation, where lysosomal pH under normal 
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conditions is around 4 or 5.  Traditionally, Hsp90 inhibitors possess basic nitrogens, which are  
protonated in the lysosome of a cell, and through a process known as pH partitioning these 
protonated molecules can either be released to the cytoplasm or sequestered in the lysosome.
38
 
By trapping the inhibitors in the lysosome, inhibitors cannot bind Hsp90 which is found 
predominately in the cytosol. The lysosome of a malignant cell’s pH is neutral which does not 
protonate basic nitrogens and results in distribution into the cytosol at higher concentrations, 
allowing the inhibitor to target Hsp90.
39-40
 
B. Neuroprotective Agents 
 
The accumulation of misfolded proteins can lead to neurodegenerative diseases such as 
Alzheimer’s, Parkinson’s, and Huntington’s which can be characterized by plaque formation.
41-42
 
The function of molecular chaperones can be exploited for the treatment of various 
neurodegenerative diseases, where these plaques may be removed or disaggregated. Alzheimer’s 
disease is caused through formation of β-amyloid (Aβ) plaques and hyperphosphorylation of the 
Tau protein, which leads to the aggregation of neurofibrillary tangles.
43
  
Figure 4 - Hsp90 inhibitors function for treatment of neurodegenerative diseases 
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Through inhibition of Hsp90, Heat Shock Factor-1 (HSF-1) is released from the intact 
multiprotein complex, wherein it trimerizes, becomes hyperphosphorylated and translocates to 
the nucleus and binds to multiple heat shock elements (Figure 4).
44-46
 Binding of these heat shock 
elements, results in the translocation of Hsp90, Hsp70, Hsp40 and Hsp27, producing the heat 
shock response. This effect allows for modulation of Hsp90 to be used as a potential target for 
the treatment of neurodegenerative diseases.
47
 A study conducted by Dou and coworkers showed 
that the N-terminal inhibitor, GDA, manifested increased levels of soluble phosphorylated tau 
and a decrease in aggregated tau tangles.
48
 Studies have also demonstrated that using GDA for 
treatment of neurodegenerative diseases exhibits minimal toxicities, which has been a limiting 
factor in the development of GDA as an  anti-cancer drug.
47,49
  
 
Figure 5 - Neuroprotective novobiocin analogue A4 
 
The use of GDA for a treatment for neurodegenerative diseases remains a tool for 
researchers, because GDA exhibits a cytotoxic profile with a small therapeutic window. This 
allows efforts to be focused on the development of other Hsp90 modulators that eliminate the 
toxicity from the drug profile. The novobiocin analogue A4 (Figure 5), developed in the Blagg 
Laboratory, has shown great promise as a neuroprotective agent and does not manifest 
cytotoxicity in assays up to 100 µM.
50
 Hsp90 provides a novel target for neuroprotection, 
through the induction of the heat response, and appears able to slow/halt/reverse the progression 
some of these diseases. 
10 
 
V. Natural Product Inhibitors of Hsp90 
 
Targeting ATP binding sites is a common practice for medicinal chemists and has lead to the 
development of many therapeutics.
51
 As stated above, ATP binds the N-terminus of Hsp90 in a 
unique bent conformation that is present in the GHKL superfamily of proteins. This unique 
binding site allows for selective structural features to be designed into Hsp90 inhibitors. Clinical 
trials for select Hsp90 inhibitors have shown potency, but the toxicities and side effects from the 
compounds have become a limiting factor. Dose dependant hepatotoxicity and gastrointestinal 
toxicities are hindering preclinical development of GDA and associated analogues.
52
 Natural 
selection and stresses placed on organisms require they develop a defense to these stresses, 
resulting in an organism developing highly specific and effacious compounds. These compounds 
show a vast variation of scaffolds but still bind to a specific binding site, which allows for 
medicinal chemists a diverse set of tools for development of Hsp90 inhibitiors.
53
 
A. Geldanamycin and Derivatives 
 
Figure 6 - Geldanamycin and related analogues 
 
 Geldanamycin (Figure 6), a naturally occurring ansamycin was originally discovered in 
1970. Although fermentation of Streptomyces hygroscopicus, allows GDA to be produced in 
11 
 
multigram quantities the first total synthesis was not accomplished until 2002.
54-55
 This work 
produced by Andrus and coworkers yielded a mixture GDA and (-)-o-Quinogeldanamycin in low 
yields.
56
 GDA was initially evaluated in various antimicrobial assays and it showed good activity 
against Alternizaria, Pythium, Botrytis and Penicillium with a minimal inhibitory concentration 
(MIC) of 2mg/mL against Tetrahymena pyriformis.
54
 Further testing demonstrated GDA 
expressed anti-proliferative activity against a wide range of tumor cell lines.
57
 It was originally 
believed that GDA’s anti-proliferative activity was manifested through direct inhibition of a 
tyrosine kinase, v-Src, which modulates general signaling pathways that regulate the growth and 
proliferation of cancer cells.
58
 Upon further evaluation it was determined that GDA was inactive 
against purified v-Src protein, suggesting that it was manifesting its activity through an alternate 
mechanism.
59
 Whitesell and Neckers determined that GDA binds Hsp90 through affinity 
purification and determined that the effects observed for v-Src was the result of downstream 
properties manifested through inhibition of Hsp90.
60
  
The first co-crystal structure of GDA to Hsp90 was reported by Stebbins and coworkers 
wherein GDA was thought to bind to client protein binding site.
61
 Fortunately, additional studies 
revealed that upon GDA binding to Hsp90 directly affects ATPase activity, suggesting to 
competitive inhibition of the ATP binding pocket. A second co-crystal structure published in 
1997, correctly identified GDA binding to the ATP binding pocket.
13
 Interestingly, this structure 
identified two key features that have become significant in the drug discovery efforts to 
determine structure-activity relationships (SAR). The first key feature was that GDA binds 
Hsp90 in a unique bent conformation and contains a cis-amide bond, which has been isomerized 
from the trans-conformation present in its native structure.
62
 This changes the shape of GDA 
from the less rigid, flat conformation to the conformationally rigid bent conformation observed 
12 
 
in the co-crystal structure. The second key feature is that GDA binds Hsp90 in such a manner 
that allows the quinone moiety to project towards the surface of the protein, which allows for 
modifications to the 17-position without the loss of inhibitory activity.
13,62
 
Further in vivo studies with GDA have shown that the quinone ring appears to be directly 
associated with some of the toxicity associated with the molecule. The quinone participates in 
redox cycling, allowing for the release of superoxide and semiquinone radicals upon exposure to 
cytochrome P450 reductase.
63
 Additionally, the labile nature of the methoxy substituent at the 
17-position of GDA has been implicated in the hepatotoxicity.
64
 The 17-position projects away 
from the binding pocket, allowing substitution at this location without effecting GDA’s affinity 
for Hsp90.
13,65
  Therefore, analogues were designed to incorporate electron rich substituents at 
the 17-position that decrease the electron deficient nature of the quinone, which allows for an 
increased stability.
66
 The most potent analogue identified was 17-(allylamino)-17-
demethoxygeldanamycin 17-AAG (Figure 6). Although 17-AAG showed an improvement over 
GDA, 17-AAG exhibited poor solubility, suggesting additional analogues were needed to 
improve aqueous solubility. In 2004, Kosan Biosciences reported 17-DMAG (Figure 6), through 
incorporation of a tertiary ammonium group. The ammonium group is protonated at 
physiological pH, which increases solubility and allows for the potential of oral 
administration.
52,67
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B. Radicicol and Related Analogues 
 
  
  
Radicicol (RDC) is a 14 membered macrolide originally isolated in 1953 from Monosporium 
bonorden and used as an antifungal agent (Figure 7).
68
 In similar fashion to GDA, RDC was 
believed to bind v-Src specifically, although further studies showed its ability to suppress the 
transformation of oncogenes.
69
 Additionally, RDC has been shown to be the most potent natural 
product inhibitor of Hsp90, functioning as a competitive inhibitor of the N-terminal ATP binding 
pocket.
65
 In 1998, Nakano and coworkers demonstrated the ability of radicicol analogues to bind 
Ras and Src transformed cells, which relates directly to Hsp90 inhibition, and suppression of the 
ATPase activity.
70
  
A co-crystal structure of RDC bound to Hsp90 shows a similar conformation to the native 
structure of RDC alone, which is an inflexible ring system that allows for binding to both the 
activated and unactivated forms of Hsp90 with equal affinity.
65
 Although RDC exhibits a strong 
affinity for Hsp90 against purified protein, manifesting an IC50 of 23 nM, it unfortunately does 
not manifest any activity in vivo. RDC’s activity in vivo is a consequence of the α,β,γ,δ-
unsaturated carbonyl and electrophilic epoxide ring, which will be converted to various inactive 
metabolites.
71
 Further investigation of the crystal structure shows the resorcinol ring to bind deep 
into the ATP binding pocket, establishing essential hydrogen bonding interactions. The phenol at 
Figure 7 - Radicicol and related analogues 
14 
 
the 3-position provides a hydrogen bond with Asp79 and a water molecule that mimics the key 
interactions observed in the co-crystal structure with adenine. Additionally, the phenol at the 5-
position forms a hydrogen bond with Leu34 and the chlorine appears to partially fill a 
hydrophobic cavity.
65,72
  
SAR studies have shown through synthetic modification that the in vivo metabolism can be 
minimized through reduction of its electrophilic nature. The synthesis of compounds that replace 
the α,β,γ,δ-carbonyl for an oxime maintain potent anti-proliferative activities, and continue to 
induce degradation of Hsp90 dependent client proteins (Figure 7).
73-75
 Danishefsky and 
coworkers developed a synthesis that allowed for the preparation of multiple analogues, which 
led to the first SAR studies between Hsp90 and RDC. This study identified that the orientation of 
the macrocycle needs to maintain the conformation observed in the natural product for inhibitory 
activity.
76
 Removal of the electrophilic epoxide for a structurally similar cyclopropyl resulted in 
retention of activity, highlighting the conformation of the macrocycle is more important than 
hydrogen bonds formed by the epoxide shown in figure. 7.
76
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C. Novobiocin and Analogues 
 
 
The coumermycin family of antibiotics has been used for their ability to inhibit type II 
topoisomerases including DNA gyrase, which is a member of the GHKL superfamily.
14
 The 
coumermycin antibiotic family includes novobiocin, chlorobiocin and coumermycin A1 (figure 
8), all of which have been isolated from various strains of spreptomyces.
77-80
 Neckers and co-
workers identified novobiocin to bind a previously unidentified C-terminal binding pocket, 
although the affinity was relatively weak, and inducing the degradation of the Hsp90 client 
proteins at ~700 µM in SKBr3 cells.
81-82
  
Figure 8 - Novobiocin and various natural product inhibitors of Hsp90 C-terminus 
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Novobiocin is composed of three distinct regions: the benzamide side chain, the coumarin 
core, and the noviose sugar. Each of these regions can be modified chemically, which allows for 
the development of analogues to probe for specific SAR at each location. Initial SAR studies 
conducted by the Blagg Laboratory revealed several structural features that are critical for 
manifesting the observed activities. The synthesis of A4 (Figure 5) showed that truncation of the 
benzamide side chain, removal of the 4-hydroxy substituent, and modification to the noviose 
sugar results in a 70 increase in activity.
83
 This result led to the development of an additional set 
of natural products, DHN1 and DHN2, which confirmed that lacking the compounds 4-hydroxyl 
group and 3’carbamate facilitate Hsp90 inhibition.
84
 Further SAR studies showed the benzamide 
side chain is required for cytotoxicity, and that a hydrogen bond acceptor in the meta or para 
positions, or an aryl side chain were the most effective.
85
 These studies also showed that 
incorporation of a heterocyclic side chain is well tolerated and can actually be used to increase 
solubility.
85
 To date the Blagg laboratory has produced many compounds that manifest IC50 
values in the low to mid nanomolar range. 
 
D. Epigallocatechin-3-gallate (EGCG) 
 
Figure 9 - Structure of Epigallocatechin-3-gallate 
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EGCG (Figure 9), is the main polyphenolic compound extracted from green tea.
86-87
 In 2003 
Palermo and coworkers attributed the anticancer effects of EGCG to the Aryl Hydrocarbon 
Receptor (AhR). AhR is a ligand-activated transcription factor, which upon binding translocates 
to the nucleus, dimerizes with the AhR nuclear translocator protein (ARNT) and promotes 
transcription.
86,88-89
 Follow-up studies using affinity chromatography showed that EGCG did not 
directly inhibit AhR, instead they determined that EGCG binds the Hsp90.
90
 Truncation of 
Hsp90 showed that the C-terminus binds to immobilized EGCG, suggesting that binding occurs 
in the ATP binding site similar to novobiocin.
7,90
  
EGCG is composed of three distinct regions: the catechin core, the gallate side chain, and the 
aryl linked side chain. The majority of the SAR developed for the EGCG scaffold has focused on 
removal of various the various phenols, resulting in modest changes in biological activity.
91-93
 
These studies elucidated that removing phenols generally decreases the anti-proliferative activity 
against several biological targets.
93
 A more thorough study that investigates significant 
modifications to other structural moieties is required to better define SAR for the EGCG core. It 
is proposed that studies of this type will transform EGCG into a lead structure for development 
of anti-cancer therapeutics. 
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Chapter 2 
Cyclopropyl Derivatives of Radamide 
I. Introduction 
 
The development of N-terminal Hsp90 inhibitors has been facilitated by rational drug 
design, which enables the observation of interactions that natural product inhibitors make with 
the protein.
94
 There are currently several research groups targeting the Hsp90 N-terminus using 
small molecule inhibitors.
95-97
 As discussed in Chapter 1, examination of the binding orientation 
of the endogenous ligand, ATP, and natural product inhibitors, GDA and RDC, reveals that they 
bind in a similar, but unique, bent conformation. This bent conformation is specific to the GHKL 
superfamily of proteins, which is comprised of DNA Gyrase, Histidine kinase, Hsp90, and MutL.  
Key hydrogen bonding interactions are made by known inhibitors with distinct areas of 
the ATP binding pocket. For example, the majority of contacts made by GDA are due to the 
quinone occupying the same space as of the phosphate group of ATP. In contrast, the resorcinol 
of RDC binds deep into the ATP binding pocket and mimics the purine core. It was hypothesized 
that fusion of the active moieties of GDA and radicicol into one chimeric molecule would allow 
for an increase in Hsp90 affinity due to capitalization of both sets of interactions. This hypothesis 
was tested by Clevenger and co-workers through the development of radamide (figure 14), a 
hybridized small molecule that demonstrated low micromolar anti-proliferative activity due to 
Hsp90 inhibition. The co-crystal structure of radamide bound to Hsp90 demonstrated that the 
flexible linker maintained a linear conformation, thus preventing the quinone to rotate into the 
phosphate pocket. The use of conformational constraint to insert a predisposed bent 
conformation into the molecule through incorporation of a cis-cyclopropyl linker was proposed 
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to achieve this goal. It was hypothesized that biasing the linker with this structural modification 
would orient the quinone of radamide directly into the phosphate pocket.  
The majority of research in the Hsp90 field has focused on development of inhibitors that 
target Hsp90, without any focus on the differences among the various protein isoforms. 
Emerging research that explored the unique binding pockets of Hsp90α and β in direct 
comparison to Grp94 has allowed for the development of isoform-specific inhibitors. 
Examination of the various binding pockets has shown that the movement of a lysine residue 
enables access to a new hydrophobic pocket in Grp94 by us. In contrast, the phosphate binding 
pocket of Hsp90α, which is larger and less exclusive, the corresponding pocket in Grp94 is 
constricted, which restricts binding to this pocket. The cis-cyclopropyl radamide analogues take 
advantage of differences between the phosphate binding pockets, allowing for binding to the α-
isoform selectively and development of first-in -class Hsp90β-selective inhibitors. The design, 
synthesis and evaluation of radamide-based inhibitors containing a cis-cyclopropyl linkage are 
discussed herein. 
II. Comparison of Hsp90 Crystal Structures 
 
Co-crystal structures of several natural product inhibitors of the Hsp90 N-terminus bound 
to Hsp90 have been solved. The co-crystal structure of ADP bound to Hsp90 shows the 
conformation of the ligand in the binding pocket and can be used to develop small molecule 
inhibitors that capitalize on those interactions. As shown in Figure 10, the N-terminal binding 
pocket is comprised of two distinct subpockets, one that binds the purine base and the other, 
which is the phosphate binding region.  
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Figure 10 - Identification of the Hsp90 N-terminal ATP binding site 
 
As described in Chapter 1, this ATP binding site contains a Bergerat fold, which forms a 
pocket behind the α-helix and allows the purine base of ADP to bind within this cavity. The 
second pocket is an extended purine pocket, but is located on top of α-helix. This region is 
oriented to accommodate the unique bent conformation of inhibitors, enabling them to bind 
Hsp90 with high affinity and establish interactions with the purine pocket and the α-helix.
62,65
 
Additionally, co-crystal structures highlight specific interactions made between the protein and 
ligand. The natural products GDA and RDC exhibit good affinity for Hsp90, manifesting KD 
values of 1215 µM and 19 µM, respectively.
60,69-70
  
A. Hsp90 Co-crystal Structure with ADP 
 
In 1998 Obermann and co-workers reported the co-crystallization of Hsp90 in the 
presence of ATPγS, which yielded the structure of ADP bound to the N-terminal domain of 
human Hsp90. This structure identified two key features about the N-terminus. First, it was 
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determined that ADP shares a binding pocket with GDA, indicating a conserved ATP binding 
site. Second, solving this co-crystal structure confirmed that ADP, rather than ATP, was bound 
to the active site, indicating that the γ-phosphate is hydrolyzed.
98
  
 
Figure 11 - Key hydrogen bonds made between ADP and Hsp90 
 
As seen in Figure 11, the purine base binds deep into the N-terminal ATP pocket. 
Adenosine interacts with yeast Hsp90 through an intricate network of hydrogen bonds, both 
directly and indirectly through water-mediated interactions. Key interactions of adenosine with 
Hsp90 are made by the nitrogen at the 1-position bonding through a conserved water molecule to 
Gly83, Asp79 and Thr 171.  Moreover, the nitrogen at the 6-position exhibits a direct hydrogen 
bond with Asp93, in addition to water-mediated hydrogen bonds with the backbone of Leu34. 
The 7-position of the adenine ring also forms water-mediated hydrogen bonds directly with the 
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Hsp90 backbone at Asn92.
65,98-99
 While the adenosine base projects down into the pocket, the 
sugar and phosphate portion of ADP project outward into a solvent-exposed region of the 
protein. The hydroxyl group at the 2-position on the ribose sugar interacts directly with Asn37, 
while the hydrogen on the 3-position hydroxyl group bonds through a conserved water molecule. 
Finally, the phosphate region of ADP binds to a small groove found in the phosphate binding 
region along the α-helix of Hsp90. The α-phosphate interacts directly with Phe124, while Gly121 
and Gly 123 interact through a conserved water molecule. The β-phosphate interacts directly 
with Lys96 and Asp40, while also interacting through water-mediated hydrogen bonds to Gly123 
and Gly118.
98-99
  
Investigation into the binding orientation of ADP shows that it displays the unique bent 
conformations previously described. The adenine base binds deep into the pocket, which allows 
the phosphate region to curl around top of the α-helix. As discussed in Chapter 1, this binding 
orientation mimics that adopted by other members of the GHKL superfamily and N-terminal 
inhibitors.
14
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B. Hsp90 Co-crystal Structure with Geldanamycin 
 
 
Figure 12 - Hydrogen bonds made between GDA and Hsp90 
 
In 1997, Stebbins and co-workers were able to solve the co-crystal structure of GDA 
bound to yeast Hsp90. As seen in Figure 12, GDA binds within the N-terminal Hsp90 binding 
site in a similar manner to ADP, wherein the carbamate binds in the purine pocket. Although, it 
does not bind as deeply within the pocket, it maintains many of the same interactions as ADP. 
Specifically, the amino portion of the carbamate interacts directly with Asp79 and, through a 
conserved water molecule, with Leu34. Moreover, the carbonyl oxygen indirectly interacts with 
Asp79, Gly83 and Thr171 through a single conserved water molecule.
61,99
 Upon binding, the 
orientation of the GDA amide bond rotates from trans to cis, which allows GDA to adopt a 
higher affinity, bent conformation.
62
 The new orient
100
ation places the quinone on top of the α-
helix, mimicking the phosphate tail of ADP and allowing the quinone to make many of the same 
interactions as the phosphate region of ADP. Specifically, the amide interacts through both the 
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carbonyl oxygen and nitrogen directly with Phe124 and Gly123, respectively. The quinone is 
able to interact with Asp40 and Lys98 through both of the carbonyl oxygens, while the methoxy 
group at the 17-position interacts directly with Lys44.
61,99
 
Analysis of Hsp90 binding to either the endogenous ligand, ADP or to GDA highlights 
one prominent difference amongst the co-crystal structures. While the aromatic quinone portion 
of GDA maintains many of interactions as the phosphate tail of ADP, the macrocyclic portion 
does not appear to maintain these interactions. 
C. Hsp90 Co-crystal Structure with Radicicol 
 
 
Figure 13 - Hydrogen bonds made between RDC and Hsp90 
 
In 1999 Roe and co-workers solved the co-crystal structure of RDC bound to the N-
terminal ATP binding site. Figure 13 shows that, unlike GDA, the macrocycle of RDC does not 
bind within the purine portion of the binding pocket. Instead, the resorcinol ring binds deep into 
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the pocket in a manner similar to the purine base, maintaining many of the same interactions 
with Hsp90 as ADP.
65
 Interactions of the resorcinol with Hsp90 are shown in Figure 13. One key 
interaction involves a hydrogen bond between the phenol ortho to the methyl ester and Asp79. 
This phenol, in addition to the carbonyl oxygen of the methyl ester, interacts through a conserved 
water molecule with Asp79, Gly83, and Thr171, similar to ADP. Moreover, the phenol in the 
para position makes an interaction with Leu34 through a conserved water molecule.
99
 
Orientation of the resorcinol ring allows the chlorine to interact through van der Waals forces 
with the Phe124, strengthening the binding orientation.
65
 RDC naturally exhibits a bent 
orientation in solution, which allows the macrocycle to bend on top of the α-helix.
65
  Despite this 
predisposed bent conformation, the macrocyclic portion of RDC does not maintain many 
interactions with the protein and only the epoxide oxygen interacts directly with Lys44.  
Analysis of Hsp90 interactions with RDC as compared with ADP reveals two important 
observations. Firstly, the binding conformation of the resorcinol and adenine rings allows both to 
bind deep into the pocket and establish many of the same interactions. Next, the macrocycle of 
RDC does not make many specific interactions with Hsp90, supporting that further interactions 
in this region of the molecule should increase the affinity of RDC-based analogues for Hsp90. 
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III. Development of radamide a Chimera of Radicicol and Geldanamycin 
 
 
Figure 14 - Radicicol and geldanamycin combined into a chimeric molecule radamide 
 
Through analysis of the co-crystal structures of GDA and RDC, it becomes clear that 
each molecule affords different interactions with Hsp90. The carbamate of GDA does not bind as 
deeply into the purine binding pocket as the purine base, which does not enable it to adopt the 
same orientation and make the same interactions. The aromatic quinone projects into the 
phosphate binding region, creating a significant hydrogen bonding network with Hsp90. In 
contrast, the resorcinol of RDC binds deeper into the ATP binding pocket and, through 
interactions, orients itself in the same fashion as ADP.
65
 Unfortunately, the RDC macrocycle 
maintains only one interaction with Hsp90. In 2004, Clevenger and co-workers designed and 
synthesized radamide, a chimeric molecule combining the GDA and RDC through a flexible 
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carbon tether as shown in figure 14.
101
 This flexible linker allows the resorcinol to maintain its 
binding orientation in the purine pocket that it observed for RDC and allows the quinone to bend 
over the α-helix and capitalize on the intricate hydrogen bonding network as shown as part of 
GDA. Radamide manifests IC50 values of 18.6 µM and 23.7 µM in MCF-7 and SKBr3 breast 
cancer cells, respectively. Further investigation into the radamide scaffold, probed the optimal 
linker length and investigated bioisosteric replacements for the quinone.
99
 
 
Figure 15 - Hydrogen bonds made between radamide and Hsp90 
 
In 2009 Immormino and co-workers reported the co-crystal structure of radamide bound 
to the Hsp90 N-terminus. The binding orientation of radamide provides insight into the weaker 
binding affinity of radamide when compared to the natural products, GDA and RDC. As seen in 
Figure 15, the quinone of radamide does not project over in the phosphate binding pocket, 
partially due to the linear conformation maintained by the flexible linker. Thus, it was proposed 
that incorporation of conformational constraint within the flexible linker would force the quinone 
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to project into the phosphate binding pocket. Subsequently, compounds have been developed to 
contain a cis-cyclopropane ring to bias analogues into the desired bent conformation and 
capitalize on the interactions made between the quinone of GDA and Hsp90. 
IV. Hsp90 Isoforms 
 
The Hsp90 family of proteins is comprised of four distinct isoforms that are localized to 
cellular compartments. There are two forms of Hsp90 found in the cytoplasm. Hsp90α, the 
inducible cytosolic form, comprises the majority of Hsp90 that is found in the cell.  In contrast, 
Hsp90β is the constitutively active form and is the minor isoform found in the cytoplasm.
9,102
 
Glucose Regulating Protein 94 (Grp94) is the Hsp90 isoform found in the endoplasmic 
reticulum, while Tumor Necrosis Factor(TNF) Receptor-Associated Protein-1 (TRAP-1) is 
located in the mitochondrial matrix.
102
 The majority of research to date has focused on the 
cytosolic forms, often involving a mixture of α and β since the two isoforms are difficult to 
separate. Since a mixture of Hsp90 isoforms is often employed in studies, little is known about 
the specific interactions of client proteins. Hsp90 has been shown to play a role in cell survival 
and the progression of cell death, through apoptosis or necrosis.
103
 High expression of Hsp90α 
appears to be associated with tumor progression and cell cycle regulation.
102
 Many of the known 
inhibitors of Hsp90α and β target the N-terminus, which express highly conserved ATP binding 
sites.
104-105
 Although there is basic understanding of Hsp90 chaperone function, little is known 
about how each specific isoform function in this process.
102
  
In 2009 Immormino and co-workers sought to identify differences in the ATP binding 
pockets of Grp94 and Hsp90 using the inhibitors GDA and radamide. This study showed that in 
order for GDA to bind Grp94, the protein must undergo conformational changes to accommodate 
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the ligand. The quinone of GDA exhibits a steric clash with a glycine residue, which forms the 
lid of the ATP pocket, which undergoes rotation to allow binding. In contrast, radamide binds to 
Grp94 without the need for glycine to rotate, indicating that radamide binds differently than 
GDA (Figure 16).
106-107
  
 
Examination of the two structures shows that the lid of the pocket is the structural feature 
that differentiates the two isoforms. This attribute enables each to accommodate small molecules 
and offers the potential of each isoform to be selectively inhibited. The flexible linker of 
radamide allows for the quinone to adopt different orientations when binding the two proteins. 
The co-crystal structure of radamide bound to Hsp90 shows the quinone to extend toward the 
solvent-exposed portion of the ATP binding pocket. In contrast, the co-crystal structure of 
radamide bound to Grp94 shows that the small molecule adopts a different conformation, 
allowing the quinone to project into a Grp94 hydrophobic pocket that is not found in Hsp90.
106
 
  
 
Figure 16 - Binding orientation of radamide to Hsp90 (left) and Grp94 (right) 
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Small molecule 5’-N-ethylcarboxamideadenosine (NECA) was the first reported molecule to 
take advantage of key interactions with the Grp94-specific hydrophobic pocket, producing a Kd 
of 200 nM for binding to Grp94. In contrast, NECA did not demonstrate a detectable binding 
affinity for Hsp90.
108
 Radamide is the second molecule reported to interact with this hydrophobic 
binding pocket, manifesting a Kd value of 520 nM for Grp94 and 870 nM for Hsp90, reflecting 
~2-fold selectivity for Grp94.
106
 These compounds validate the opportunity to synthesize 
isoform-selective inhibitors, which would enable the design of new compounds built upon the 
radamide scaffold that target either Hsp90 or Grp94. 
The design of isoform-selective inhibitors is a promising area of study. The co-crystal 
structures in Figure 16 show that the Hsp90 phosphate binding pocket is wider when compared 
to that of Grp94, potentially due to conformational changes in the protein to accommodate the 
hydrophobic pocket. Using the radamide scaffold, it is possible to incorporate additional 
conformational constraint to project the quinone on top of the α-helix and maintain interactions 
with the protein. This modification would allow analogues to bind Hsp90 isoforms with better 
affinity than Grp94, due to unfavorable interactions between the quinone moiety and the 
narrower phosphate binding region found in Grp94. 
V. cis-Cyclopropyl radamide 
 
Conformational constraint has been used by medicinal chemists as a tool to reduce 
entropy of a molecule and thus the energy required to achieve the conformation required for 
binding.
100,109
  This structural design imparts an advantageous reduction of overall free energy 
upon binding its biological target.
110
 When GDA binds Hsp90, it gives rise to an entropic 
penalty, resulting from isomerization of the amide bond. While GDA exhibits a linear orientation 
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in solution, it binds Hsp90 in a bent conformation. The previously described entropic penalty 
created by isomerization of its natural trans-amide bond into the cis-amide conformation found 
in the co-crystal structure is part of this conformational change.
62
 Molecular modeling studies 
indicate that this isomerization process requires between 2.2-6.6 kcal/mol of energy.
99
 It is 
proposed that locking GDA in its cis conformation would eliminate the entropic penalty and 
allow GDA to bind with favorable entropy. As previously discussed, the co-crystal structure of 
radamide revealed that it binds Hsp90 in a linear fashion, corresponding directly with the trans-
amide orientation of GDA. Through modification of its flexible linker to predispose radamide 
into a bent conformation, it would be conformationally locked into a cis-amide orientation, 
mimicking that observed in the co-crystal structure of GDA. In 2009, Duerfeldt and co-workers 
synthesized radamide analogues that locked the amide of radamide into a cis orientation. These 
compounds manifested a 5-fold increase in affinity for Hsp90.
111
 Additionally, in 2009 Hadden 
and co-workers investigated modifications to the flexible linker that involved introduction of cis 
and trans olefins. Unfortunately, integration of the olefins did not result in increased Hsp90 
affinity.
99
  
32 
 
 
 
Figure 17 - Molecular modeling of cyclopropyl radamide bound to Hsp90 
 
As shown in Figure 17, molecular modeling studies involving the radamide scaffold 
demonstrated that modification to the flexible linker, specifically through incorporation of a cis-
cyclopropyl tether, would bias the quinone into the phosphate binding pocket. These molecular 
modeling results are in accordance with the work published by Hadden and co-workers, in which 
they demonstrated that a 3-carbon tether connecting the resorcinol to the amide carbonyl was 
optimal.
99
 Moreover, it was proposed that the cis-cyclopropyl tether would bias the radamide 
scaffold into a bent conformation, which would remove the entropic penalty associated with 
binding and thus, increase affinity of such analogues for Hsp90. As demonstrated in molecular 
models, the cis-cyclopropyl linker extends the quinone portion of radamide toward the phosphate 
binding pocket, and exposes it to the solvent-exposed area of the binding pocket. This modeling 
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study is in agreement with the co-crystal structure of radamide bound to Hsp90, in which the 
quinone projects into the solvent-exposed phosphate binding pocket.
106
  
VI. Synthesis of cis-cyclopropyl radamide analogues 
 
As discussed above, molecular modeling studies published by Hadden and co-workers 
confirm that inhibition of Hsp90 is a function of both linker length and quinone 
conformation.
99,106
 In an effort to further improve affinity, conformationally constrained 
radamide analogues containing different linker lengths and a cis-cyclopropane ring as part of 
these linkers were developed. The length of the cyclopropyl linkage is defined by the number of 
carbons between the resorcinol and amide carbonyl, which is connected to the quinone moiety. 
The two different linker lengths investigated contained 3- and 4-carbons. The syntheses of these 
analogues were accomplished through development of each individual resorcinolic and quinone 
portion, followed by subsequent coupling of the two fragments.  
A. Three-Carbon Cyclopropyl Linker 
 
 
Figure 18 – Structure of the 3-carbon cyclopropyl radamide analogue 
 
Due to incorporation of the cyclopropyl ring, the route used to access radamide and 
various analogues could not be employed. Thus, synthesis of the 3-carbon tethered analogue 
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(Figure 18) involved development of a new route for the preparation of the resorcinol, which was 
ultimately coupled to the previously described, protected hydroquinone. 
 
Scheme 1 - Synthetic steps toward the fully functionalized resorcinol ring 
 
  As shown in Scheme 1, synthesis of the 3-carbon linked analogue began by protection of 
methyl 3,5-dihydroxyphenylacetate as the corresponding alkoxy ethers. Next, the ester in 
protected resorcinol 1 was reduced to the corresponding aliphatic alcohol, 2 allowing for 
selective and nearly quantative ortho-bromination of the resorcinol ring.
112
 Bromination at this 
stage of the synthesis serves as a functionality that can be readily converted to the desired methyl 
ester at a later stage and one that blocks this position from reacting during subsequent steps. 
Acetylation of alcohol 3 furnished protected intermediate 4, which may be chlorinated in good 
yield to give 5.
113
 Solvolysis was employed to excise the acetate ester group and furnish 
resorcinol 6, which was subsequently oxidized to corresponding aldehyde, 7, using Dess-Martin 
Periodinane (DMP). With all of the desired functionalities installed on the resorcinol ring, the 
cis-cyclopropyl linker was installed.  
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Scheme 2 - Installation of the cis-cyclopropyl tether 
 
  The cis-cyclopropyl linker was next synthesized. Using the Still-Gennari modification of 
the Horner-Wadsworth-Emmons olefination, aldehyde 7 was converted to the corresponding cis-
α,β-unsaturated methyl ester, 7a.
114
 
1
HNMR analyses of the olefinic protons of ester 7a revealed 
coupling constants of 11.4 Hz, confirming formation of the desired cis olefin. Next, reduction of 
the α,β-unsaturated ester yielded the corresponding alcohol, 8, in excellent yield over two steps. 
The olefinic alcohol was designed to adopt the proper configuration required for application of 
the Charette modification of the Simmons-Smith cyclopropanation reaction.
115-116
 As shown in 
Scheme 2, these conditions involve use a butyl boronic ester and formation of a carbenoid to 
selectively produce the desired cis-cyclopropyl alcohol 9.  
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Scheme 3 - Final synthetic efforts toward 3-carbon linked cis-cyclopropyl radamide 
 
Final steps toward the desired analogue involved exchange of the aryl bromide on 9 for a 
methyl ester. Toward this end, the aliphatic alcohol was protected as the corresponding silyl 
ether, 9a, in excellent yield. Next, lithium–halogen exchange and quenching with methyl 
chloroformate, converted the aryl bromide into methyl ester 9b. Cleavage of the silyl ether 
furnished the intact cis-cyclopropyl-containing resorcinol fragment of radamide. Synthesis of the 
quinone fragment was carried out as previously reported by Clevenger and co-workers.
101
 
Coupling of the two fragments was attempted between the cyclopropyl alcohol and protected 
quinone using a Ruthenium catalyst.
117-118
 Unfortunately, these conditions did not produce 
coupled product and an alternate coupling procedure was pursued. 
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Scheme 4 - Synthesis of 3-carbon cis-cyclopropyl radamide 
 
Oxidation of alcohol 10 to the corresponding aldehyde using DMP, followed by further 
oxidization using Pinnick conditions afforded the cis-cyclopropyl acid fragment, 11. Coupling of 
the cyclopropyl acid using DCC in toluene, as previously described for a similar system, did not 
yield the desired product.
119
 However, (1-Cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU)  in 
the presence of Hunig’s base afforded the desired cis-cyclopropyl amide 12 in good yield.
120
 
Subsequent cleavage of the alkoxy ethers using dilute acid in dioxanes produced the desired 
product, 13, without epimerization of the cis-cyclopropane in near quantative yield. 
 
38 
 
B. Four Carbon Cyclopropyl Linker 
 
 
Figure 19 - Desired 4-carbon cyclopropyl radamide analogue 
 
 
Scheme 5 - Synthesis of the 4-carbon cyclopropyl resorcinolic portion 
 
Synthesis of the 4-carbon cyclopropyl linker (figure 19), followed a similar series of 
reactions as the radamide synthesis.
99,101
 In contrast to the 3-carbon analogue, the resorcinol ring 
of the 4-carbon linked analogue is fully functionalized prior to installation of the cyclopropyl 
linker. Cleavage of the silyl groups on methyl 4,6-bis((tert-butyldimethylsilyl)oxy)-3-chloro-2-
methylbenzoate 14 and protection of the resultant resorcinol as alkoxy ethers yielded 
functionalized resorcinol 15 in good yield. Next, modification of the linker started with 
alkylation of the benzylic position using LDA and allyl bromide to furnish compound 16 in 
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nearly quantitative yield. Oxidation of the terminal olefin to the corresponding aldehyde, 17, was 
accomplished using osmium tetraoxide and N-morpholine oxide (NMO).  
 
Scheme 6 - Synthetic efforts toward the 4-carbon radamide analogue 
 
The Still-Gennari modification of the Horner-Wadsworth-Emmons olefination was 
carried out using aldehyde, 17, to furnish cis olefin 17a.
114
 NMR analyses revealed that the 
coupling constants for the olefinic protons were 11.5 Hz, confirming formation of the desired cis 
olefin. Selective reduction of the aliphatic ester was accomplished using DIBAL-H at -78°C to 
give the corresponding alcohol, 17b, in modest yield.
121
 Using similar methodology as employed 
for the 3-carbon linker, properly configured alcohol 17b was exposed to the Charette 
modification of the Simmons-Smith cyclopropanation reaction to selectively yield cis-
cyclopropyl alcohol, 18, in near quantative yield.
115-116
 As described previously, a ruthenium-
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catalyzed coupling reaction was attempted.
117-118
 These coupling conditions did not yield desired 
product and recovery of the alcohol was accomplished by washing the crude reaction mixture 
with dilute acid. As described with the 3-carbon constrained analogue, an alternative strategy 
was employed to accomplish this coupling reaction. 
 
Scheme 7 - Synthesis of 4-carbon cyclopropyl radamide analogue 
 
Oxidation of cyclopropyl alcohol 18 to aliphatic aldehyde 18a was accomplished using 
DMP. The aldehyde was immediately oxidized to the corresponding acid, 19 using Pinnick 
conditions. As observed with the 3-carbon analogue, coupling attempts between cyclopropyl acid 
and the protected quinone using DCC in toluene were unsuccessful.
119
 In contrast, reaction of 
cyclopropyl acid 19 and the protected quinone portion in the presence of Hunig’s base and 
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COMU yielded the desired 4-carbon tethered cyclopropyl radamide analogue, 20, in excellent 
yield.
120
 Global cleavage of all alkoxy ethers was accomplished without epimerization using 
dilute hydrochloric acid in dioxanes to produce the desired final 4-carbon cis-cyclopropyl 
radamide analogue, 21, in nearly quantative yield.  
C. Biological Evaluation of cis-cyclopropyl analogues: 
 
Table 2 - Anti-proliferative activities of select radamide analogues 
Compound Structure 
MCF7 
(µM) 
SKBr3 
(µM) 
Two Carbon  
radamide 
 
 
 
14.0 ± 1.4
a 
23.0 ± 1.2 
Three Carbon 
radamide 
 
 
 
11.9 ± 0.4 14.5 ± 0.8 
Four Carbon 
radamide 
 
 
 
11.6 ± 0.8 12.4 ± 0.4 
cis-olefin 
radamide 
 
 
 
45.5 ± 4.0 71.1 ± 4.1 
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a
Values represent mean ± standard deviation for at least two separate experiments performed in 
triplicate. 
Upon synthesis of the cyclopropyl radamide analogues, the compounds were evaluated 
for their anti-proliferative activity against SKBr3 (estrogen receptor negative, Her2 over-
expressing breast cancer cells) and MCF-7 (estrogen receptor positive breast cancer cells). As 
shown in Table 1, values obtained upon testing the cyclopropyl radamide analogues were 
directly compared with the previously described radamide analogues with variable linker lengths 
as well as the olefins prepared by Hadden and co-workers.
99
 
 Examination of the data confirmed that conformational constraint of the linker with a cis-
cyclopropyl linker led to decreases in activity of the radamide scaffold. It is proposed that the 
flexible linker allows the quinone moiety to adopt an orientation more favorable for binding to 
Hsp90. However, direct comparison of the 4-carbon cyclopropyl radamide analogue to the 
closest related analogue, the cis-olefin, indicates a slight improvement in activity. An interesting 
trans-olefin 
radamide 
 
 
 
16.5 ± 2.7 26.7 ± 1.8 
13 
 
 
 
39.6 ± 1.5 51.2 ± 9.95 
21 
 
 
 
34.9 ± 0.51 36.1 ± 3.2 
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trend is observed when comparing the linker lengths for these analogues. A direct relationship 
exists between linker length and activity, such that as the flexible linker length of radamide is 
increased, the inhibitory concentration decreases and activity improves. A similar trend is 
observed when examining the cyclopropyl-containing scaffolds, such that the 4-carbon linker is 
more active than the 3-carbon linker. This observation is in direct contrast to the trends predicted 
by molecular modeling.  
VII. Conclusions and Future work 
 
 The cis-cyclopropyl radamide analogues although were not as active as predicted but 
allowed for the development of a synthesis able to make modifications to the radamide scaffold. 
The results indicate that the bent conformation seen in the cis-cyclopropyl and cis-olefinic 
analogues appear to be negatively affecting the cellular activity of these compounds. The newly 
developed synthesis allows for the development of various heterocycles and carbocycles to be 
incorporated into the radamide scaffold, which can be applied to further analogue development. 
Substitution of a trans-olefin for a cis olefin would allow for incorporation of trans-cyclopropyl 
analogues, which would more closely mimic the conformation of the flexible linker and 
determine if the extended conformation seen in the crystal structure modifies the cellular activity 
of analogues in this series. The yeast data indicates that 13 shows two-fold selectivity for Hsp90β 
resulting in a first in class compound. Further development of analogues incorporating this cis 
conformation can be used to increase the affinity for Hsp90β and increase the cellular activity. 
The inhibitors developed through this work can be used to elucidate the specific interactions 
between the Hsp90β and various client proteins. 
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Chapter 2 – Experimental 
 
1 
2-(3,5-bis(methoxymethoxy)phenyl)ethanol (1). A solution of  (1.01 grams, 5.54 mmol) in 
THF (25 mL) was cooled to 0°C and treated with diisopropylethylamine (5.8 mL, 33.2 mmol), 
followed by MOMCl (5.6 mL, 33.2 mmol), which was allowed to warm to room temperature 
overnight. The reaction was quenched by the addition of H2O and extracted with EtOAc (3 x 150 
mL). The combined organic fractions were washed with saturated aqueous NaCl, dried 
(Na2SO4), filtered, and concentrated. The residue was purified via column chromatography (SiO2 
20% EtOAc:Hexanes) to afford 1 as a colorless oil (1.088g, 73%): 
1
H NMR (400 MHz, CDCl3) δ 
6.67 (d, J = 2.1 Hz, 1H), 6.64 (d, J = 2.2 Hz, 2H), 5.16 (s, 4H), 3.71 (s, 3H), 3.58 (s, 2H), 3.49 (s, 
6H);  
13
C NMR (126 MHz, CDCl3) δ 171.7, 158.3, 136.1, 110.7, 103.6, 94.5, 77.3, 77.0, 76.8, 
56.1, 52.1, 41.3; IR (film) νmax 2952, 1740, 1597 1460, 1438, 1400, 1325, 1288, 1251, 1215, 
1145, 1083, 1021, 993, 937, 921 844cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C13H18O6Na, 293.1001; found, 293.0993. 
 
2 
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(3,5-bis(methoxymethoxy)phenyl)methanol (2). A solution of 1 (1.06 grams, 3.93 mmol) in 
DCM (20 mL) was cooled to -78°C and treated with fresh 1.0 M DIBAL-H solution (8.7 mL, 
8.65 mmol), this solution was stirred at -78°C for 30 min, then allowed to warm to 0°C. Once the 
reaction was shown to be complete by TLC the reaction was quenched by the addition of 
saturated Sodium Potassium Tartrate solution, extracted with EtOAc (3 x 150 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 50% 
EtOAc:Hexanes) to afford 2  as a pale yellow oil (0.876 g, 92%): 
1
H NMR (400 MHz, CDCl3) δ 
6.64 (t, J = 2.2 Hz, 1H), 6.59 (d, J = 2.2 Hz, 2H), 5.16 (s, 4H), 3.87 (q, J = 6.3 Hz, 2H), 3.49 (s, 
6H), 2.83 (t, J = 6.5 Hz, 2H), 1.46 (t, J = 6.0 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 158.4, 
141.0, 110.3, 102.9, 94.4, 63.4, 56.1, 39.4; IR (film) νmax 3423(br), 2950, 2825, 1595, 1458, 
1440, 1400, 1321, 1288, 1215, 1143, 1081, 1043, 975, 924, 844 cm
-1
; HRMS (ESI+) m/z: [M + 
Na]+ calcd for  C12H18O5Na, 265.1052; found, 265.1040. 
 
 
3 
(2-(2-bromo-3,5-bis(methoxymethoxy)phenyl)ethanol (3). A solution of 2 (0.853 grams, 3.52 
mmol) in CHCl3 (15 mL) at room temperature was treated with N-Bromosuccinimide (0.634 g, 
3.56 mmol) in 3 portions over 5 min. Upon completion of reaction by TLC the reaction was 
quenched by the addition of saturated Na2S2O3 and Na2HCO3 (1:1), extracted with CHCl3 (3 x 
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100 mL). The combined organic fractions were washed with aqueous NaCl, dried (Na2SO4), 
filtered, and concentrated. The residue was purified via column chromatography (SiO2, 30% 
EtOAc:Hexanes) to afford 3  as a yellow oil (1.125g, 99%): 
1
H NMR (400 MHz, CDCl3) δ 6.79 
(d, J = 2.7 Hz, 1H), 6.70 (d, J = 2.7 Hz, 1H), 5.24 (s, 2H), 5.16 (s, 2H), 3.90 (q, J = 6.5 Hz, 2H), 
3.54 (s, 3H), 3.49 (s, 3H), 3.05 (t, J = 6.7 Hz, 2H); 
13
C NMR (126 MHz, CDCl3) δ 157.0, 154.7, 
139.8, 111.9, 107.4, 103.3, 95.2, 94.6, 77.3, 77.0, 76.8, 62.0, 56.5, 56.2, 39.8; IR (film) νmax 
3419(br), 2931, 1585, 1452, 1396, 1317, 1213, 1134, 1085, 1041, 1016, 972, 923, 845 cm
-1
; 
HRMS (ESI+) m/z: [M + Na]+ calcd for  C12H17BrO5Na, 343.0157; found, 343.0160. 
 
 
4 
2-bromo-3,5-bis(methoxymethoxy)phenethyl acetate (4). A solution of 3 (1.03 grams, 3.22 
mmol) in DCM (15 mL) was cooled to 0°C and treated with acetic anhydride (1.0 mL, 9.66 
mmol), 4-dimethylaminopyridine (0.040 g, 0.32 mmol) and triethylamine (1.4 mL, 9.66 mmol) 
which was monitored by TLC. Upon consumption of starting material the reaction was quenched 
by the addition of saturated NH4Cl and extracted with EtOAc (3 x 150 mL). The combined 
organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated. The residue was purified via column chromatography (SiO2 30% EtOAc:Hexanes) 
to afford 4  as a colorless oil (1.06 g, 91%): 
1
H NMR (400 MHz, CDCl3) δ 6.79 (d, J = 2.7 Hz, 
1H), 6.68 (d, J = 2.7 Hz, 1H), 5.24 (s, 2H), 5.15 (s, 2H), 4.31 (t, J = 7.0 Hz, 2H), 3.53 (s, 3H), 
47 
 
3.48 (s, 3H), 3.10 (t, J = 7.0 Hz, 2H), 2.06 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 171.0, 157.0, 
154.6, 139.2, 111.7, 107.4, 103.5, 95.2, 94.6, 77.3, 77.0, 76.8, 63.3, 56.5, 56.1, 35.7, 21.0; IR 
(film) νmax 2956, 1739, 1587, 1454, 1319, 1238, 1154, 1085, 1041, 1018, 923 cm
-1
; HRMS 
(ESI+) m/z: [M + Na]+ calcd for  C14H19BrO6, 385.0263; found, 385.0255. 
 
5 
2-bromo-6-chloro-3,5-bis(methoxymethoxy)phenethyl acetate (5). A solution of 4 (0.916 
grams, 2.53 mmol) in THF (15 mL) cooled to 0°C and was treated with N-Chlorosuccinimide 
(0.610 g, 4.55 mmol) over 5 min. The reaction was stirred at 0°C for 2 h then warmed to room 
temperature and monitored by TLC. Upon consumption of X by TLC the reaction was quenched 
by the addition of saturated Na2S2O3, extracted with EtOAc (3 x 150 mL). The combined organic 
fractions were washed with aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified via column chromatography (SiO2, 30% EtOAc:Hexanes) to afford 5  as a 
yellow oil (0.903 g, 90%): 
1
H NMR (400 MHz, CDCl3) δ 7.02 (s, 1H), 5.24 (d, J = 2.8 Hz, 4H), 
4.31 (t, J = 7.2 Hz, 2H), 3.54 (s, 6H), 3.42 (t, J = 7.2 Hz, 2H), 2.07 (s, 3H). 
13
C NMR (126 MHz, 
CDCl3) δ 171.0, 153.0, 152.7, 136.9, 118.2, 108.9, 103.4, 95.5, 77.3, 77.0, 76.8, 61.9, 56.6, 33.7, 
21.1; IR (film) νmax 3384, 2958, 2829, 2358, 2341, 1739, 1574, 1442, 1323, 1232, 1165, 1109, 
1091, 1064, 1046, 972, 937, 923, 831 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for   
C14H18BrClO6Na, 418.9873; found, 418.9872.  
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6 
2-(2-bromo-6-chloro-3,5-bis(methoxymethoxy)phenyl)ethanol (6). A solution of 5 (1.03 
grams, 2.6 mmol) in a mixture of MeOH and H2O (9:1, 15 mL) was treated with Potassium 
Carbonate (1.10 g, 7.8 mmol). Upon consumption of starting material by TLC the reaction was 
quenched by the addition of H2O, extracted with EtOAc (3 x 150 mL). The combined organic 
fractions were washed with aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified via column chromatography (SiO2, 30% EtOAc:Hexanes) to afford 6 as an 
amorphous colorless solid (0.731g, 79%): 
1
H NMR (400 MHz, CDCl3) δ 7.01 (s, 1H), 5.24 (d, J 
= 2.8 Hz, 4H), 3.89 (dd, J = 13.4, 7.2 Hz, 2H), 3.53 (s, 6H), 3.38 (t, J = 7.3 Hz, 2H); 
13
C NMR 
(126 MHz, CDCl3) δ 153.0, 152.8, 137.4, 118.0, 108.8, 103.1, 95.4, 77.3, 77.0, 76.8, 61.0, 56.6, 
37.7; IR (film) νmax 3222(br), 2958, 2349, 2333, 1577, 1444, 1308, 1242, 1167, 1089, 1045, 
1022, 939, 844 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C12H16BrClO5Na, 376.9767; 
found, 376.9763. 
 
7 
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2-(2-bromo-6-chloro-3,5-bis(methoxymethoxy)phenyl)acetaldehyde (7). A solution of 6 
(0.699 grams, 1.97 mmol) in DCM (10 mL) was treated with Dess-Martin Periodinane (0.996g, 
2.36 mmol) and allowed to react overnight. The reaction was quenched by the addition of a (1:1) 
mixture of saturated aqueous sodium bicarbonate and sodium thiosulfate, extracted with EtOAc 
(3 x 100 mL). The combined organic fractions were dried (Na2SO4), filtered, and concentrated. 
The residue was run through a silica plug (SiO2, 30% EtOAc:Hexanes) to afford 7 as an 
amorphous pale yellow solid (0.688g, 99%): 
1
H NMR (400 MHz, CDCl3) δ 9.74 (s, 1H), 9.74 (s, 
1H), 7.28 (s, 2H), 7.10 (s, 1H), 7.10 (s, 1H), 5.26 (d, J = 2.4 Hz, 5H), 5.26 (d, J = 2.4 Hz, 5H), 
4.24 (d, J = 1.1 Hz, 2H), 4.24 (d, J = 1.1 Hz, 2H), 3.54 (s, 7H), 3.54 (s, 7H); 
13
C NMR (126 
MHz, CDCl3) δ 197.0, 153.2, 152.9, 133.0, 118.2, 108.8, 103.8, 95.5, 77.3, 77.0, 76.8, 56.6, 
48.9; IR (film) νmax 2956, 2830, 2725, 1724, 1593, 1471, 1433, 1400, 1315, 1296, 1263, 1222, 
1153, 1108, 1043, 968, 937, 827 756, 715 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C12H14BrClO5Na, 374.9611; found, 374.9603. 
 
 
8 
(Z)-4-(2-bromo-6-chloro-3,5-bis(methoxymethoxy)phenyl)but-2-en-1-ol (8). A solution of 
18-crown-6  (2.61 grams, 9.9 mmol) in THF (50 mL) was added methyl 2-(bis(2,2,2-
trifluoroethoxy)phosphoryl)acetate (0.47 mL, 2.2 mmol) and cooled to -78°C followed by 
treatment of a 0.5 M solution of KHMDS in toluene (5.0 mL, 2.5 mmol) and stirred for 45 min. 
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A separate solution of the crude aldehyde (0.699 grams, 1.98 mmol) was dissolved in THF (10 
mL) and cooled to -78°C and added dropwise to first solution and stirred for 30 min at -78°C. 
The reaction was quenched by the addition of saturated aqueous ammonium chloride and 
extracted with EtOAc (3x150mL). The combined organic fractions were washed with aqueous 
NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via column 
chromatography (SiO2, 30% EtOAc:Hexanes) to afford crude α,β ester as a yellow oil (0.683g, 
85%): 
1
H NMR (400 MHz, CDCl3) δ 7.02 (s, 1H), 6.07 (dt, J = 11.4, 6.3 Hz, 1H), 5.93 (dt, J = 
11.4, 2.2 Hz, 1H), 5.24 (s, 4H), 4.47 (dd, J = 6.3, 2.2 Hz, 2H), 3.80 (s, 3H), 3.53 (s, 6H);  
A solution of the α,β ester 7a (0.624 grams, 1.53 mmol) in THF (10 mL) was cooled to -
78°C and treated dropwise with fresh 1.0M solution of DIBAL-H in THF (3.4 mL, 3.4 mmol), 
this solution was stirred at -78°C for 30 min, then allowed to warm to 0°C. Once the reaction 
was shown to be complete by TLC the reaction was quenched by the addition of saturated 
aqueous sodium potassium tartrate solution, extracted with EtOAc (3 x 100 mL). The combined 
organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated. The residue was purified via column chromatography (SiO2 40% EtOAc:Hexanes) 
to afford 8 as a pale yellow oil (0.498 g, 86%): 
1
H NMR (400 MHz, CDCl3) δ 7.00 (s, 1H), 5.73 
(ddd, J = 11.0, 5.5, 3.5 Hz, 1H), 5.53 (dd, J = 6.7, 5.4 Hz, 1H), 5.24 (d, J = 2.5 Hz, 4H), 4.44 (t, J 
= 6.0 Hz, 2H), 3.86 (dd, J = 7.1, 1.5 Hz, 2H), 3.53 (s, 7H), 1.38 (t, J = 5.9 Hz, 1H); 
13
C NMR 
(126 MHz, CDCl3) δ 152.8, 139.0, 129.9, 127.3, 117.5, 108.3, 102.9, 95.5, 63.5, 61.0, 59.0, 56.6, 
33.3; IR (film) νmax 3404, 2931, 2829, 2347, 1573, 1442, 1400, 1321, 1222, 1153, 1089, 1037, 
929, 723 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C14H18BrClO5Na, 402.9924; found, 
402.9915. 
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9 
((1S,2S)-2-(2-bromo-6-chloro-3,5-bis(methoxymethoxy)benzyl)cyclopropyl)methanol (9). A 
solution of 8 (0.442 grams, 1.16 mmol) in DCM (5 mL) was added (4R,5R)-2-Butyl-N,N,N',N'-
tetramethyl-1,3,2-dioxaborolane-4,5-dicarboxamide (0.32 mL, 1.22 mmol) and stirred for 30 
min. A second solution of 1.1M ZnEt2 (4.75 mL, 5.22 mmol) in Toluene was added to DCM (10 
mL) at 0°C was added DME (0.75 mL, 5.22 mmol) followed by dropwise addition of 
Diiodomethane (0.85 mL, 10.44 mmol) and stirred for 15 minutes. Solution containing 8 was 
added dropwise to the second solution, warmed to room temperature and react overnight. The 
reaction was quenched by addition of saturated ammonium chloride solution and extracted with 
EtOAc (3 x 100 mL). The combined organic fractions were washed with saturated aqueous 
NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via column 
chromatography (SiO2 40% EtOAc:Hexanes) to afford 9 as a colorless oil (0.436 g, 95%): [α]D
25
 
= -25.33  (c = 0.198 CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 7.00 (s, 1H), 5.25 (d, J = 2.9 Hz, 
4H), 3.67 (dd, J = 5.8, 3.6 Hz, 1H), 3.58 (dd, J = 5.7, 3.6 Hz, 1H), 3.54 (d, J = 3.5 Hz, 6H), 3.38 
(s, 1H), 2.94 (dd, J = 13.6, 10.0 Hz, 1H), 1.41 (s, 1H), 1.35 (d, J = 4.2 Hz, 1H), 1.29 – 1.18 (m, 
1H), 0.69 (dt, J = 8.4, 4.2 Hz, 1H), 0.56 – 0.49 (m, 1H); 
13
C NMR (126 MHz, CDCl3) δ 153.0, 
141.4, 117.5, 108.4, 102.8, 95.5, 71.9, 70.6, 63.5, 59.1, 56.6, 32.5, 18.5, 15.1, 9.2; IR (film) 
νmax 3379(br), 2931, 2391, 1573, 1440, 1400, 1321, 1222, 1153, 1091, 1035, 929 cm
-1
; HRMS 
(ESI+) m/z: [M + Na]+ calcd for  C15H20BrClO5Na, 417.0080; found, 417.0077. 
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10 
Methyl-3-chloro-2-(((1S,2S)-2-(hydroxymethyl)cyclopropyl)methyl)-4,6-
bis(methoxymethoxy)benzoate (10). A solution of 9 (0.453 grams, 1.15 mmol) in DMF (6 mL) 
was added Imidazole (0.248 grams, 3.45 mmol) followed by addition of tert-
butylchlorodimethylsilane (0.530 grams, 3.45 mmol) at room temperature and stirred overnight. 
The reaction was quenched with H2O and extracted with EtOAc (3 x 50 mL). The combined 
organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated to produce silyl protected alcohol (~99% yield). This residue carried on without 
further purification.  
A solution of the residue (0.562 grams, 1.1 mmol) in THF (6 mL) was cooled to -78°C 
and treated by dropwise addition of n-BuLi (0.5 mL, 1.22 mmol) and stirred for 20 min at -78°C 
and added methyl chloroformate (0.15 mL, 1.7 mmol) dropwise at -78°C for 30 min. It was then 
warmed to room temperature and stirred for 30 min. The reaction was then quenched by addition 
of H2O and extracted with EtOAc (3 x 50 mL). The combined organic fractions were washed 
with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated to produce desired 
benzoic ester (0.19 grams, 35%). This residue carried on without further purification.  
A solution of this residue (0.19 grams, 0.39 mmol) in THF (3 mL) was added 
tetrabutylammonium fluoride (1.2 mL, 1.17 mmol) at room temperature and stirred until reaction 
was shown to be complete by TLC. The reaction was quenched by addition of saturated 
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ammonium chloride and extracted with EtOAc (3 x 50 mL). The combined organic fractions 
were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified via column chromatography (SiO2 40% EtOAc:Hexanes) to afford 10  over 
three steps as a colorless oil (0.105 g, 23%): [α]D
25
 = -25.38 (c=0.0524 CHCl3); 
1
H NMR (400 
MHz, CDCl3) δ 6.95 (s, 1H), 5.27 (s, 2H), 5.17 (s, 2H), 3.91 (s, 3H), 3.83 (d, J = 5.1 Hz, 1H), 
3.65 – 3.56 (m, 1H), 3.53 (s, 3H), 3.49 (s, 3H), 3.12 (dd, J = 14.0, 4.2 Hz, 1H), 2.57 (dd, J = 
14.0, 9.1 Hz, 1H), 1.50 (s, 1H), 1.31 – 1.15 (m, 2H), 0.71 (td, J = 8.5, 5.0 Hz, 1H), 0.31 (q, J = 
5.4 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 168.1, 154.5, 153.3, 139.3, 119.7, 117.0, 101.7, 
95.2, 95.1, 63.2, 56.5, 56.4, 52.5, 29.6, 18.7, 15.8, 9.5; IR (film) νmax 2952, 2829, 2358, 2341, 
1728, 1593, 1579, 1467, 1433, 1398, 1321, 1261, 1220, 1153, 1107, 1093, 1037, 968, 931, 827, 
784, 713 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C17H23ClO7Na, 397.1030; found, 
387.1037. 
 
11 
(1S,2S)-2-(2-chloro-6-(methoxycarbonyl)-3,5-
bis(methoxymethoxy)benzyl)cyclopropanecarboxylic acid (11). A solution of 10 (0.08 grams, 
0.214 mmol) in DCM (2 mL) was cooled to 0°C and treated with Dess-Martin Periodinane 
(0.111 grams, 0.26 mmol), which was stirred at 0°C for 1 hr then allowed to warm to room 
temperature and stirred for 3 hrs. The reaction was quenched by the addition of a (1:1) mixture of 
saturated aqueous sodium bicarbonate and sodium thiosulfate, allowed to stir for 30 min, and 
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extracted with EtOAc (3 x 30 mL). The combined organic fractions were washed with saturated 
aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was used without further 
purification. 
 The residue was dissolved in t-BuOH (1.0 mL) and 2-methyl-2-butene (0.70 mL, 6.12 
mmol), while a separate solution of 80% sodium chlorite (0.133 grams, 1.16 mmol)  in a 
buffered aqueous solution of sodium phosphate monobasic (0.189 grams, 1.53 mmol)  in H2O (3 
mL).  The oxidizing solution was added dropwise to the solution containing the aldehyde and 
allowed to react for 12 hrs. This reaction was diluted with saturated aqueous NaH2PO4 and 
extracted with DCM (3 x 50 mL), dried (Na2SO4), filtered, and concentrated to afford 11  as a 
pale yellow oil (0.68 g, 82%): [α]D
25
 = -30.23 (c= 0.030 CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 
6.97 (s, 1H), 5.27 (s, 2H), 5.17 (s, 2H), 3.93 (s, 3H), 3.53 (s, 3H), 3.49 (s, 3H), 3.11 (dd, J = 
14.1, 3.8 Hz, 1H), 2.92 (dd, J = 14.0, 9.6 Hz, 1H), 1.80 (td, J = 8.2, 5.5 Hz, 1H), 1.76 – 1.66 (m, 
1H), 1.26 (m, 1H), 1.09 (td, J = 8.3, 4.8 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 178.9, 167.7, 
154.4, 153.2, 138.3, 120.4, 117.2, 101.9, 95.1, 56.5, 52.5, 28.6, 21.6, 18.5, 14.7; IR (film) νmax 
2952, 2850, 2358, 2341, 1731, 1693, 1593, 1467, 1433, 1400, 1321, 1296, 1263, 1220, 1191, 
1155, 1107, 1091, 1041, 968, 927, 713 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C17H21ClO8Na, 411.0823; found, 411.0830. 
 
12 
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Methyl-3-chloro-2-(((1S,2S)-2-((4-methoxy-2,5-
bis(methoxymethoxy)phenyl)carbamoyl)cyclopropyl)methyl)-4,6-
bis(methoxymethoxy)benzoate (12). A solution of 11 (18 mg, 0.046 mmol) in (0.5 mL) DMF 
was added to a premade solution of (12 mg, 0.046 mmol) of 4-methoxy-2,5-
bis(methoxymethoxy)aniline
101
 in (0.5 mL) of DMF and cooled to 0°C followed by the dropwise 
addition of diisopropylethyl amine (16 µL, 0.092 mmol)  and COMU (20 mg, 0.046 mmol). This 
was stirred for 1 hr at 0°C, then allowed to warm to room temperature and stirred for an 
additional 2 hrs. The solution was diluted with EtOAc (50 mL) and washed with 1 N HCl (10 
mL), saturated aqueous NaHCO3 (10 mL), and saturated aqueous NaCl (3 x 30 mL). The organic 
fraction was dried (Na2SO4), filtered, and concentrated. The residue was purified via column 
chromatography (SiO2 45% EtOAc:Hexanes) to afford 11 as a yellow oil (22.4 mg, 79%): [α]D
25
 
= -18.39 (c=0.0112 CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 8.27 (s, 1H), 7.84 (s, 1H), 6.95 (s, 
1H), 6.83 (s, 1H), 5.26 (s, 2H), 5.20 (d, J = 5.7 Hz, 5H), 5.16 (d, J = 0.8 Hz, 2H), 3.95 (s, 3H), 
3.86 (s, 3H), 3.58 – 3.51 (m, 9H), 3.48 (s, 3H), 3.02 (ddd, J = 23.0, 14.1, 5.9 Hz, 2H), 1.69 (t, J = 
6.8 Hz, 1H), 1.62 – 1.54 (m, 1H), 1.41 – 1.32 (m, 1H), 1.00 (td, J = 8.1, 4.7 Hz, 1H); 
13
C NMR 
(126 MHz, CDCl3) δ 169.0, 167.7, 154.3, 153.1, 146.1, 141.4, 140.8, 139.0, 122.1, 120.4, 117.2, 
110.8, 101.8, 101.0, 96.3, 95.2, 56.4, 52.6, 28.7, 21.9, 20.6, 12.6; IR (film) νmax 3350, 2952, 
2925, 2829, 1730, 1674, 1593, 1523, 1450, 1392, 1321, 1263, 1218, 1141, 995, 970, 929, 831, 
754 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C28H36ClNO12Na, 636.1824; found, 
636.1804. 
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13 
Methyl-3-chloro-2-(((1S,2S)-2-((2,5-dihydroxy-4-
methoxyphenyl)carbamoyl)cyclopropyl)methyl)-4,6-dihydroxybenzoate (13).  12 (19 mg, 
0.031 mmol) was dissolved in a 4 N solution of HCl in Dioxanes (1.5 mL) and stirred for 10 min. 
The reaction was quenched by addition of H2O, extracted with EtOAc (3 x 25 mL) The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 4% 
MeOH:CHCl3) to afford 13  as a pale yellow oil (13.4 mg, 98%): [α]D
25
 = -6.17 (c = 0.007 
CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 11.33 (s, 1H), 8.66 (s, 1H), 7.54 (s, 1H), 6.61 (s, 1H), 
6.60 (s, 1H), 6.53 (s, 1H), 6.15 (s, 1H), 5.28 (s, 1H), 3.99 (s, 3H), 3.88 (s, 3H), 1.80 (td, J = 8.2, 
5.3 Hz, 1H), 1.57 – 1.50 (m, 1H), 1.40 (dt, J = 6.9, 5.1 Hz, 1H), 1.09 (td, J = 8.3, 4.6 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 171.7, 171.0, 170.8, 163.0, 156.2, 145.7, 142.7, 142.4, 139.1, 
118.0, 107.8, 107.0, 103.3, 102.8, 56.1, 52.5, 29.1, 22.2, 21.1, 13.2; IR (film) νmax 3018, 2399, 
1658, 1604, 1496, 1434, 1319, 1238, 1207, 1172, 1122, 754, 669 cm
-1
; HRMS (ESI+) m/z: [M + 
Na]+ calcd for  C20H20ClNO8Na, 460.0775; found, 460.0757. 
 
15 
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Methyl 2,4-bis(methoxymethoxy)-6-methylbenzoate (15).  A solution of methyl 14
101
 (4.54 
grams, 10.2 mmol) in THF (50 mL) was treated with a 1.0 M solution of tetrabutylammonium 
fluoride (30 mL, 30 mmol) and allowed to stir for 12 hours. The reaction was quenched by the 
addition of saturated aqueous ammonium chloride and extracted with EtOAc (3 x 150 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 30% 
EtOAc:Hexanes) to afford crude product as a colorless oil (2.15g, 97%) 
The crude product (2.15 grams, 9.95 mmol) in THF (50 mL) was cooled to 0°C and 
treated dropwise with diisopropylethyl amine (7.0 mL, 39.8 mmol) followed by the addition of 
MOMCl (6.75 mL, 39.8 mmol) and allowed to warm to room temperature overnight. The 
reaction was quenched by the addition of H2O and extracted with EtOAc (3 x 150mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 20% 
EtOAc:Hexanes) to afford 14 over two steps as a colorless oil (2.679g, 87%): 
1
H NMR (400 
MHz, CDCl3) δ 6.91 (s, 1H), 5.26 (s, 2H), 5.16 (s, 2H), 3.92 (s, 3H), 3.52 (s, 3H), 3.48 (s, 3H), 
2.33 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 167.9, 154.1, 152.9, 135.3, 120.0, 117.4, 101.4, 
95.1, 56.5, 56.3, 52.4, 17.6; IR (film) νmax 3419, 2952, 2347, 1731, 1595, 1477, 1433, 1400, 
1321, 1261, 1220, 1135, 1108, 1041, 962, 931, 827, 713 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ 
calcd for  C13H17ClO6Na, 327.0611; found, 327.0599. 
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16 
methyl 2-(but-3-en-1-yl)-3-chloro-4,6-bis(methoxymethoxy)benzoate (16).  A solution of 14 
(1.27 grams, 4.19 mmol) in THF (25 mL) was treated with a fresh 1.0M solution of Lithium 
Diisopropylamine (4.6 mL, 4.6 mmol) at -78°C and stirred for 5 min. followed by the addition of 
Allyl Bromide (0.55 mL, 6.3 mmol) at -78°C and warmed to room temperature. The reaction was 
quenched by the addition of H2O and extracted with EtOAc (3 x 100 mL). The combined organic 
fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. 
The residue was purified via column chromatography (SiO2 30% EtOAc:Hexanes) to afford 15 
as a colorless oil (1.346 g, 93%): 
1
H NMR (500 MHz, CDCl3) δ 6.93 (s, 1H), 5.98 – 5.82 (m, 
1H), 5.27 (s, 2H), 5.17 (s, 2H), 5.15 – 4.95 (m, 2H), 3.91 (s, 3H), 3.53 (s, 3H), 3.49 (s, 3H), 2.86 
– 2.70 (m, 2H), 2.35 (ddd, J = 11.0, 7.9, 6.7 Hz, 2H); 
13
C NMR (126 MHz, CDCl3) δ 167.8, 
154.4, 153.1, 138.9, 137.7, 119.8, 116.9, 115.0, 101.6, 95.1, 77.3, 77.0, 76.8, 56.5, 56.4, 52.3, 
33.4, 31.5; IR (film) νmax 2952, 2829, 2359, 1731, 1593, 1471, 1433, 1398, 1319, 1261, 1220, 
1155, 1108, 1093, 1045, 962, 937, 921, 831, 713 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C16H21ClO6Na, 367.0924; found, 367.0910. 
 
17 
methyl 3-chloro-4,6-bis(methoxymethoxy)-2-(3-oxopropyl)benzoate (17). A solution of 15 
(1.57 grams, 4.56 mmol) in a mixture of THF:H2O (1.5 : 1.0, 30 : 10 mL) was treated with 
Osmium tetraoxide (0.48 mL, 0.3%/wt) and Sodium metaperiodide (2.94 grams, 13.7 mmol) and 
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allowed to react overnight. The reaction was diluted with H2O and extracted EtOAc (3 x 150 
mL). The combined organic fractions were washed with aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2, 20% 
EtOAc:Hexanes) to afford 16 as a yellow oil (1.018 g, 64%): 
1
H NMR (500 MHz, CDCl3) δ 9.84 
(s, 1H), 6.96 (s, 1H), 5.27 (s, 2H), 5.17 (s, 2H), 3.90 (s, 3H), 3.53 (s, 3H), 3.49 (s, 3H), 2.99 (dd, 
J = 9.3, 6.6 Hz, 2H), 2.82 (dd, J = 9.3, 6.5 Hz, 2H); 
13
C NMR (126 MHz, CDCl3) δ 200.8, 167.5, 
154.5, 153.4, 137.6, 119.7, 116.7, 101.9, 95.1, 56.6, 56.4, 52.5, 43.3, 24.4; IR (film) νmax 2952, 
2906, 2829, 1724, 1593, 1473, 1433, 1400, 1321, 1298, 1263, 1223, 1155, 1107, 1094, 1043, 
968, 939, 827, 756, 713 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C15H19ClO7Na, 
369.0717; found, 369.0724. 
 
 
18 
(Z)-methyl 3-chloro-2-(5-methoxy-5-oxopent-3-en-1-yl)-4,6-bis(methoxymethoxy)benzoate 
(18). A solution of 18-crown-6 (3.80 grams, 14.3 mmol) in THF (50 mL) was added methyl 2-
(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (0.64 mL, 3.0 mmol) and cooled to -78°C followed 
by treatment with a 0.5M solution of KHMDS in toluene (6.3 mL, 3.15 mmol) and stirred for 45 
min. A separate solution of 16 (0.988 grams, 2.86 mmol) was dissolved in THF (10 mL) and 
cooled to -78°C and added dropwise to the first solution and stirred for 30 min at -78°C. The 
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reaction was quenched by the addition of saturated aqueous ammonium chloride and extracted 
with EtOAc (3x150mL). The combined organic fractions were washed with aqueous NaCl, dried 
(Na2SO4), filtered, and concentrated. The residue was run through a plug (SiO2, 20% 
EtOAc:Hexanes) to afford crude cis-ester as a pale yellow oil as a yellow oil (1.073g, 93%):  
1
H 
NMR (400 MHz, CDCl3) δ 6.94 (s, 1H), 6.26 (dt, J = 11.5, 7.3 Hz, 1H), 5.81 (dt, J = 11.5, 1.5 
Hz, 1H), 5.26 (s, 2H), 5.16 (s, 2H), 3.91 (s, 3H), 3.72 (s, 3H), 3.53 (s, 3H), 3.48 (s, 3H), 2.96 (dd, 
J = 9.7, 5.7 Hz, 2H), 2.89 – 2.76 (m, 2H). 
A solution of crude cis-ester (0.061 grams, 0.15 mmol) in DCM (1.5 mL) was cooled to -
78°C and treated with fresh 1.0M solution of DIBAL-H (0.25 mL, 0.23 mmol), this solution was 
stirred at -78°C and monitored by TLC. Once the reaction was shown to be complete by TLC the 
reaction was quenched by the addition of MeOH at -78°C and allowed to warm to room 
temperature. Once the reaction was warmed to room temperature saturated sodium potassium 
tartrate was added to the stirring solution and extracted with EtOAc (3 x 30 mL). The combined 
organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated. The residue was purified via column chromatography (SiO2 2% MeOH:DCM) to 
afford crude alcohol as a pale yellow oil (0.024g, 43%): 
1
H NMR (400 MHz, CDCl3) δ 6.93 (s, 
1H), 5.75 – 5.53 (m, 2H), 5.26 (s, 2H), 5.16 (s, 2H), 4.18 (d, J = 5.9 Hz, 2H), 3.91 (d, J = 3.2 Hz, 
3H), 3.53 (s, 3H), 3.48 (s, 3H), 2.82 – 2.66 (m, 2H), 2.50 – 2.28 (m, 2H), 1.47 (s, 1H). 
A solution of crude alcohol (0.104 grams, 0.28 mmol) in DCM (1.5 mL) was added 
(4R,5R)-2-Butyl-N,N,N',N'-tetramethyl-1,3,2-dioxaborolane-4,5-dicarboxamide (0.09 mL, 0.30 
mmol) and stirred for 30 min. A second solution of ZnEt2 (1.2 mL, 1.26 mmol) in DCM (2 mL) 
at 0°C was added DME (0.19 mL, 1.26 mmol) followed by dropwise addition of Diiodomethane 
(0.21 mL, 2.52 mmol) and stirred for 15 minutes. The solution containing the alcohol was added 
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dropwise to the solution containing the carbenoid, warmed to room temperature and allowed to 
react overnight. The reaction was quenched by addition of saturated ammonium chloride solution 
and extracted with EtOAc (3 x 150 mL). The combined organic fractions were washed with 
saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via 
column chromatography (SiO2 2% MeOH:DCM) to afford 18 (0.083g, 76%) as a colorless oil: 
[α]D
25
 = -15.89 (c = 0.041 CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 6.92 (s, 1H), 5.26 (s, 2H), 5.16 
(s, 2H), 3.92 (s, 3H), 3.72 (dd, J = 11.4, 6.7 Hz, 1H), 3.59 – 3.54 (m, 1H), 3.52 (s, 3H), 3.48 (s, 
3H), 2.81 (ddd, J = 9.6, 6.4, 2.9 Hz, 2H), 1.81 – 1.54 (m, 3H), 1.18 (ddd, J = 8.4, 6.6, 5.7 Hz, 
1H), 1.01 – 0.92 (m, 1H), 0.75 (td, J = 8.4, 4.7 Hz, 1H), 0.01 (dd, J = 10.4, 5.4 Hz, 1H); 
13
C 
NMR (126 MHz, CDCl3) δ 168.1, 154.4, 153.1, 139.2, 119.6, 116.8, 101.5, 95.1, 63.0, 56.5, 
56.3, 52.5, 32.4, 28.5, 18.6, 16.2, 9.0; IR (film) νmax 2950, 2829, 2362, 1730, 1591, 1467, 1433, 
1400, 1319, 1263, 1220, 1184, 1153, 1108, 1093, 1045, 962, 933, 831, 713 cm
-1
; HRMS (ESI+) 
m/z: [M + Na]+ calcd for  C18H25ClO7Na, 411.1187; found, 411.1182. 
 
 
19 
(1S,2R)-2-(2-chloro-6-(methoxycarbonyl)-3,5-
bis(methoxymethoxy)phenethyl)cyclopropanecarboxylic acid (19). A solution of 18 (0.088 
grams, 0.226 mmol) in DCM (2 mL) was cooled to 0°C and treated with (0.114 grams, 0.27 
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mmol) Dess-Martin Periodinane, which was stirred at 0°C for 1 hr then allowed to warm to room 
temperature and stirred for 3 hrs. The reaction was quenched by the addition of a (1:1) solution 
of saturated Sodium Bicarbonate and saturated Sodium Thiosulfate and allowed to stir for 30 min 
and extracted with EtOAc (3 x 50 mL). The combined organic fractions were washed with 
saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via 
column chromatography (SiO2 40% EtOAc:Hexanes) to afford crude aldehyde as a colorless oil 
(0.059g, 68%). 
 The crude aldehyde was dissolved in t-BuOH (1 mL) and treated with of 2-methyl-2-
butene (0.65 mL, 5.51 mmol), while a separate solution of sodium chlorite (0.118 grams, 1.04 
mmol) in a buffered solution of made of  sodium phosphate monobasic (0.169 grams, 1.38 
mmol) in H2O (3 mL).  The oxidizing solution was added dropwise to the solution containing 
aldehyde and allowed to react for 12 hrs. This reaction was diluted with saturated aqueous 
NaH2PO4 and extracted with DCM (3 x 50 mL), dried (Na2SO4), filtered, and concentrated to 
afford 19 as a pale yellow oil (0.58 g, 94%): [α]D
25
 = -11.53 (c = 0.0189 CHCl3); 
1
H NMR (500 
MHz, CDCl3) δ 6.83 (s, 1H), 5.16 (d, J = 2.4 Hz, 2H), 5.07 (s, 2H), 3.82 (s, 3H), 3.44 (s, 3H), 
3.39 (s, 3H), 2.80 – 2.65 (m, 2H), 1.82 (td, J = 8.6, 1.5 Hz, 2H), 1.67 – 1.59 (m, 1H), 1.32 – 1.25 
(m, 1H), 1.01 (td, J = 8.1, 4.5 Hz, 1H), 0.90 (dt, J = 7.3, 5.1 Hz, 1H); 
13
C NMR (126 MHz, 
CDCl3) δ 178.3, 167.8, 154.3, 153.1, 138.7, 120.1, 117.2, 102.0, 95.3, 95.1, 56.5, 56.3, 52.4, 
31.4, 26.6, 22.7, 18.2, 14.1; IR (film) νmax 2952, 2831, 1731, 1695, 1591, 1456, 1433, 1398, 
1319, 1259, 1220, 1182, 1155, 1107, 1091, 1043, 962, 939, 923, 831, 713 cm
-1
; HRMS (ESI+) 
m/z: [M + Na]+ calcd for  C18H23ClO8Na, 425.0979; found, 425.0972. 
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20 
Methyl-3-chloro-2-(2-((1R,2S)-2-((4-methoxy-2,5-
bis(methoxymethoxy)phenyl)carbamoyl)cyclopropyl)ethyl)-4,6-
bis(methoxymethoxy)benzoate (20). A solution of 19 (0.015 grams, 0.037 mmol) in DMF (0.5 
mL) was added to a premade solution of 4-methoxy-2,5-bis(methoxymethoxy)aniline (0.010 
grams, 0.037 mmol) in DMF (0.5 mL) and cooled to 0°C followed by the dropwise addition of 
diisopropylethyl amine (0.013 mL, 0.075 mmol)  and COMU (0.016 grams, 0.037 mmol). This 
was stirred for 1 hr at 0°C, then allowed to warm to room temperature and stirred for an 
additional 2 hrs. The solution was diluted with EtOAc (50 mL) and washed with 1 N HCl, 
saturated aqueous NaHCO3, and saturated aqueous NaCl. The organic fraction was dried 
(Na2SO4), filtered, and concentrated. The residue was purified via column chromatography (SiO2 
2% MeOH:DCM) to afford 20 (0.0195 g, 84%) as a yellow oil: [α]D
25
 = -17.72 (c = 0.010 
CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 8.14 (s, 1H), 7.69 (s, 1H), 6.78 (s, 1H), 6.72 (s, 1H), 5.23 
– 4.94 (m, 8H), 3.88 – 3.73 (m, 6H), 3.44 (t, J = 4.0 Hz, 6H), 3.41 (s, 3H), 3.38 (s, 3H), 2.77 – 
2.66 (m, 2H), 1.81 (ddd, J = 15.5, 12.9, 7.6 Hz, 2H), 1.63 – 1.55 (m, 2H), 1.05 – 0.98 (m, 1H), 
0.96 – 0.88 (m, 1H); 
13
C NMR (126 MHz, CDCl3) δ 168.9, 167.8, 154.3, 153.0, 146.0, 141.3, 
140.8, 139.0, 122.2, 120.0, 117.1, 110.7, 101.5, 101.0, 96.3, 95.1, 56.4, 52.4, 31.5, 29.8, 26.7, 
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21.7, 21.4, 11.8; IR (film) νmax 2952, 2852, 1728, 1677, 1591, 1523, 1469, 1392, 1319, 1265, 
1213, 1186, 1151, 1108, 1081, 1043, 991, 970, 923, 869, 833, 713 cm
-1
; HRMS (ESI+) m/z: [M 
+ Na]+ calcd for  C29H38ClO12Na, 650.1980; found, 650.1960. 
 
21 
methyl3-chloro-2-(2-((1R,2S)-2-((2,5-dihydroxy-4-
methoxyphenyl)carbamoyl)cyclopropyl)ethyl)-4,6-dihydroxybenzoate (21).  20 (0.017 
grams, 0.027 mmol) was dissolved in a 4 N solution of HCl in Dioxanes (1.5 mL) and stirred for 
10 min. The reaction was quenched by addition of H2O, extracted with EtOAc (3 x 25 mL) The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 4% 
MeOH:CHCl3) to afford 21 (0.0084g, 69%) as a pale yellow oil: [α]D
25
 = -1.43 (c = 0.0042 
CHCl3); 
1
H NMR (400 MHz, CDCl3) δ 11.40 (s, 1H), 8.67 (s, 1H), 7.45 (s, 1H), 6.58 (s, 1H), 
6.53 (s, 1H), 6.49 (s, 1H), 6.14 (s, 1H), 5.26 (s, 1H), 3.96 (s, 3H), 3.86 (s, 3H), 3.25 – 3.17 (m, 
2H), 1.95 – 1.84 (m, 2H), 1.76 (td, J = 7.9, 5.3 Hz, 1H), 1.41 (dt, J = 15.7, 7.9 Hz, 1H), 1.20 – 
1.12 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 171.7, 171.0, 163.0, 156.1, 145.6, 142.8, 142.6, 
139.0, 118.1, 118.0, 107.7, 103.3, 102.5, 56.1, 52.4, 32.5, 26.6, 22.4, 20.8, 12.8; IR (film) νmax 
3352, 2952, 2358, 2341, 1654, 1602, 1496, 1436, 1319, 1240, 1205, 1172, 1120, 948, 873, 844, 
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804, 754, 721 cm
-1
; HRMS (ESI+) m/z: [2M + Na]+ calcd for  C42H44Cl2N2O16Na, 925.1966; 
found, 925.1924. 
Anti-proliferation Assay 
 MCF-7 and SKBr3 cells were maintained in a 1:1 mixture of Advanved DMEM/F12 
(Gibco) supplemented with non-essential amino acids, L-glutamine (2 mM), streptomycin (500 
µg/mL), penicillin (100 units/mL), and 10% FBS. Cells were grown to confluence in a 
humidified atmosphere (37°C, 5% CO2), seeded (2000/well, 100 µL) in 96-well plates, and 
allowed to attach overnight. Each compound or GDA at varying concentrations in DMSO (1% 
DMSO final concentration) was added, and cells were returned to the incubator for 72 hours. At 
72 hours, the number of viable cells was determined using an MTS/PMS cell proliferation kit 
(Promega) per the manufacturer’s instructions. Cells incubated in 1% DMSO were used as 100% 
proliferation, and values were adjusted accordingly. IC50 values were calculated from separate 
experiments performed in triplicate using GraphPad Prism.  
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Chapter 3 
 Development of (-)-Epigallocatechin 3-gallate (EGCG) as an Hsp90 Inhibitor 
I. Introduction 
 
 Green tea, the second most widely consumed beverage worldwide, contains a class of 
polyphenolic catechins that account for approximately 40% of the total dry weight of green tea 
leaves. (-)-Epigallocatechin 3-gallate (EGCG) shown in 
figure 20 is the main polyphenolic catechin within this 
class, which, because of its anti-oxidative properties, has 
been considered as a potential treatment for several 
diseases.
122-125
 Moreover, anti-tumor properties have been 
associated with EGCG. Although the pathway through 
which EGCG exerts its anti-cancer activity is unknown, 
cyclin dependant kinases, mitogen-activated protein 
kinase (MAPK), matrix metalloproteinases, proteosomes, DNA methyltransferase, BCL-2, 
receptor tyrosine kinase (RTK) pathways, aryl hydrocarbon receptor (AhR) and Hsp90 have 
been implicated as potential targets for EGCG.
90,126
  
 In an effort to elucidate the mechanism through which EGCG exerts its activity, its 
interaction with the aryl hydrocarbon receptor (AhR) was identified. EGCG was believed to bind 
the AhR and act as an antagonist, thereby preventing tumor progression. However, this activity 
was subsequently attributed to the ability of EGCG to bind Hsp90.  
 
Figure 20 - Structure of EGCG 
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Knowledge that EGCG binds Hsp90 and subsequent studies identified this interaction to 
be specific to the C-terminus and were essential in guiding the design of Hsp90-specific 
inhibitors based upon the EGCG scaffold. Computer modeling of EGCG using a model of the 
Hsp90 C-terminal nucleotide binding site allowed the potential identification of key substitutions 
for explorations aimed at increasing its affinity for Hsp90.
127
 Structural similarities between 
EGCG and the KU series of novobiocin analogues allowed for the incorporation of previously 
determined SAR into the development of EGCG-based inhibitors.  
II. EGCG as an AhR Antagonist 
 
 AhR is a ligand-activated transcription factor, which, upon activation by flavonoids, 
environmental contaminants or indoles, mediates the toxic effects of these molecules. AhR is 
found in a dormant state in the cellular cytoplasm and associates with two Hsp90 homodimers, 
XAP2, and p23.
128
 Upon ligand binding, a cascade occurs, including translocation to the nucleus, 
release of the Hsp90 homodimers, and dimerization with aryl hyrdocarbon receptor nuclear 
translocator (AHRT).
88
 This AhR-AHRT complex binds consensus sequences located in the 
promoter regions of responsive genes to modulate transcription (Figure 21). The mechanism of 
forming the intact complex and translocation into the cell nucleus are not well characterized, but 
experiments using 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) have resulted in the proposed 
mechanism described in Figure 2. TCDD-induced CYP1A1 gene expression studies indicated 
that the TCDD-AHRT complex enhances translation through specific interactions with genomic 
sequences, resulting in increased CYP1A1 expression levels.
129
 Subsequent studies using Hepa 
1c1c7 cells, which are deficient in AHRT, did not show increased levels of CYP1A1 and 
confirmed the essential role of AHRT in mediating the observed changes in expression. 
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Figure 21 - Mechanism of AhR-mediated transcription 
 
Figure 22 - Antagonists of AhR: TCDD (left), 3M4NF (center), and DIM (right) 
 
 Hsp90 has been implicated as an essential component in this pathway, specifically 
mediating proper folding and stabilizing the intact complex. Additional studies have shown that 
while in Hsp90 is complexed with AhR, it inhibits transcriptional activation either through 
interfering with ARNT dimerization or blocking interactions with the C-terminal transactivation 
domains or other cofactors.
130-131
 Two of the most characterized AhR antagonists are 3’-
methoxy-4’-nitroflavone (3M4NF), a synthetic flavonoid, and 3,3’-diindolylmethane (DIM), an 
indole derivative (Figure 22). These inhibitors function as antagonists through direct competitive 
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binding to the AhR ligand binding site. Although both molecules target the same binding site, 
they produce divergent effects on AhR. 
 
Figure 23 - 3M4NF-mediated mechanism of AhR inhibition 
 
Binding of the inhibitor, 3M4NF, to the AhR complex results in a conformational change 
within the AhR complex, which prevents exposure of its nuclear localization sequence. Because 
this sequence is not recognizable, the AhR complex is unable to translocate to the nucleus of the 
cell and the intact complex is retained in the cytoplasm (Figure 23). In contrast, binding of DIM 
to AhR does not inhibit complex formation or translocation into the nucleus. However, once in 
the nucleus, the DIM-bound complex is unable to recruit the proper cofactors to initiate 
transcription (Figure 24). These findings indicate that structurally diverse molecules are capable 
of binding and inhibiting AhR through divergent mechanisms. 
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Figure 24 - DIM-mediated mechanism AhR inhibition 
 
 In 2005 Palermo and co-workers identified that EGCG antagonizes AhR. Due to 
structural similarities between EGCG and 3M4NF, this group proposed that EGCG was 
functioning as a competitive inhibitor of AhR. However, competitive binding assays using low-
affinity conditions did not produce the expected results, suggesting EGCG does not bind directly 
to the AhR. Further investigation indicated that EGCG binds Hsp90, allowing for nuclear 
translocation of the AhR complex, but this complex is unable to bind DNA thus is unable to 
promote gene transcription. In 2009 Yin and co-workers sought to identify the binding site of 
EGCG on Hsp90. As previously discussed, GDA and novobiocin bind to and inhibit Hsp90 
through interactions with N-terminal and C-terminal nucleotide binding sites, respectively. 
Proteolytic footprinting is a technique used to characterize Hsp90 inhibitors based upon the 
differential fragmentation patterns of Hsp90 produced upon exposure to each inhibitor. Based 
upon the class of inhibitors used, a unique footprint for N-terminal inhibitors and C-terminal 
inhibitors is observed. Thus, the EGCG footprinting experiments, in combination with Hsp90 
terminus-specific antibodies, determined that EGCG binds to a 50 kDa band located within the 
Hsp90 C-terminus. Comparison of these proteolytic footprints of EGCG to those for novobiocin 
71 
 
confirmed the two to be very similar, indicating that EGCG binds the C-terminus.
132
 The 
proposed mechanism of AhR inhibition by EGCG is summarized in Figure 25. 
 
Figure 25 - EGCG-mediated mechanism of AhR inhibition 
 
 Further investigation into EGCG inhibition of Hsp90 was executed using a firefly 
luciferase assay. This assay employs Hsp90 to refold heat denatured firefly luciferase and 
examines the ability of a compound to interfere with this normal Hsp90 function. Hsp90, Hsp70, 
and Hsp40, isolated from rabbit reticulysate and incubated with EGCG, showed concentration-
dependent inhibition of luciferase refolding. This data further confirms that EGCG manifests its 
activity through Hsp90 inhibition and validated this compound as a novel scaffold for use in the 
development of C-terminal Hsp90 inhibitors. 
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III. EGCG Analogue Development 
 
 
 
Figure 26 - Overlay of EGCG (green, left) and KU-113 (white, right) 
 
A co-crystal structure with the Hsp90 C-terminal nucleotide binding site has not yet been 
solved. The known natural antibiotic novobiocin, however, has been identified as a C-terminal 
binding agent, manifesting an IC50 of ~700 µM against SKBr3 cancer cells. In 2008, Burlison 
and co-workers modified the novobiocin benzamide side chain to improve the anti-cancer 
activity of this scaffold, identifying KU-113 (Figure 26) as a potent analogue. As seen in Figure 
26, structural comparison of EGCG to low micromolar C-terminal novobiocin analogue KU-113 
(IC50 = 1.5 ± 0.1 µM), revealed the two compounds to exhibit several structural similarities. By 
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aligning the catechin core of EGCG with the coumarin core of KU-113, a similar substitution 
pattern becomes evident. The important positions of the KU compounds, especially the 3- and 7-
positions, align well with the same positions on EGCG. The noviose sugar, attached through at 
the 7-position of the coumarin core, has primarily been proposed as a structural feature that can 
be modified to increase solubility of inhibitors. In addition to the noviose sugar, the 3-position is 
appended to the biaryl amide, which was identified as a side chain capable of increasing anti-
Hsp90 activity. The overlay of EGCG with KU-113 shows the D-ring at the 3-position of EGCG 
to align and share a common orientation with the benzamide side chain. Using this insight, it was 
proposed that SAR elucidated for the novobiocin scaffold, specifically with respect to the 
benzamide side chain, could be applied to the EGCG scaffold to improve its Hsp90 affinity. 
Incorporation of the prenylated and biaryl side chains, known to result in potent novobiocin 
analogues upon attachment to the novobiocin scaffold, were selected as structural motifs capable 
of increasing activity when attached to EGCG. Based upon the structural alignment, the 2-
position aryl-linked phenolic ring does not appear make important interactions and was therefore 
removed from the EGCG analogues, without altering Hsp90 affinity. 
A. Computer Modeling of EGCG with the C-terminal Model of Hsp90 
 
 Numerous analogues containing modifications to the benzamide side chain, coumarin 
core, and noviose sugar of novobiocin provided a substantial data that could be used to create a 
CoMFA model. Laura Peterson, a co-worker in the Blagg laboratory, in association with Dr. 
Verkhivker, was instrumental in the development of a C-terminal Hsp90 model, which was 
subsequently applied to the rational development of EGCG analogues. Modeling EGCG to the 
Hsp90 C-terminus nucleotide site, provided insight into its potential binding orientation. 
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Figure 27 - Modeling of EGCG in the Hsp90α C-terminal model 
 
 The modeling study (figure 27) demonstrates that the catechin, comprised of the A- and 
B-rings, sits in a spacious region of the binding pocket. As such, this portion of the scaffold 
appears to make essential interactions with the pocket and thus, only slight modifications are 
likely tolerated without the loss of activity. EGCG binds in a slightly bent conformation, 
allowing the catechin core to interact on one side, while the ester linked D-ring interacts with the 
opposing side. The D-ring of EGCG appears to make key interactions with the binding pocket, 
contacts that can be taken advantage of to increase its Hsp90 affinity. The meta position of the 
D-ring appears to fit into a cavity that would potentially allow for the incorporation of functional 
groups of various bulk. Substitution at the adjacent meta position appears to project directly into 
the protein, thus substitution at the second meta position is thought to be detrimental to Hsp90 
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affinity. In addition, the para position appears to have adequate space for incorporation of 
various functional groups, although large substituents are not likely to be tolerated. Analogues 
proposed will probe the size that can be tolerated at the para position. In contrast, the C-ring 
projects out into solvent and, therefore, would not be essential for EGCG binding to Hsp90. 
Thus, it is envisioned that the C-ring can be excised altogether without compromising the affinity 
of EGCG for Hsp90. Incorporation of a hydrophobic group in place of the C-ring could be used 
to increased analogue solubility similar to the manner in which noviose assists novobiocin.  
B. Design of Initial EGCG Analogues 
 
 In 2008 Jia and co-workers were investigating the effects of EGCG on human 
hemoglobin and determined that EGCG was capable of producing hydrogen peroxide in vivo.
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EGCG reacts with dissolved oxygen in aqueous media, initiating the production of H2O2. Upon 
further investigation, EGCG was found to produce a molar equivalent of H2O2 in solution.
133-134
 
Analogues based upon EGCG still have the ability to produce H2O2 unless specific structural 
modifications are incorporated to avoid this issue. A study by Arakawa and co-workers showed 
that increasing the concentration of H2O2 with and without similar concentrations of EGCG 
produced similar antibacterial results. This data indicates that the bactericidal properties of 
EGCG are likely be attributed to the generation of H2O2 rather than EGCG itself.
135
 With this 
property of EGCG in mind, SAR development needed to focus on an inhibitor of Hsp90 that 
does not produce H2O2. Masking the phenols of the catechin as methyl ethers was proposed as a 
structural modification that could be employed to prevent formation of H2O2, which results upon 
oxidation of the catechol to the ortho quinone. Since, it was understood that oxidation of the 
catechol on the EGCG D-ring under physiological pH has the ability to generate ortho-quinones, 
these electron deficient quinones would have the ability to covalently modify Hsp90 and further 
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supported masking the phenols as methyl ethers.
136
 Thus, initial analogues were designed to 
mask the EGCG phenols as methyl ethers. Next, as stated above, it was proposed that 
modifications to the D-ring will allow for the most significant gains in activity and consequently, 
choices of benzoic acids were carefully considered.  
IV. Synthesis of the Methyl Ether Catechin and Analogues 
 
 
Scheme 8 - Retrosynthetic analysis of EGCG analogues 
 
 Retrosynthesis of the EGCG analogues is illustrated in Scheme 8. The intact catechin and 
the various benzoic acids could be coupled together using standard esterification conditions, 
which allow for addition of the functionalized D-ring portion of the EGCG analogues at a late 
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stage in the synthesis. Cyclization of the desired 6–membered catechin could then be 
accomplished from the allylated dimethoxy phenol precursor.  
 
Scheme 9 - Diol formation in the methyl ether protected catechin 
 
 As shown in Scheme 9, preparation of the methyl ether catechin began by allylation of 
dimethoxy phenol upon heating allyl bromide in the presence of base to produce 22. Subsequent 
Claisen rearrangement using dimethylaluminum chloride produced the desired allylated phenol 
23 in nearly quantative yield. Dihydroxylation of the terminal olefin with osmium tetraoxide and 
N-morpholine N-oxide gave the corresponding diol, 24, in good yield.
137
  
As shown in Scheme 10, several approaches were utilized in an attempt to install the 
toluene sulfonyl ester onto the primary alcohol 24. Treatment of 24 with pyridine and tosyl 
chloride did not produce the desired primary toluene sulfonic ester 24a, but rather the phenolic 
sulfonic ester 25.
138-139
 Although the phenolic toluene sulfonic ester 25 was carried into 
cyclization conditions, this resulted in production of a 5-membered catechin and the desired 6-
membered catechin. A second approach involved treatment of 24 with diisopropylethyl amine 
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Scheme 10 - Attempts to produce the primary toluene sulfonyl ester 
 
with tosyl chloride at 0°C. This sequence did not result in good conversion and attempts to 
improve the yield by performing the reaction at room temperature or for longer duration resulted 
in a mixture of tosylated products. Finally, a modified synthetic strategy that allowed for 
selective tosylation of the primary alcohol was employed, involving silyl protection of phenol 23 
followed by dihydroxylation of the terminal olefin to produce 23a. Tosylation of the primary 
alcohol using the procedure enlisting diisopropylethyl amine provided 24b in poor yields. 
Unfortunately, this reaction sequence did not produce desired products in adequate yields and 
was ultimately abandoned. 
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Scheme 11 - Synthesis of the methyl ether catechin 
 
 The first sequence shown in Scheme 11, was ultimately chosen due to its ability to 
convert all of the starting material to the desired phenolic toluene sulfonic ester 25.
138
 Next, 
cyclization of 25 was accomplished by treatment with base in methanol, producing a 1:1 mixture 
of the corresponding 5-membered catechin in addition to the desired 6-membered catechin. 
Unfortunately, these catechins were inseparable to be separated via column chromatography, so 
the secondary alcohol was acetylated to aid in separation. Acetylation was accomplished by 
treatment of diisopropylethyl amine and acetyl chloride at 0 °C, leading to products that could 
easily be separated via column chromatography to produce desired catechin 27.
140
 Solvolysis of 
27, using base in a mixture of methanol and water, produced the desired 6-membered catechin, 
28, in excellent yield. 
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Scheme 12 - Synthesis of desired phenolic D-ring benzoic acids 
 
 The various D-rings were either commercially available benzoic acids or synthesized 
sequentially. D-ring methyloxy phenols were commercially available, while the phenolic 
analogues were synthesized as the corresponding silyl protected phenols. Synthesis of the 
prenylated and biaryl acids was accomplished following established procedures.
84-85
 Three of the 
four phenolic D-ring analogues were synthesized using the same conversions, as shown in 
Scheme 12. Phenolic benzaldehydes 29–31 were protected as the corresponding silyl ethers, 
upon treatment with imidazole and tert-butyldimethylchlorosilane, to produce corresponding 
benzaldehydes 29b–31b in good yields. The protected silyl ethers were subsequently oxidized 
using Pinnick conditions to afford the benzoic acids, 29c–31c. Synthesis of the remaining 
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resorcinol analogue began by esterification with refluxing 3,5-dihydroxybenzoic acid in 
methanol and thionyl chloride to afford 32. Protection of the phenols was accomplished using 
similar conditions as described above, followed by reduction of afford the ester to the 
corresponding primary alcohol 32b.
141
  Oxidation of the primary alcohol to the corresponding 
benzaldehyde was accomplished using DMP. Finally, Pinnick conditions were employed to 
quantitatively convert 32b to the desired acid, 32c. 
 
Scheme 13 - Coupling of the methyl D-ring analogues 
 
 Following preparation of the desired catechin along with the desired various D-ring 
derivatives, coupling of the two fragments was attempted. The secondary alcohol of the catechin 
was found to react with the corresponding phenolic and methoxy benzoic acids, upon activation 
with N,N’-Dicyclohexylcarbodiimide (DCC) and a catalytic amount of DMAP in excellent yields 
(Scheme 13). Once prepared, the resulting products were screened against MCF-7 and SKBr3 
breast cancer cells for their anti-proliferative activities. The results from this screen are shown in 
Table 3. 
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Table 3 - Antiproliferative data of the methyl D-ring analogues 
Analogue Structure 
MCF7 
(µM) 
SKBr3 
(µM) 
EGCG
142
 
 
150  
33a 
 
8.91 ± 0.81
a 
14.14 ± 5.98 
33b 
 
1.89 ± 0.32 >100 
33c 
 
36.7 ± 7.83 >100 
33d 
 
10.22 ± 0.175 >100 
33e 
 
31.62 ± 1.43 >100 
33f 
 
>100 >100 
a
Values represent mean ± standard deviation for at least two separate experiments performed in 
triplicate 
 The methyl ether analogues manifested a wide range of activities. Computer modeling 
indicated that substitution in the meta position would project along the protein and lead to 
favorable interactions. In agreement with this proposal, analogue 33b exhibits an IC50 of 
approximately 2µM, which compares well to EGCG, which manifests an IC50 value of 150 µM. 
As described above, substitution at the para position orients the molecule towards one side of the 
pocket, which may allow for small substitutions at this position. Analogue 33c increases the 
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affinity for Hsp90 by taking advantage of this small space, thus increasing in the anti-
proliferative activity approximately 4-fold compared to EGCG. As the model suggests, the 
combination of meta and para analogues into catechol substitution on the D-ring should increase 
interactions with the protein. However, the para substitution appears to push into size limitations 
that are incorporated at this position. Although the model suggests this combination would 
increase the interactions and lead to compounds possessing higher affinity for Hsp90, this was 
not observed. There is an approximate 5-fold reduction in the anti-proliferative activity when 
comparing 33b to 33d. Additionally, the model suggests that analogues possessing a resorcinol 
substitution would potentially create an inhibitor–protein steric clash, because the additional 
meta substitution projects into the protein based on the computer modeling. The resorcinol 
analogue 33e, decreases affinity as predicted for Hsp90 approximately 15-fold based on the 
observed anti-proliferative activity. Finally, the 3,4,5-trimethoxy substituted analogue 33f 
incorporates meta substitutions, allowing for access to the pocket that would increase affinity or 
ultimately project into the protein and create steric interactions with Hsp90 and decrease affinity. 
As discussed previously, para substitution may not allow for substitutions at this position, which 
explains the decrease in Hsp90 inhibitory activity observed for this compound.  
 
Scheme 14 - Synthesis of the phenolic derivatives of the D-ring 
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These initial analogues gave valuable insight into the potential binding orientation of the 
EGCG analogues based on our computer model. The apparent size constraints at the para 
position can be investigated through removal of this methyl ether to yield the corresponding 
phenol. A series of phenolic analogues, as described above, would also investigate the effect of 
potential hydrogen bond donors in the meta and para positions. Synthesis of the phenolic 
analogues was accomplished using DCC/DMAP coupling of the methyl ether catechin 28 with 
benzoic acids 29c–32c in modest to excellent yields (Scheme 14). Next, silyl deprotection using 
TBAF produced the desired phenol. Unfortunately, the catechol derivative 35c was unable to be 
collected via column chromatography, likely due to oxidation to the ortho quinone, which 
subsequently bound to the silica column. The anti-proliferative activities of the series of phenolic 
derivatives are found in Table 4. 
Table 4 - Antiproliferative activity of the D-ring phenolic derivatives 
Analogue Structure 
MCF7 
(µM) 
35a 
 
38.74
a 
35b 
 
52.34 
35d 
 
>100 
a
Values represent mean ± standard deviation for one experiment performed in triplicate 
 
 Phenolic analogues generally manifested significant decreases in activity. As described 
above the incorporation of a methoxy group at the para position may push the size constraints 
allowed in this position does not seem to be the determining factor. In contrast, the 
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corresponding phenol 35b revealed that removal of the methyl group at the para position 
resulted in a 2-fold decrease in Hsp90 inhibition. In a similar manner, the meta substitution 
showed a greater decrease in activity, manifesting approximately a 17-fold reduction in 
inhibitory activity for the free phenol 35a versus 33b. These phenolic modifications to the D-ring 
suggest that hydrogen bond donors located at either the meta or para positions are detrimental to 
anti-proliferative activity.   
 
Scheme 15 - Synthesis of the novobiocin-inspired D-ring analogues 
 
 Finally, SAR for the benzamide side chain of the KU series of novobiocin analogues 
developed by Burlison and co-workers was incorporated into the EGCG scaffold. Computer 
modeling predicted that the prenylated side chain found in the natural product novobiocin would 
align well with the predicted orientation of EGCG analogues. The addition of the more active 
biaryl side chain from the KU series of compounds also suggested a favorable binding 
orientation with Hsp90. The syntheses of both the prenylated and the biaryl acids have been 
previously reported. Coupling of these two molecules was accomplished using DCC/DMAP to 
afford desired products in excellent yields (Scheme 15). Upon preparation of the desired 
compounds, they were evaluated for anti-proliferative activity (Table 5). 
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Table 5 - Antiproliferative activity of the KU series of inhibitors 
Analogue Structure MCF7 (µM) 
36a 
 
51.82 ± 1.94
a 
36b 
 
>100 
a
Values represent mean ± standard deviation for at least two separate experiments 
performed in triplicate 
 
Biological results of the KU series of inhibitors revealed that incorporation of the 
prenylated side chain maintains mid-micromolar activity and approximately a 17-fold increase in 
activity when compared to novobiocin. Computer modeling shows that the meta prenyl group 
could project alongside Hsp90, allowing for hydrophobic interactions that increase affinity for 
Hsp90. Additionally, the acetate group located in the para position would probe for polar 
contacts with the protein pocket. As described previously, computer modeling also showed a 
potential size constraint for substitutions at the para position. In comparison to the methoxy and 
the phenolic derivatives at this location, manifesting IC50 values of 36.7 and 52.3, respectfully, 
the acetate group is still relatively small and incorporates a hydrogen bond acceptor without 
limiting the size of this pocket. In a similar manner as the prenylated side chain, the biaryl D-ring 
analogue investigated hydrophobic interactions in the meta cavity, while incorporating the most 
active substituent tested at the para position. If the predicted SAR trends would be maintained 
from the KU series to the EGCG series, the biaryl D-ring analogue would be more active than 
the prenyl side chain. Unfortunately, the biaryl side chain analogue 36b was not active at the 
concentrations tested, which indicates that novobiocin and EGCG have distinct binding 
orientations and do not directly overlap. 
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V. Design of Various Catechin Cores 
 
While previously described analogues have allowed for the development of various 
inhibitors to probe interactions with the D-ring of EGCG, other regions of EGCG may also 
improve Hsp90 inhibitory activity. Modifications of the catechin would identify the importance 
of the A-ring resorcinol found on EGCG. Removal of the 5- and 7-methoxy groups would give 
the corresponding phenyl catechin, which would explore the importance of the resorcinol 
functionality. Moreover, development of other catechins would allow for direct comparison to 
the methyl ether catechin. 
A. Synthesis of the Phenyl Catechin 
 
 
Scheme 16 - Synthesis of the phenolic intermediate 
 
 Synthesis of the phenyl catechin followed the same series of transformations as those 
employed in the synthesis of the methyl catechin. Starting from phenol a similar series of 
transformations were followed to afford the desired phenyl catechin as shown in Scheme 16. 
Allylation of phenol 37, followed by the catalyzed Claisen rearrangement produced 38 in 
excellent yield. Dihydroxylation of the terminal olefin 39, followed by phenolic toluene sulfonic 
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esterification was accomplished using the optimized conditions as described previously to give 
40.
138
 
 
Scheme 17 - Synthesis of the phenyl catechin 
 
 The phenolic toluene sulfonic ester was cyclized by the addition of base in methanol to 
produce a 1:1 mixture of the 5- and 6-membered phenyl catechins 41a–b. Unfortunately, as was 
the case previously, these catechins were inseparable via column chromatography and 
acetylation was employed to obtain the desired 6-membered catechin 42.
140
 Finally, solvolysis of 
the protected precursor 42 produced the desired phenyl catechin 43 in excellent yield. 
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Scheme 18 - Synthesis of various phenyl catechin analogues 
 
 The various D-rings chosen, attached using standard DCC/DMAP conditions, were 
selected based upon multiple factors. The first benzoic acid chosen was based on the most active 
compound in the methyl ester series 44a, which manifested an IC50 of 1.89 µM. Next, to further 
investigate whether the SAR developed for the KU series of compounds and be applied to the 
catechin scaffolds, both the prenylated and biaryl analogues were also synthesized producing 44b 
and 44c, respectfully. These molecules were evaluated against MCF-7 breast cancer cells. Data 
obtained from biological testing is shown in Table 6.  
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Table 6 - Anti-proliferative activity of phenyl catechin analogues 
Analogue Compound 
MCF7 
(µM) 
44a 
 
>100
a 
44b 
 
40.55 ± 13.19 
44c 
 
>100 
 
a
Values represent mean ± standard deviation for at least two separate experiments 
performed in triplicate. 
 The anti-proliferative results revealed a range of activities for various analogues. Overall, 
it was demonstrated that removal of both methoxy ethers on the catechin is detrimental to 
activity. Comparison of the most active inhibitor, 33b, which contains a methoxy meta to the 
phenyl ring, 44a, clearly demonstrates that removal of the methoxy groups decreases activity. 
When the prenyl side chain is appended, in the case of 44b, a slight increase in activity is 
observed, while the biaryl-containing analogue 44c remains inactive. While these results do not 
seem to show a consistent trend, it is proposed that removal of the methoxy groups should 
eliminate interactions between the inhibitor and the protein and decrease activity. Thus, this 
catechin was not pursued further.  
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B. Western Blot analysis of 33b 
 
 
Figure 28 - Western blot analyses of Hsp90 client protein degradation assays against MCF-7 
cells following treatment with EGCG analogue 33b. Concentrations (in μM) are indicated above 
each lane, GDA (Geldanamycin 500 nM) and DMSO were used as positive and negative 
controls, respectively. 
 To confirm that EGCG analogues were exhibiting their anti-proliferative effects through 
Hsp90 inhibition, analogue 33b was evaluated for its ability to induce degradation of Hsp90 
client proteins. Inhibitors that target Hsp90 demonstrate a dose-dependant degradation of client 
proteins at a concentration that corresponds with its IC50 value against the same cell line. 
Moreover, a hallmark of C-terminal inhibition is that the amount of Hsp90 remains constant at 
all concentrations tested. As seen in Figure 28, it appears as though Raf is the only client protein 
that is affected upon treatment with 33b and its degradation does not occur near the measured 
IC50 value (1.89 ± 0.32 µM). This data suggests this molecule does not manifest its inhibitory 
activity through Hsp90 inhibition. Further analysis is needed to determine the mechanism 
through which 33b manifests its anti-proliferative activity. 
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 Development of the methyl ether and phenyl catechins has demonstrated a wide range of 
activities upon incorporation of D-ring analogues. Comparison of the methyl ether catechin to 
the phenyl catechin demonstrates the influence of substitutions to the catechin moiety, notably 
including a significant reduction in activity upon removal of the methoxy groups. To further 
explore the catechin scaffold, development of 5- and 7-phenolic catechins were pursued. It is 
important to note that the 7-phenolic catechin would result in the direct connectivity seen in the 
KU series of coumarin compounds. 
C. Synthesis of a 5-hydroxy catechin 
 
 
Scheme 19 - Synthesis of the primary toluene sulfonyl ester 
 
 Synthesis of a 5-hydroxy catechin was accomplished following a similar series of 
transformations as described for both the methyl ether and phenyl catechins. As seen in Scheme 
19, resorcinol can be protected as the corresponding alkoxy ethers 45, which allows for ortho-
lithiation to afford the allylated resorcinol 46. Dihydroxylation of the terminal olefin 47, 
followed by toluene sulfonyl esterification of primary alcohol 47a was accomplished in good 
overall yields.
138
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Scheme 20 - Synthesis of the protected 5-phenol catechin 
 
 Primary toluene sulfonic ester 47a allowed cyclization to the desired 5-phenolic catechin. 
Next, acidic removal of the alkoxy ethers produces the phenolic resorcinol 47b in excellent yield. 
Cyclization using the same conditions as described above produced the desired 5-hydroxy 
catechin 48 without the need for additional acetate protection during purification. Finally, 
selective protection of the phenol as the benzyl ether 49 was necessary to allow coupling of the 
catechin with the various benzoic acids. 
D. Synthesis of the 7-hydroxy catechin 
 
 
Scheme 21 - Synthesis of the dihydroxylated phenolic intermediate 
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 Preparation of the 7-hydroxy catechin employs the same transformations that have been 
described for the other catechins. Although synthesis of the 7-hydroxy catechin also begins with 
resorcinol, selective silylation of one phenol allowed access to a different scaffold in a minimal 
amount of steps. Allylation of the free hydroxyl using already established conditions produces 
51, which was subsequently exposed to Claisen conditions gave the desired allylated 
intermediate 52. Dihydroxylation of the terminal olefin yielded 53, which was very similar to 
intermediates produced in both the phenyl and methyl catechins. Development of the 7-hydroxy 
catechin followed the synthetic steps previously described for the phenyl and methyl ether 
protected catechin.  
 
Scheme 22 - Synthesis of the desired benzyl ether protected 7-hydroxyl catechin 
 
 Synthesis of the desired 7-hydroxyl catechin proceeded with the optimized conditions 
described above for toluene sulfonic esterification of phenol 53.
138
 The catechin was then 
cyclized through addition of base to produce a 1:1 mixture of the 5- and the desired 6-membered 
catechins 54a–b. Unfortunately, these cyclization conditions proceeded via removal of the silyl 
protecting group and produced catechins, which were not separable via column chromatography 
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and were thus pushed on to benzyl ether protection. Protected catechins 55a–b, unfortunately, 
remained inseparable as well. Finally, acetate protection of the corresponding alcohols provided 
the separable 6-membered catechin 56 in overall good yield.
140
 Finally, solvolysis afforded the 7-
benzyl ether catechin 57 in good yield. 
VI. Conclusions 
 
 Development of the EGCG scaffold to produce compounds capable of targeting 
biologically relevant proteins is an area that should be pursued. Green tea has been used for 
centuries in the treatment of various disease states. The ability to isolate and fine tune the activity 
of active constituents like EGCG for the treatment of the various diseases is an exciting avenue 
for the development of therapeutics. Analogues containing the methyl ether catechin showed 
promise, manifesting a wide range of activities. However, Western blot analyses demonstrated 
that compounds of this type do not manifest their anti-proliferative activity through inhibition of 
Hsp90. In agreement with the model, the phenyl catechin showed a decrease in activity 
compared to the most active inhibitor. Further studies need to be carried out to explore tolerable 
substitutions that can be made to the EGCG scaffold without compromising its ability to inhibit 
Hsp90. Overall, EGCG represents a promising new scaffold upon which to build Hsp90 C-
terminal inhibitors. 
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22 
1-(allyloxy)-3,5-dimethoxybenzene (22):  A solution of 3,5-dimethoxyphenol (1.046 grams, 6.8 
mmol) was dissolved in acetone (35 mL)  was treated with potassium carbonate (2.84 grams, 
20.4 mmol) and allyl bromide (1.8 mL, 20.4 mmol), then the solution was heated to reflux for 12 
hours. This reaction was cooled to room temperature and quenched by the addition of H2O, 
extracted with EtOAc (3 x 150 mL). The combined organic fractions were washed with saturated 
aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via column 
chromatography (SiO2 30% EtOAc:Hexanes) to afford 22 (1.216g, 92%) as a colorless oil: 
1
H 
NMR (500 MHz, CDCl3) δ 6.13 (d, J = 2.1 Hz, 2H), 6.12 (d, J = 2.0 Hz, 1H), 6.11 – 6.03 (m, 
1H), 5.44 (ddd, J = 17.2, 3.2, 1.6 Hz, 1H), 5.31 (dq, J = 10.5, 1.4 Hz, 1H), 4.52 (dt, J = 5.4, 1.5 
Hz, 2H), 3.79 (s, 6H).; 
13
C NMR (126 MHz, CDCl3) δ 161.5 (2x), 160.5, 133.1, 117.8, 93.6, 
93.1, 68.9, 55.3; IR (film) νmax 2999, 2939, 2839, 1600, 1475, 1458, 1423, 1205, 1193, 1154, 
1064, 927, 817 cm
-1
; HRMS (ESI+) m/z: [M +]+ calcd for  C11H14O3, 194.0943; found, 
194.0948 
 
23 
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2-allyl-3,5-dimethoxyphenol (23): A solution of 22 (1.12 grams, 5.8 mmol) was dissolved in 
DCM (30 mL) and treated dropwise with 1.0M solution of dimethylaluminum chloride (12.2 mL, 
12.2 mmol) and stirred until TLC revealed complete consumption of starting material. The 
reaction was quenched by the addition of 1.0 N HCl, extracted with EtOAc (3 x 150 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 20% 
EtOAc:Hexanes) to afford 23 (0.997g, 89%) as a colorless oil: 
1
H NMR (500 MHz, CDCl3) δ 
6.13 (d, J = 2.4 Hz, 1H), 6.11 (d, J = 2.4 Hz, 1H), 5.98 (ddt, J = 17.1, 10.0, 6.0 Hz, 1H), 5.17 – 
5.09 (m, 3H), 3.80 (s, 3H), 3.79 (s, 3H), 3.44 – 3.38 (m, 2H).; 
13
C NMR (126 MHz, CDCl3) δ 
159.7, 158.7, 155.9, 136.8, 115.4, 105.6, 93.7, 91.6, 55.8, 55.3, 27.0.; IR (film) νmax 3433(br), 
2939, 2839, 1616, 1596, 1510, 1456, 1423, 1203, 1157, 1120, 1095, 1072, 1053, 985, 945, 912, 
813 cm
-1
; HRMS (ESI+) m/z: [M + H]+ calcd for  C11H14O3H, 195.1021; found, 195.1026. 
 
 
24 
3-(2-hydroxy-4,6-dimethoxyphenyl)propane-1,2-diol (24): A solution of 23 (3.9 grams, 20.13 
mmol) was dissolved in a (1.5 : 1.0) mixture of THF and H2O (66 mL : 33 mL) respectively was 
treated with 4-methylmorpholine N-oxide (3.53 grams, 30.2 mmol) followed by dropwise 
addition of a 4% Osmium tetraoxide solution in H2O (0.85 mL, 2.13 mmol). This was allowed to 
stir for 18 hours before it was diluted with H2O and extracted with EtOAc (3 x 250 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
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and concentrated. The residue was purified via column chromatography (SiO2 2% 
MeOH:CHCl3) to afford 24 (3.99g, 87%) as a colorless oil: 
1
H NMR (500 MHz, CDCl3) δ 6.19 
(d, J = 2.4 Hz, 1H), 6.10 (d, J = 2.4 Hz, 1H), 4.05 (dtd, J = 6.7, 5.6, 4.5 Hz, 1H), 3.79 (d, J = 4.3 
Hz, 6H), 3.64 (dd, J = 11.2, 4.5 Hz, 1H), 3.48 (dd, J = 11.2, 6.8 Hz, 1H), 2.98 – 2.79 (m, 2H).; 
13
C NMR (126 MHz, CDCl3) δ 160.0, 158.9, 157.1, 104.8, 94.7, 91.4, 72.9, 65.2, 55.7, 55.3, 
26.0.; IR (film) νmax 3359(br), 3001, 2937, 2840, 1618, 1595, 1514, 1456, 1425, 1363, 1338, 
1301, 1201, 1172, 1147, 1108, 1053, 1026, 979, 933, 815 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ 
calcd for  C11H16O5Na, 251.0895; found, 251.0893. 
 
 
27 
5,7-dimethoxychroman-3-yl acetate (27): A solution of 24 (3.95 grams, 17.3 mmol) was 
dissolved in DCM (80 mL) and cooled to 0°C, treated with pyridine (6.0 mL, 73.5 mmol) and 
allowed to stir for 5 minutes. Finally para-toluenesulfonyl chloride (3.61 grams, 19.0 mmol) was 
added and allowed to warm to room temperature after 1 hour. This was allowed to react for 12 
hours and quenched by the addition of H2O and extracted with EtOAc (3 x 250 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 40% 
EtOAc:Hexanes) to afford crude phenolic sulfonic ester 25 (5.41g) as a yellow oil. 
99 
 
 This oil was dissolved in MeOH (60 mL) and treated with potassium carbonate (3.146 
grams, 22.7 mmol) and monitored by TLC. Once the TLC showed the consumption of starting 
material the solution was filtered and washed with EtOAc, dried (Na2SO4), filtered and 
concentrated. This produced an inseparable mixture of compounds 26a-b (20% 
EtOAc:Hexanes), as a colorless oil (2.071g). 
 The mixture of compounds (1.34g, 6.36 mmol) was dissolved in DCM (30 mL) and 
cooled to 0°C and was treated with diisopropylethyl amine (2.22 mL, 12.7 mmol) and stirred for 
5 minutes then acetyl chloride (0.46 mL, 6.36 mmol) was added dropwise and allowed to warm 
to room temperature over 12 hours. The reaction was quenched by the addition of H2O and 
extracted with EtOAc (3 x 100 mL). The combined organic fractions were washed with saturated 
aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via column 
chromatography (SiO2 10% EtOAc:Hexanes) to afford 27 (0.386 g, 24%) over 3 steps as a 
colorless oil: 
1
H NMR (500 MHz, CDCl3) δ 6.10 (d, J = 1.9 Hz, 1H), 6.03 (d, J = 2.0 Hz, 1H), 
5.04 (dtd, J = 9.6, 7.3, 3.6 Hz, 1H), 4.33 (dd, J = 11.9, 3.6 Hz, 1H), 4.21 (dd, J = 11.9, 7.4 Hz, 
1H), 3.81 (s, 3H), 3.78 (s, 3H), 3.21 (dd, J = 15.1, 9.6 Hz, 1H), 2.84 (dd, J = 15.1, 7.2 Hz, 1H), 
2.13 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 170.9, 161.8, 161.0, 156.6, 104.8, 91.3, 88.5, 81.17, 
66.0, 55.6, 55.4, 29.1, 20.9; IR (film) νmax 3434(br), 2943, 2840, 2358, 1741, 1612, 1504, 1452, 
1367, 1234, 1217, 1199, 1133, 1099, 1043, 983, 937, 810 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ 
calcd for  C13H16O5Na, 275.0895; found, 275.0898. 
 
28 
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5,7-dimethoxychroman-3-ol (28): A solution of 27 (0.128 grams, 0.51 mmol in a (9:1) mixture 
of MeOH : H2O (2.7 mL : 0.3 mL) was treated with potassium carbonate (0.213 grams, 1.53 
mmol) and allowed to react for 4 hours. The reaction was quenched by the addition of saturated 
aqueous ammonium chloride and extracted with EtOAc (3 x 50 mL). The combined organic 
fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. 
The residue was purified via column chromatography (SiO2 30% EtOAc:Hexanes) to afford 28 
(0.090g, 84%) as a colorless oil: 
1
H NMR (500 MHz, CDCl3) δ 5.98 (d, J = 2.0 Hz, 1H), 5.94 (d, 
J = 2.0 Hz, 1H), 4.86 (dtd, J = 10.0, 6.9, 3.3 Hz, 1H), 3.77 – 3.61 (m, 8H), 3.05 (dd, J = 15.0, 9.5 
Hz, 1H), 2.76 (dd, J = 15.0, 7.0 Hz, 1H), 1.93 (s, 1H); 
13
C NMR (126 MHz, CDCl3) δ 161.7, 
161.0, 156.7, 105.5, 91.2, 88.5, 84.3, 65.2, 55.6, 55.4, 28.4; IR (film) νmax 3428(br), 2937, 
2840, 2358, 1623, 1612, 1504, 1452, 1429, 1357, 1217, 1199, 1134, 1099, 1045, 1008, 937, 810 
cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C11H14O4Na, 233.0790; found, 233.0792. 
 
29c 
3-((tert-butyldimethylsilyl)oxy)benzoic acid (29c): A solution of 3-hydroxybenzaldehyde (0.22 
grams, 1.8 mmol) was dissolved in DMF (4.5 mL) and treated sequentially with imidazole (0.308 
grams, 4.5 mmol) and tert-butyl(chloro)dimethylsilane (0.545 grams, 3.6 mmol) for 12 hours. 
The reaction was quenched by the addition of H2O and extracted with EtOAc (3 x 50 mL). The 
combined organic fractions were washed with H2O (3 x 50 mL), saturated aqueous NaCl, dried 
(Na2SO4), filtered and concentrated to afford 29b as a crude colorless oil and used without 
further purification: 
1
H NMR (400 MHz, CDCl3) δ 9.97 (s, 1H), 7.49 (dt, J = 7.5, 1.3 Hz, 1H), 
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7.42 (t, J = 7.8 Hz, 1H), 7.34 (dd, J = 2.4, 1.5 Hz, 1H), 7.12 (ddd, J = 8.0, 2.5, 1.1 Hz, 1H), 1.01 
(s, 9H), 0.24 (s, 7H). 
 The crude oil 29b (0.305 grams, 1.29 mmol) was dissolved in t-BuOH (7 mL) and treated 
with 2-methyl-2-butene (5.0 mL, 46.4 mmol), while a separate solution of sodium chlorite (1.01 
grams, 8.8 mmol) in a buffered solution of made of sodium phosphate monobasic (1.41 grams, 
11.6 mmol) in H2O (22 mL).  The oxidizing solution was added dropwise to the solution 
containing 29b and allowed to react for 12 hrs. This reaction was diluted with saturated aqueous 
NaH2PO4 and extracted with DCM (3 x 50 mL), dried (Na2SO4), filtered, and concentrated to 
afford 29c without further purification (0.3113g, 96%) as a pale yellow oil: 
1
H NMR (500 MHz, 
CDCl3) δ 7.74 (m, 1H), 7.59 (dd, J = 2.3, 1.7 Hz, 1H), 7.36 (t, J = 7.9 Hz, 1H), 7.11 (ddd, J = 
8.1, 2.5, 1.0 Hz, 1H), 1.02 (s, 9H), 0.25 (s, 6H); 
13
C NMR (126 MHz, CDCl3) δ 172.0, 156.2, 
130.9, 129.9, 126.2, 123.6, 121.9, 26.0 (3x), 18.6, 4.0 (2x); IR (film) νmax 3421(br), 2950, 2853, 
2526, 1697, 1602, 1581, 1485, 1452, 1415, 1299, 1240, 1164, 1103, 1080, 964, 837, 783 cm
-1
; 
HRMS (ESI+) m/z: [M + Na]+ calcd for  C13H20O3SiNa, 275.1079; found, 275.1070. 
 
30c 
4-((tert-butyldimethylsilyl)oxy)benzoic acid (30c): A solution of 4-hydroxybenzaldehyde 
(0.226 grams, 1.85 mmol) was dissolved in DMF (4.5 mL) and treated sequentially with 
imidazole (0.316 grams, 4.6 mmol) and tert-butyl(chloro)dimethylsilane (0.560 grams, 3.7 
mmol) for 12 hours. The reaction was quenched by the addition of H2O and extracted with 
EtOAc (3 x 50 mL). The combined organic fractions were washed with H2O (3 x 50 mL), 
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saturated aqueous NaCl, dried (Na2SO4), filtered and concentrated.  The residue was carried on 
without further purification to afford 30b as a crude colorless oil and used without further 
purification. 
 This crude benzaldehyde 30b was dissolved in t-BuOH (2 mL) and treated with 2-
methyl-2-butene (1.6 mL, 14.8 mmol), while a separate solution of sodium chlorite (0.319 
grams, 2.8 mmol) in a buffered solution of made of sodium phosphate monobasic (0.444 grams, 
3.7 mmol) in H2O (7 mL).  The oxidizing solution was added dropwise to the solution containing 
30b and allowed to react for 12 hrs. This reaction was diluted with saturated aqueous NaH2PO4 
and extracted with DCM (3 x 50 mL), dried (Na2SO4), filtered, and concentrated to afford 30c 
(0.095g, 21%) over 2 steps as a pale yellow oil without further purification: 
1
H NMR (500 MHz, 
CDCl3) δ 8.02 (m, 2H), 6.89 (m, 2H), 0.99 (s, 9H), 0.24 (s, 6H).; 
13
C NMR (126 MHz, CDCl3) δ 
172.1, 161.0, 132.5 (2x), 122.4, 120.1 (2x), 25.7 (3x), 18.4, 4.2 (2x). IR (film) νmax 2927, 2856, 
2667, 2549, 1668, 1602, 1512, 1469, 1427, 1317, 1271, 1168, 1103, 914, 862, 837, 781 cm
-1
; 
HRMS (ESI+) m/z: [M + Na]+ calcd for  C13H20O3SiNa, 275.1079; found, 275.1071. 
 
31c 
3,4-bis((tert-butyldimethylsilyl)oxy)benzoic acid (31c): A solution of 3,4-
hydroxybenzaldehyde (0.302 grams, 2.19 mmol) was dissolved in DMF (5.5 mL) and treated 
sequentially with imidazole (0.679 grams, 9.9 mmol) and tert-butyl(chloro)dimethylsilane (1.32 
grams, 8.76 mmol) for 12 hours. The reaction was quenched by the addition of H2O and 
extracted with EtOAc (3 x 50 mL). The combined organic fractions were washed with H2O (3 x 
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50 mL), saturated aqueous NaCl, dried (Na2SO4), filtered and concentrated.  The residue was 
carried on without further purification to afford 31b as a crude colorless oil and used without 
further purification. 
 The crude oil 31b was dissolved in t-BuOH (1 mL) and treated with 2-methyl-2-butene (1 
mL, 7.9 mmol), while a separate solution of sodium chlorite (0.173 grams, 1.5 mmol) in a 
buffered solution of made of sodium phosphate monobasic (0.245 grams, 2.0 mmol) in H2O 
(3.75 mL).  The oxidizing solution was added dropwise to the solution containing 31b and 
allowed to react for 12 hrs. This reaction was diluted with saturated aqueous NaH2PO4 and 
extracted with DCM (3 x 50 mL), dried (Na2SO4), filtered, and concentrated to afford 31c 
(0.0732g, 9%) over 2 steps as a pale yellow oil without further purification: 
1
H NMR (500 MHz, 
CDCl3) δ 7.65 (dd, J = 8.3, 2.1 Hz, 1H), 7.61 (d, J = 2.1 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 1.02 
(d, J = 3.3 Hz, 18H), 0.26 (d, J = 4.8 Hz, 12H).; 
13
C NMR (126 MHz, CDCl3) δ 172.0, 152.6, 
146.9, 124.6, 122.9, 122.5, 120.7, 26.0 (3x), 26.0 (3x), 18.7, 18.6, 4.0 (2x), 3.9 (2x); IR (film) 
νmax 2954, 2929, 2858, 1687, 1596, 1574, 1514, 1433, 1392, 1293, 1253, 1124, 1103, 973, 893, 
853, 781 cm
-1
; HRMS (ESI+) m/z: [M +]+ calcd for  C19H34O4Si2Na, 382.1996; found, 
382.2004. 
 
32b 
(3,5-bis((tert-butyldimethylsilyl)oxy)phenyl)methanol (32b): A solution of methyl 3,5-
dihydroxybenzoate(cite) (0.250 grams, 1.49 mmol) was dissolved in DMF (5.0 mL) and treated 
sequentially with imidazole (0.460 grams, 6.7 mmol) and tert-butyl(chloro)dimethylsilane (0.902 
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grams, 5.96 mmol) for 12 hours. The reaction was quenched by the addition of H2O and 
extracted with EtOAc (3 x 50 mL). The combined organic fractions were washed with H2O (3 x 
50 mL), saturated aqueous NaCl, dried (Na2SO4), filtered and concentrated.  The colorless oil 
was carried on without further purification. 
 A suspension of lithium aluminum hydride (0.125 grams, 3.23 mmol) was made in THF 
(5 mL) and cooled to 0°C. A second solution of the crude oil (0.583 grams, 1.47 mmol) was 
dissolved in THF (5 mL), cooled to 0°C and added dropwise to the suspension. The reaction was 
allowed to stir until TLC showed consumption of starting material. The reaction was quenched 
by the addition of H2O and extracted with EtOAc (3 x 50 mL). The combined organic fractions 
were washed with H2O (3 x 50 mL), saturated aqueous NaCl, dried (Na2SO4), filtered and 
concentrated.  The residue was purified via column chromatography (SiO2 5% EtOAc:Hexanes) 
to afford 32b (0.254g, 46%) over 2 steps as a colorless oil: 
1
H NMR (500 MHz, CDCl3) δ 6.47 
(d, J = 2.2 Hz, 2H), 6.25 (s, 1H), 4.57 (s, 2H), 0.97 (s, 18H), 0.19 (s, 12H); 
13
C NMR (126 MHz, 
CDCl3) δ 156.7, 143.1, 111.8, 111.2, 65.2, 25.7 (3x), 25.6 (3x), 18.2 (2x), 4.5 (4x); IR (film) 
νmax 3352(br), 2954, 2885, 1589, 1450, 1361, 1334, 1253, 1164, 1029, 1002, 981, 939, 831, 779 
cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C19H36O3Si2Na, 391.2101; found, 391.2104. 
 
32c 
3,5-bis((tert-butyldimethylsilyl)oxy)benzoic acid (32c): A solution of 32b (0.232 grams, 0.63 
mmol) was dissolved in DCM (4 mL) and treated with pyridinium chlorochromate (0.164 grams, 
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0.76 mmol) and allowed to react for 12 hrs. The solution was diluted with diethyl ether (10 mL) 
and allowed to stir for 10 min, filtered through a Celite plug (EtOAc), dried (Na2SO4), filtered 
and concentrated. The pale yellow residue was used without further purification: xx 
 The crude residue (0.168 grams, 0.46 mmol) was dissolved in t-BuOH (2 mL) and treated 
with 2-methyl-2-butene (2 mL, 16.6 mmol), while a separate solution of sodium chlorite (0.358 
grams, 3.13 mmol) in a buffered solution of made of sodium phosphate monobasic (0.505 grams, 
4.14 mmol) in H2O (8.0 mL).  The oxidizing solution was added dropwise to the solution 
containing crude aldehyde and allowed to react for 12 hrs. This reaction was diluted with 
saturated aqueous NaH2PO4 and extracted with DCM (3 x 50 mL), dried (Na2SO4), filtered, and 
concentrated to afford 32c (0.1584g, 66%) over 2 steps as a pale yellow oil without further 
purification: 
1
H NMR (500 MHz, CDCl3) δ 7.07 (s, 1H), 6.72 (s, 1H), 6.36 (s, 1H), 0.78 (s, 9H), 
0.15 (s, 6H); 
13
C NMR (126 MHz, CDCl3) δ 170.0, 157.3 (2x), 138.3, 118.4, 114.4 (2x), 25.5 
(6x), 18.2 (2x), 4.2 (4x); IR (film) νmax 2956, 2858, 1704, 1589, 1458, 1382, 1336, 1255, 1170, 
1031, 1006, 852, 829, 813, 781 cm
-1
 HRMS (ESI+) m/z: [M +]+ calcd for  C19H34O4Si2Na, 
382.1996; found, 382.1994. 
 
33a 
5,7-dimethoxychroman-3-yl benzoate (33a): To a stirring solution of 28 (0.018 grams, 0.086 
mmol) and benzoic acid (0.022 grams, 0.172 mmol) in DCM (1 mL) was added N,N’-
dicyclohexylcarbodiimide (0.036 grams, 0.172 mmol) and 4-(dimethylamino)pyridine (0.001 
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grams, 0.008 mmol) simultaneously. This was allowed to react for 12 hours and quenched by the 
addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions were 
washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue 
was purified via column chromatography (SiO2 15% EtOAc:Hexanes) to afford 33a (0.0266g, 
98%) as an amorphous white solid: 
1
H NMR (500 MHz, CDCl3) δ 8.04 (m, 2H), 7.57 (t, J = 7.4 
Hz, 1H), 7.43 (t, J = 7.0 Hz, 2H), 6.12 (d, J = 2.2 Hz, 2H), 5.53 (s, 1H), 4.31 (ddd, J = 56.3, 29.2, 
6.7 Hz, 2H), 3.81 (s, 6H), 2.99 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 166.1, 159.6, 158.8, 
155.1, 133.1, 130.0, 129.8, 128.3, 100.5, 93.2, 91.8, 66.8, 66.0, 55.4, 24.9; IR (film) νmax 2937, 
2840, 1716, 1620, 1593, 1498, 1450, 1353, 1315, 1287, 1217, 1201, 1178, 1142, 1128, 1110, 
1070, 1056, 1026, 945, 813, 711 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C18H18O5Na, 
337.1052; found, 337.1058. 
 
33b 
5,7-dimethoxychroman-3-yl 3-methoxybenzoate (33b): To a stirring solution of 28 (0.018 
grams, 0.086 mmol) and 3-methoxybenzoic acid (0.026 grams, 0.172 mmol) in DCM (1 mL) 
was added N,N’-dicyclohexylcarbodiimide (0.035 grams, 0.172 mmol) and 4-
(dimethylamino)pyridine (0.001 grams, 0.008 mmol) simultaneously. This was allowed to react 
for 12 hours and quenched by the addition of H2O and extracted with DCM (3 x 25 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 15% 
EtOAc:Hexanes) to afford 33b (0.0246g, 83%) as an amorphous white solid: 
1
H NMR (400 
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MHz, CDCl3) δ 7.62 (m, 1H), 7.55 (dd, J = 2.6, 1.5 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.10 (ddd, 
J = 8.3, 2.7, 1.0 Hz, 1H), 6.11 (s, 2H), 5.51 (qd, J = 5.2, 2.2 Hz, 1H), 4.29 (m, 2H), 3.84 (s, 3H), 
3.80 (s, 3H), 3.79 (s, 3H), 2.92 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 166.0, 159.5, 158.8, 
155.1, 131.3, 129.4, 122.2, 119.4, 114.3, 100.5, 93.1, 91.8, 66.8, 66.1, 55.4, 24.9; IR (film) νmax 
2937, 2837, 1716, 1620, 1593, 1498, 1463, 1454, 1431, 1353, 1321, 1276, 1218, 1201, 1145, 
1128, 1103, 1047, 813, 755 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C19H20O6Na, 
367.1158; found, 367.1165. 
 
33c 
5,7-dimethoxychroman-3-yl 4-methoxybenzoate (33c): To a stirring solution of 28 (0.020 
grams, 0.095 mmol) and 4-methoxybenzoic acid (0.029 grams, 0.19 mmol) in DCM (1 mL) was 
added N,N’-dicyclohexylcarbodiimide (0.040 grams, 0.19 mmol) and 4-(dimethylamino)pyridine 
(0.001 grams, 0.009 mmol) simultaneously. This was allowed to react for 12 hours and quenched 
by the addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions 
were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified via column chromatography (SiO2 15% EtOAc:Hexanes) to afford 33c 
(0.0232g, 71%) as an amorphous white solid: 
1
H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 8.9 Hz, 
2H), 6.90 (d, J = 8.9 Hz, 2H), 6.11 (s, 2H), 5.49 (qd, J = 5.1, 2.2 Hz, 1H), 4.28 (m, 2H), 3.86 (s, 
3H), 3.79 (d, J = 1.8 Hz, 6H), 2.92 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 165.8, 163.5, 159.5, 
158.8, 155.1, 131.8, 129.1, 122.4, 113.6, 100.7, 93.1, 91.7, 66.9, 65.6, 55.4, 24.9; IR (film) νmax 
2935, 2839, 1710, 1620, 1606, 1510, 1498, 1461, 1442, 1421, 1353, 1317, 1268, 1217, 1201, 
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1166, 1145, 1128, 1112, 1101, 1056, 1027, 945, 846, 811 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ 
calcd for  C19H20O6Na, 367.1158; found, 367.1157. 
 
 
33d 
5,7-dimethoxychroman-3-yl 3,4-dimethoxybenzoate (33d): To a stirring solution of 28 (0.021 
grams, 0.1 mmol) and 3,4-dimethoxybenzoic acid (0.037 grams, 0.2 mmol) in DCM (2 mL) was 
added N,N’-dicyclohexylcarbodiimide (0.042 grams, 0.2 mmol) and 4-(dimethylamino)pyridine 
(0.002 grams, 0.01 mmol) simultaneously. This was allowed to react for 12 hours and quenched 
by the addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions 
were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified via column chromatography (SiO2 15% EtOAc:Hexanes) to afford 33d 
(0.0362g, 97%) as an amorphous white solid: 
1
H NMR (400 MHz, CDCl3) δ 7.66 (dd, J = 8.4, 
2.0 Hz, 1H), 7.53 (d, J = 2.0 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 6.11 (s, 2H), 5.49 (qd, J = 5.1, 2.3 
Hz, 1H), 4.27 (m, 2H), 3.93 (s, 3H), 3.92 (s, 3H), 3.80 (s, 3H), 3.79 (s, 3H), 2.93 (m, 2H
13
C 
NMR (126 MHz, CDCl3) δ 165.8, 159.6, 158.8, 155.1, 153.1, 148.6, 123.9, 122.5, 112.1, 110.1, 
100.6, 93.1, 91.7, 66.9, 65.8, 56.0, 55.4, 55.4, 24.9; IR (film) νmax 2958, 1839, 1710, 1620, 
1596, 1514, 1498, 1463, 1454, 1419, 1352, 1288, 1273, 1220, 1201, 1176, 1132, 1107, 1056, 
1024, 912, 813, 763, 730 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C20H22O7Na, 
397.1263; found, 397.1267.  
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33e 
5,7-dimethoxychroman-3-yl 3,5-dimethoxybenzoate (33e): To a stirring solution of 28 (0.020 
grams, 0.095 mmol) and 3,5-dimethoxybenzoic acid (0.036 grams, 0.19 mmol) in DCM (1 mL) 
was added N,N’-dicyclohexylcarbodiimide (0.040 grams, 0.19 mmol) and 4-
(dimethylamino)pyridine (0.001 grams, 0.01 mmol) simultaneously. This was allowed to react 
for 12 hours and quenched by the addition of H2O and extracted with DCM (3 x 25 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 15% 
EtOAc:Hexanes) to afford 33e (0.0301g, 85%) as an amorphous white solid: 
1
H NMR (400 
MHz, CDCl3) δ 7.17 (d, J = 2.4 Hz, 2H), 6.64 (t, J = 2.4 Hz, 1H), 6.10 (s, 2H), 5.48 (dt, J = 5.1, 
2.8 Hz, 1H), 3.82 (s, 6H), 3.80 (s, 3H), 3.79 (s, 3H), 2.92 (m, 2H); 
13
C NMR (126 MHz, CDCl3) 
δ 165.8, 160.6, 159.6, 158.8, 155.1, 131.9, 107.5, 105.5, 100.5, 93.1, 91.8, 66.7, 66.3, 55.6, 55.4, 
24.9; IR (film) νmax 2953, 2839, 1716, 1618, 1596, 1498, 1458, 1427, 1357, 1319, 1301, 1234, 
1203, 1153, 1147, 1128, 1051, 910, 813, 765, 730 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C20H22O7Na, 397.1263; found, 397.1260.  
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33f 
5,7-dimethoxychroman-3-yl 3,4,5-trimethoxybenzoate (33f): To a stirring solution of 28 
(0.017 grams, 0.081 mmol) and 3,4,5-trimethoxybenzoic acid (0.034 grams, 0.162 mmol) in 
DCM (1 mL) was added N,N’-dicyclohexylcarbodiimide (0.033 grams, 0.162 mmol) and 4-
(dimethylamino)pyridine (0.001 grams, 0.008 mmol) simultaneously. This was allowed to react 
for 12 hours and quenched by the addition of H2O and extracted with DCM (3 x 25 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 30% 
EtOAc:Hexanes) to afford 33f (0.0242g, 74%) as an amorphous white solid: 
1
H NMR (400 
MHz, CDCl3) δ 7.28 (s, 2H), 6.11 (s, 2H), 5.49 (qd, J = 5.1, 2.8 Hz, 1H), 4.26 (m, 2H), 3.90 (s, 
3H), 3.88 (s, 6H), 3.80 (s, 3H), 3.78 (s, 3H), 2.95 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 165.7, 
159.6, 158.8, 155.1, 152.9, 142.4, 125.1, 107.0, 100.6, 93.1, 91.7, 66.8, 66.3, 60.9, 56.3, 55.4, 
50.9, 25.0; IR (film) νmax 2941, 2839, 1712, 1620, 1591, 1500, 1460, 1415, 1357, 1336, 1249, 
1224, 1201, 1178, 1145, 1137, 1056, 1004, 972, 813 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd 
for  C21H24O8Na, 427.1369; found, 427.1375. 
 
 
35a 
5,7-dimethoxychroman-3-yl 3-hydroxybenzoate (35a): To a stirring solution of 28 (0.021 
grams, 0.1 mmol) and benzoic acid 29c (0.049 grams, 0.2 mmol) in DCM (1 mL) was added 
111 
 
N,N’-dicyclohexylcarbodiimide (0.041 grams, 0.2 mmol) and 4-(dimethylamino)pyridine (0.002 
grams, 0.01 mmol) simultaneously. This was allowed to react for 12 hours and quenched by the 
addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions were 
washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue 
was carried on without further purification. 
The crude residue (0.055 grams, 0.124 mmol) was dissolved in THF (2 mL) and treated 
with tetrabutylammonium fluoride (0.38 mL, 0.372 mmol) and allowed to react for 12 hrs. This 
reaction was quenched with saturated aqueous NH4Cl and extracted with EtOAc (3 x 50 mL), 
dried (Na2SO4), filtered, and concentrated to afford 35a (0.0293g, 89%) over 2 steps as an 
amorphous white solid: 
1
H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 7.7 Hz, 1H), 7.34 (t, J = 1.9 
Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.06 (m, 1H), 6.12 (d, J = 1.9 Hz, 1H), 6.06 (d, J = 2.0 Hz, 
1H), 5.17 (m, 1H), 4.97 (s, 1H), 4.49 (ddd, J = 17.9, 11.8, 4.9 Hz, 2H), 3.81 (s, 3H), 3.79 (s, 4H), 
3.29 (dd, J = 15.1, 9.6 Hz, 1H), 2.96 (dd, J = 15.2, 6.5 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 
166.2, 161.7, 161.3, 156.7, 155.6, 131.1, 129.7, 122.3, 120.3, 116.3, 105.0, 91.3, 88.5, 81.1, 66.8, 
55.6, 55.4, 29.3; IR (film) νmax 3444(br), 2954, 2856, 1718, 1625, 1602, 1508, 1463, 1452, 
1361, 1266, 1217, 1199, 1161, 1141, 1097, 1047, 910, 838, 773 cm
-1
; HRMS (ESI+) m/z: [M + 
Na]+ calcd for  C18H18O6Na, 353.1001; found, 353.0993. 
 
35b 
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5,7-dimethoxychroman-3-yl 4-hydroxybenzoate (35b): To a stirring solution of 28 (0.021 
grams, 0.1 mmol) and benzoic acid 29c (0.050 grams, 0.2 mmol) in DCM (1 mL) was added 
N,N’-dicyclohexylcarbodiimide (0.043 grams, 0.2 mmol) and 4-(dimethylamino)pyridine (0.003 
grams, 0.01 mmol) simultaneously. This was allowed to react for 12 hours and quenched by the 
addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions were 
washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue 
was carried on without further purification. 
The crude residue (0.033 grams, 0.074 mmol) was dissolved in THF (2 mL) and treated 
with tetrabutylammonium fluoride (0.25 mL, 0.222 mmol) and allowed to react for 12 hrs. This 
reaction was quenched with saturated aqueous NH4Cl and extracted with EtOAc (3 x 50 mL), 
dried (Na2SO4), filtered, and concentrated to afford 35b (0.0172g, 52%) over 2 steps as an 
amorphous white solid: 
1
H NMR (400 MHz, CDCl3) δ 7.94 (m, 2H), 6.85 (m, 2H), 6.11 (d, J = 
1.9 Hz, 1H), 6.05 (d, J = 2.0 Hz, 1H), 5.16 (m, 2H), 4.48 (qd, J = 11.8, 5.2 Hz, 2H), 3.82 (s, 3H), 
3.78 (s, 3H), 3.27 (dd, J = 15.1, 9.5 Hz, 1H), 2.95 (dd, J = 15.1, 6.8 Hz, 1H).
13
C NMR (126 
MHz, CDCl3) δ 166.1, 161.7, 161.2, 159.8, 156.6, 132.2, 122.4, 115.2, 104.9, 91.3, 88.5, 81.2, 
66.3, 55.6, 55.4, 29.3; IR (film) νmax 3519(br), 2954, 2856, 1718, 1625, 1602, 1508, 1452, 
1242, 1217, 1199, 1161, 1141, 1097, 1047, 1010, 983, 910, 838, 773 cm
-1
; HRMS (ESI+) m/z: 
[M + Na]+ calcd for  C18H18O6Na, 353.1001; found, 353.0996. 
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35d 
5,7-dimethoxychroman-3-yl 3,5-dihydroxyenzoate (35d): To a stirring solution of 28 (0.020 
grams, 0.095 mmol) and benzoic acid 31c (0.073 grams, 0.19 mmol) in DCM (2 mL) was added 
N,N’-dicyclohexylcarbodiimide (0.040 grams, 0.19 mmol) and 4-(dimethylamino)pyridine 
(0.002 grams, 0.01 mmol) simultaneously. This was allowed to react for 12 hours and quenched 
by the addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions 
were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was carried on without further purification. 
The crude residue (0.0445 grams, 0.077 mmol) was dissolved in THF (2 mL) and treated 
with tetrabutylammonium fluoride (0.25 mL, 0.232 mmol) and allowed to react for 12 hrs. This 
reaction was quenched with saturated aqueous NH4Cl and extracted with EtOAc (3 x 50 mL), 
dried (Na2SO4), filtered, and concentrated to afford 35d (0.0181g, 55%) over 2 steps as an 
amorphous white solid: 
1
H NMR (400 MHz, CDCl3) δ 6.96 (d, J = 2.3 Hz, 2H), 6.58 (t, J = 2.3 
Hz, 1H), 6.12 (d, J = 1.9 Hz, 1H), 6.06 (d, J = 1.9 Hz, 1H), 5.54 (s, 2H), 5.15 (m, 1H), 4.45 (m, 
2H), 3.81 (s, 3H), 3.78 (s, 3H), 3.28 (dd, J = 15.2, 9.6 Hz, 1H), 2.95 (dd, J = 15.2, 6.3 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 165.8, 161.7, 161.5, 156.8, 156.7, 131.9, 109.3 (2x), 107.5, 
105.2, 91.2, 88.6, 81.0, 68.6, 67.0, 55.7, 55.4, 29.3; IR (film) νmax 3434(br), 2954, 2858, 1720, 
1625, 1612, 1508, 1463, 1421, 1307, 1255, 1215, 1201, 1143, 1101, 1047, 995, 981, 898, 821, 
781 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C18H18O7Na, 369.0950; found, 369.0941.  
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36a 
5,7-dimethoxychroman-3-yl 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (36a): To a 
stirring solution of 28 (0.022 grams, 0.105 mmol) and 4-acetoxy-3-(3-methylbut-2-en-1-
yl)benzoic acid(cite) (0.052 grams, 0.21 mmol) in DCM (2 mL) was added N,N’-
dicyclohexylcarbodiimide (0.044 grams, 0.21 mmol) and 4-(dimethylamino)pyridine (0.002 
grams, 0.01 mmol) simultaneously. This was allowed to react for 12 hours and quenched by the 
addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions were 
washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue 
was purified via column chromatography (SiO2 15% EtOAc:Hexanes) to afford 33a (0.0363g, 
79%) as a colorless oil: 
1
H NMR (400 MHz, CDCl3) δ 7.87 (m, 2H), 7.08 (d, J = 8.3 Hz, 1H), 
6.10 (d, J = 1.9 Hz, 1H), 6.04 (d, J = 2.0 Hz, 1H), 5.18 (m, 2H), 4.49 (m, 2H), 3.80 (s, 3H), 3.77 
(s, 3H), 3.26 (m, 3H), 2.95 (dd, J = 15.1, 6.7 Hz, 1H), 2.33 (s, 3H), 1.75 (s, 3H), 1.71 (s, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ 170.0, 166.9, 164.9, 161.7, 161.5, 157.2, 156.8, 137.1, 131.9, 130.3, 
128.1, 127.4, 126.3, 122.3, 121.2, 103.1, 93.5, 91.9, 80.9, 67.9, 28.7, 27.5, 25.2, 20.6, 18.6; IR 
(film) νmax 2958, 2931, 1762, 1720, 1625, 1610, 1504, 1452, 1369, 1280, 1259, 1201, 1164, 
1143, 1103, 1047, 808, 757 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C25H28O7Na, 
463.1733; found, 463.1735. 
 
 
36b 
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5,7-dimethoxychroman-3-yl 3',6-dimethoxy-[1,1'-biphenyl]-3-carboxylate (36b): To a 
stirring solution of 28 (0.020 grams, 0.095 mmol) and 3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxylic acid(cite) (0.049 grams, 0.19 mmol) in DCM (1.5 mL) was added N,N’-
dicyclohexylcarbodiimide (0.039 grams, 0.19 mmol) and 4-(dimethylamino)pyridine (0.001 
grams, 0.009 mmol) simultaneously. This was allowed to react for 12 hours and quenched by the 
addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions were 
washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue 
was purified via column chromatography (SiO2 30% EtOAc:Hexanes) to afford 33a (0.040g, 
94%) as a colorless oil: 
1
H NMR (500 MHz, CDCl3) δ 8.03 (dd, J = 8.6, 2.3 Hz, 1H), 7.98 (d, J = 
2.2 Hz, 1H), 7.36 (dd, J = 11.8, 4.5 Hz, 1H), 7.08 (m, 2H), 7.00 (d, J = 8.7 Hz, 1H), 6.93 (m, 
1H), 6.10 (d, J = 2.0 Hz, 1H), 6.02 (d, J = 2.0 Hz, 1H), 5.17 (m, 1H), 4.50 (ddd, J = 18.2, 11.8, 
5.1 Hz, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 3.79 (s, 3H), 3.77 (s, 3H), 3.27 (dd, J = 15.1, 9.6 Hz, 1H), 
2.96 (dd, J = 15.1, 6.7 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 166.2, 161.7, 161.3, 160.3, 
159.2, 156.6, 138.8, 132.5, 131.1, 130.4, 129.1, 122.2, 122.0, 115.3, 112.9, 110.5, 104.9, 91.3, 
88.4, 81.2, 66.4, 55.8, 55.6, 55.3, 29.4; IR (film) νmax 3006, 2941, 2839, 1714, 1623, 1606, 
1504, 1454, 1442, 1299, 1249, 1215, 1205, 1178, 1141, 1049, 1037, 983, 810, 756 cm
-1
; HRMS 
(ESI+) m/z: [M + Na]+ calcd for  C26H26O7Na, 473.1576; found, 473.1579. 
 
37 
(allyloxy)benzene (37): A solution of phenol (0.925 g, 9.83 mmol) was dissolved in Acetone (20 
mL and treated sequentially with potassium carbonate (4.08 grams, 29.5 mmol) and allyl 
bromide (2.6 mL 29.5 mmol). The solution was heated to reflux and allowed to react for 12 
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hours. This reaction was cooled to room temperature and quenched by the addition of H2O, 
extracted with EtOAc (3 x 150 mL). The combined organic fractions were washed with saturated 
aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via column 
chromatography (SiO2 10% EtOAc:Hexanes) to afford 37 (0.7662g, 58%) as a colorless oil: 
1
H 
NMR (400 MHz, CDCl3) δ 7.31 (m, 2H), 6.97 (m, 3H), 6.09 (ddt, J = 17.2, 10.5, 5.3 Hz, 1H), 
5.44 (dq, J = 17.3, 1.6 Hz, 1H), 5.31 (dq, J = 10.5, 1.3 Hz, 1H), 4.56 (dt, J = 5.3, 1.5 Hz, 2H); 
13
C NMR (126 MHz, CDCl3) δ 158.6, 133.3, 129.7, 129.4, 120.8, 117.7, 114.9, 114.5, 68.7; IR 
(film) νmax 3454(br), 2921, 1598, 1585, 1494, 1242, 1031, 991, 925, 881, 752 cm
-1
; HRMS 
(ESI+) m/z: [M + H]+ calcd for  C9H11O, 153.0810; found, 153.0813. 
 
38 
2-allylphenol (38):  A solution of 37 (0.736 grams, 5.5 mmol) was dissolved in DCM (20 mL) 
and treated dropwise with 1.0M solution of dimethylaluminum chloride (6.0 mL, 6.0 mmol) and 
stirred until TLC revealed complete consumption of starting material. The reaction was 
quenched by the addition of 1.0 N HCl, extracted with EtOAc (3 x 150 mL). The combined 
organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated. The residue was purified via column chromatography (SiO2 30% EtOAc:Hexanes) 
to afford 38 (0.505g, 69%) as a colorless oil: 
1
H NMR (400 MHz, CDCl3) δ 7.08 (m, 2H), 6.85 
(m, 2H), 5.95 (m, 1H), 5.01 (m, 2H), 3.25 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 156.5, 136.3, 
132.6, 127.2, 125.3, 121.0, 117.9, 115.9, 33.7; IR (film) νmax 3517(br), 3076, 2977, 1637, 1591, 
1488, 1456, 1330, 1255, 1217, 1170, 916, 838, 752 cm
-1
; HRMS (ESI+) m/z: [M + H]+ calcd for  
C9H11O, 153.0810; found, 153.0816. 
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39 
3-(2-hydroxy-4,6-dimethoxyphenyl)propane-1,2-diol (39): A solution of 38 (0.460 grams, 
3.43 mmol) was dissolved in a (1.5 : 1.0) mixture of THF (14 mL) and H2O (7 mL) respectively 
was treated with 4-methylmorpholine N-oxide (0.603 grams, 5.14 mmol) followed by dropwise 
addition of a 4% Osmium tetraoxide solution in H2O (0.15 mL, 0.34 mmol). This was allowed to 
stir for 18 hours before it was diluted with H2O and extracted with EtOAc (3 x 100 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 40% 
EtOAc:Hexanes) to afford 39 (0.469g, 81%) as a colorless oil: 
1
H NMR (400 MHz, CDCl3) δ 
7.16 (m, 1H), 7.04 (dd, J = 7.5, 1.6 Hz, 1H), 6.88 (m, 2H), 4.03 (m, 1H), 3.69 (dd, J = 11.2, 3.2 
Hz, 1H), 3.49 (m, 1H), 2.83 (m, 2H); 
13
C NMR (126 MHz, CDCl3) δ 155.4, 131.4, 128.6, 124.3, 
120.5, 117.3, 65.8, 53.5, 34.9; IR (film) νmax 3341(br), 2937, 2746, 1608, 1593, 1488, 1466, 
1245, 1180, 1107, 1026, 864, 754 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C9H12O3Na, 
191.0684; found, 191.0688. 
 
 
42 
chroman-3-yl acetate (42): A solution of 39 (0.492 grams, 2.93 mmol) was dissolved in DCM 
(15 mL) and cooled to 0°C, treated with pyridine (1.1 mL, 13.2 mmol) and allowed to stir for 5 
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minutes. Finally para-toluenesulfonyl chloride (0.61 grams, 3.2 mmol) was added and allowed to 
warm to room temperature after 1 hour. This was allowed to react for 12 hours and quenched by 
the addition of H2O and extracted with EtOAc (3 x 250 mL). The combined organic fractions 
were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified via column chromatography (SiO2 30% EtOAc:Hexanes) to afford crude 
phenolic sulfonic ester 40 (0.65g) as a yellow oil. 
This oil was dissolved in MeOH (10 mL) and treated with potassium carbonate (0.449 
grams, 3.23 mmol) and monitored by TLC. Once the TLC showed the consumption of starting 
material the solution was filtered and washed with EtOAc, dried (Na2SO4), filtered and 
concentrated. This produced an inseparable mixture of compounds 41a-b (30% 
EtOAc:Hexanes), as a colorless oil (0.194g) . 
 The mixture of compounds (0.163 grams, 1.09 mmol) was dissolved in DCM (5 mL) and 
cooled to 0°C and was treated with diisopropylethyl amine (0.38 mL, 2.18 mmol) and stirred for 
5 minutes then acetyl chloride (0.09 mL, 1.1 mmol) was added dropwise and allowed to warm to 
room temperature over 12 hours. The reaction was quenched by the addition of H2O and 
extracted with EtOAc (3 x 25 mL). The combined organic fractions were washed with saturated 
aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via column 
chromatography (SiO2 10% EtOAc:Hexanes) to afford  (0.093 g, 17%) over 3 steps as a 
colorless oil: 
1
H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 7.3 Hz, 2H), 7.14 (t, J = 7.8 Hz, 1H), 
6.88 (td, J = 7.4, 0.8 Hz, 2H), 6.83 (d, J = 8.0 Hz, 1H), 5.01 (dtd, J = 9.5, 7.3, 3.6 Hz, 1H), 4.36 
(dd, J = 11.9, 3.6 Hz, 1H), 4.23 (dd, J = 11.9, 7.1 Hz, 1H), 3.33 (dd, J = 15.7, 9.5 Hz, 1H), 2.99 
(dd, J = 15.7, 7.5 Hz, 1H), 2.12 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 171.0, 159.2, 128.2, 
127.3, 125.7, 121.0, 109.7, 80.0, 66.7, 32.0, 21.1; IR (film) νmax 3442(br), 2945, 1741, 1481, 
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1461, 1369, 1222, 1166, 1114, 1043, 914, 867, 752 cm
-1
; HRMS (ESI+) m/z: [M + H]+ calcd for  
C11H13O3, 193.0865; found, 193.0867. 
 
43 
chroman-3-ol (43): A solution of 42 (0.0712 grams, 0.37 mmol) in a (9:1) mixture of MeOH : 
H2O (1.8 mL : 0.2 mL) was treated with potassium carbonate (0.154 grams, 1.11 mmol) and 
allowed to react for 4 hours. The reaction was quenched by the addition of saturated aqueous 
ammonium chloride and extracted with EtOAc (3 x 50 mL). The combined organic fractions 
were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified via column chromatography (SiO2 30% EtOAc:Hexanes) to afford 43 
(0.441g, 79%) as a colorless oil: 
1
H NMR (500 MHz, CDCl3) δ 7.19 (dd, J = 7.3, 0.9 Hz, 1H), 
7.14 (ddd, J = 8.0, 1.3, 0.7 Hz, 1H), 6.88 (td, J = 7.4, 0.9 Hz, 1H), 6.82 (m, 1H), 4.94 (dddd, J = 
9.5, 7.4, 6.4, 3.2 Hz, 1H), 3.88 (ddd, J = 12.0, 6.9, 3.2 Hz, 1H), 3.77 (dt, J = 12.1, 6.1 Hz, 1H), 
3.28 (dd, J = 15.6, 9.5 Hz, 1H), 3.04 (dd, J = 15.6, 7.4 Hz, 1H).; 
13
C NMR (126 MHz, CDCl3) δ 
159.2, 128.1, 125.1, 120.7, 109.5, 83.0, 65.0, 31.2; IR (film) νmax 3379(br), 2925, 1596, 1481, 
1461, 1325, 1230, 1097, 1047, 1014, 898, 864, 750 cm
-1
; HRMS (ESI+) m/z: [M +]+ calcd for  
C9H10O2, 150.0681; found, 150.0686. 
 
44a 
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chroman-3-yl 3-methoxybenzoate (44a): To a stirring solution of 43 (0.010 grams, 0.067 
mmol) and 3-methoxybenzoic acid (0.021 grams, 0.134 mmol) in DCM (1 mL) was added N,N’-
dicyclohexylcarbodiimide (0.029 grams, 0.134 mmol) and 4-(dimethylamino)pyridine (0.001 
grams, 0.008 mmol) simultaneously. This was allowed to react for 12 hours and quenched by the 
addition of H2O and extracted with DCM (3 x 25 mL). The combined organic fractions were 
washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue 
was purified via column chromatography (SiO2 10% EtOAc:Hexanes) to afford 44a (0.0167g, 
88%) as a colorless oil: 
1
H NMR (400 MHz, CDCl3) δ 7.96 (dd, J = 8.6, 2.2 Hz, 1H), 7.92 (d, J = 
2.2 Hz, 1H), 7.36 (t, J = 8.1 Hz, 1H), 7.19 (d, J = 7.4 Hz, 1H), 7.12 (t, J = 7.7 Hz, 1H), 7.06 (m, 
2H), 6.97 (d, J = 8.6 Hz, 1H), 6.92 (m, 1H), 6.84 (m, 2H), 5.14 (m, 1H), 4.55 (dd, J = 11.8, 3.8 
Hz, 1H), 4.48 (dd, J = 11.8, 5.9 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.41 (dd, J = 15.7, 9.6 Hz, 
1H), 3.10 (dd, J = 15.7, 6.7 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 166.0, 161.0, 160.9, 131.1, 
130.2, 129.6, 126.4, 122.3, 122.2, 120.4, 119.8, 118.6, 114.0, 80.2, 68.4, 55.8, 33.6; IR (film) 
νmax 2941, 1720, 1598, 1481, 1461, 1433, 1321, 1276, 1222, 1182, 1107, 1043, 985, 912, 873, 
788, 752 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C17H16O4Na, 307.0946; found, 
307.0947.  
 
44b 
5chroman-3-yl 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoate (44b): To a stirring solution of 
43 (0.010 grams, 0.067 mmol) and 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid(cite) (0.033 
grams, 0.134 mmol) in DCM (1 mL) was added N,N’-dicyclohexylcarbodiimide (0.029 grams, 
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0.134 mmol) and 4-(dimethylamino)pyridine (0.001 grams, 0.007 mmol) simultaneously. This 
was allowed to react for 12 hours and quenched by the addition of H2O and extracted with DCM 
(3 x 25 mL). The combined organic fractions were washed with saturated aqueous NaCl, dried 
(Na2SO4), filtered, and concentrated. The residue was purified via column chromatography (SiO2 
10% EtOAc:Hexanes) to afford 44b (0.0176g, 69%) as a colorless oil: 
1
H NMR (400 MHz, 
CDCl3) δ 7.84 (d, J = 2.1 Hz, 1H), 7.80 (dd, J = 8.4, 2.2 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 7.15 
(t, J = 7.3 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.87 (ddd, J = 16.9, 11.8, 4.4 Hz, 2H), 5.17 (m, 2H), 
4.55 (dd, J = 11.8, 3.7 Hz, 1H), 4.49 (dd, J = 11.8, 5.8 Hz, 1H), 3.41 (dd, J = 15.7, 9.6 Hz, 1H), 
3.25 (d, J = 7.1 Hz, 2H), 3.10 (dd, J = 15.7, 6.7 Hz, 1H), 2.33 (s, 3H), 1.75 (d, J = 1.0 Hz, 3H), 
1.70 (s, 3H); 
13
C NMR (126 MHz, CDCl3) δ 169.9, 165.9, 161.9, 153.2, 135.1, 131.5, 130.1, 
127.4, 127.1, 126.7, 123.2, 122.4, 121.3, 120.5, 119.8, 80.2, 68.5, 33.7, 28.1, 24.7, 20.3, 18.7; IR 
(film) νmax 3433(br), 2962, 2923, 1762, 1722, 1608, 1596, 1481, 1461, 1369, 1280, 1261, 1201, 
1164, 1114, 1014, 912, 752 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C23H24O5Na, 
403.1521; found, 403.1514. 
 
 
44c 
chroman-3-yl 3',6-dimethoxy-[1,1'-biphenyl]-3-carboxylate (44c): To a stirring solution of 43 
(0.010 grams, 0.067 mmol) and 3',6-dimethoxy-[1,1'-biphenyl]-3-carboxylic acid(cite) (0.035 
grams, 0.134 mmol) in DCM (1 mL) was added N,N’-dicyclohexylcarbodiimide (0.030 grams, 
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0.134 mmol) and 4-(dimethylamino)pyridine (0.001 grams, 0.007 mmol) simultaneously. This 
was allowed to react for 12 hours and quenched by the addition of H2O and extracted with DCM 
(3 x 25 mL). The combined organic fractions were washed with saturated aqueous NaCl, dried 
(Na2SO4), filtered, and concentrated. The residue was purified via column chromatography (SiO2 
30% EtOAc:Hexanes) to afford 33a (0.0194g, 74%) as a colorless oil: 
1
H NMR (500 MHz, 
CDCl3) δ 7.94 (dd, J = 8.6, 2.3 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.34 (dd, J = 8.8, 7.5 Hz, 1H), 
7.17 (d, J = 7.2 Hz, 1H), 7.11 (dd, J = 12.0, 4.4 Hz, 1H), 7.05 (m, 2H), 6.96 (d, J = 8.6 Hz, 1H), 
6.91 (m, 1H), 6.82 (m, 2H), 5.12 (ddd, J = 13.2, 6.3, 3.3 Hz, 1H), 4.53 (dd, J = 11.8, 3.8 Hz, 1H), 
4.47 (dd, J = 11.8, 6.0 Hz, 1H), 3.87 (s, 2H), 3.83 (s, 1H), 3.39 (dd, J = 15.7, 9.6 Hz, 1H), 3.09 
(dd, J = 15.7, 6.7 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 166.2, 160.3, 159.3, 138.7, 132.5, 
131.1, 130.4, 129.1, 128.2, 125.9, 124.8, 122.1, 120.6, 115.3, 112.8, 110.6, 109.5, 80.0, 66.5, 
55.8, 55.3, 32.2; IR (film) νmax 3434(br), 2941, 1714, 1604, 1481, 1461, 1438 1311, 1239, 
1205, 1178, 1137, 1116, 1035, 875, 752 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C24H22O5Na, 413.1365; found, 413.1374. 
 
45 
1,3-bis(methoxymethoxy)benzene (45): A suspension of sodium hydride (5.8 grams, 143.2 
mmol) in DMF (30 mL) was made at 0°C and resorcinol (3.95 grams, 143.2 mmol) dissolved in 
DMF (10 mL) was added dropwise to the suspension. Finally, MOMCl (24.0 mL, 143.2 mmol) 
was added at 0°C and allowed to warm to room temperature overnight. The reaction was 
quenched by the addition of H2O and extracted with EtOAc (3 x 150mL). The combined organic 
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fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. 
The residue was purified via column chromatography (SiO2 10% EtOAc:Hexanes) to afford 45 
as a pale yellow oil (7.166g, 99%): 
1
H NMR (500 MHz, CDCl3) δ 7.19 (t, J = 8.2 Hz, 1H), 6.74 
(t, J = 2.3 Hz, 1H), 6.71 (d, J = 2.3 Hz, 1H), 6.69 (d, J = 2.3 Hz, 1H), 5.16 (s, 4H), 3.48 (s, 6H); 
13
C NMR (126 MHz, CDCl3) δ 158.3, 130.0, 109.6, 105.0, 94.5, 56.0;  IR (film) νmax 3310(br), 
2943, 2895, 1647, 1592, 1471, 1443, 1399, 1319, 1257, 1150, 1112, 1084, 1042, 995, 773, 665 
cm
-1
; HRMS (ESI+) m/z: [M + H]+ calcd for  C10H15O4, 199.0970; found, 199.0969. 
  
46 
2-allyl-1,3-bis(methoxymethoxy)benzene (46): To a stirring solution of 45 (1.16 grams, 5.86 
mmol) in THF (30mL) was cooled to 0°C and treated dropwise with a 2.5M solution of n-butyl 
lithium (2.8 mL, 7.0 mmol) and allowed to warm to room temperature over 30 min. Allyl 
bromide (0.53 mL, 5.9 mmol) was added to the stirring solution and allowed to react for 2 hrs 
and quenched by the addition of H2O and extracted with EtOAc (3 x 100 mL). The combined 
organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and 
concentrated. The residue was purified via column chromatography (SiO2 5% EtOAc:Hexanes) 
to afford 46 (0.729g, 52%) as yellow oil: 
1
H NMR (500 MHz, CDCl3) δ 7.13 (t, J = 8.3 Hz, 1H), 
6.81 (s, 1H), 6.79 (s, 1H), 5.99 (ddt, J = 17.0, 10.0, 6.1 Hz, 1H), 5.21 (s, 4H), 4.99 (ddd, J = 
13.6, 12.1, 2.0 Hz, 2H), 3.49 (s, 6H); 
13
C NMR (126 MHz, CDCl3) δ 155.8, 136.8, 127.2, 118.3, 
114.2, 107.9, 94.4, 56.1, 27.7; IR (film) νmax 3440(br), 2954, 2900, 1637, 1595, 1469, 1440, 
1402, 1321, 1255, 1153, 1114, 1081, 1041, 995, 921, 777, 663 cm
-1
; HRMS (ESI+) m/z: [2M + 
Na]+ calcd for  C26H36O8Na, 499.2308; found, 499.2330. 
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47 
3-(2,6-bis(methoxymethoxy)phenyl)propane-1,2-diol (47): A solution of 46 (0.69 grams, 2.9 
mmol) was dissolved in a (1.5 : 1.0) mixture of THF (10 mL) and H2O (5 mL) respectively was 
treated with 4-methylmorpholine N-oxide (0.511 grams, 4.35 mmol) followed by dropwise 
addition of a 4% Osmium tetraoxide solution in H2O (0.12 mL, 0.29 mmol). This was allowed to 
stir for 18 hours before it was diluted with H2O and extracted with EtOAc (3 x 100 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 2% MeOH:DCM) 
to afford 47 (0.469g, 87%) as a yellow oil: 
1
H NMR (400 MHz, CDCl3) δ 7.15 (t, J = 8.4 Hz, 
1H), 6.83 (s, 1H), 6.81 (s, 1H), 5.23 (s, 4H), 3.97 (td, J = 5.8, 3.9 Hz, 1H), 3.61 (ddd, J = 11.8, 
8.3, 3.6 Hz, 1H), 3.52 (m, 7H), 2.99 (qd, J = 13.4, 6.6 Hz, 2H), 2.65 (d, J = 5.8 Hz, 1H), 2.41 
(dd, J = 8.2, 5.1 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 156.2, 128.0, 115.8, 108.2 (2x), 94.7 
(2x), 72.1, 66.0, 56.3, 27.3; IR (film) νmax 3436, 2933, 1595, 1467, 1255, 1182, 1153, 1105, 
1078, 1051, 1022, 919, 779 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C13H20O6Na, 
295.1158; found, 295.1148. 
 
48 
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chroman-3,5-diol (48):  A solution of 47 (4.82 grams, 17.7 mmol) was dissolved in DCM (90 
mL) and cooled to 0°C, treated with pyridine (6.5 mL, 76.6 mmol) and allowed to stir for 5 
minutes. Finally para-toluenesulfonyl chloride (3.78 grams, 19.5 mmol) was added and allowed 
to warm to room temperature after 1 hour. This was allowed to react for 12 hours and quenched 
by the addition of H2O and extracted with EtOAc (3 x 250 mL). The combined organic fractions 
were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified via column chromatography (SiO2 40% EtOAc:Hexanes) to afford crude 
phenolic sulfonic ester 47a (6.01g, 80%) as a yellow oil:  
A solution of 47a (6.01 grams, 14.1 mmol) was dissolved in MeOH (70 mL) and treated 
with an aqueous 6.0M solution of hydrochloric acid (17.5 mL) and allowed to react for 12 hours 
and quenched by pouring the reaction mixture in a saturated aqueous hydrogen bicarbonate 
solution and extracted with EtOAc (3 x 250 mL). The combined organic fractions were washed 
with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was 
purified via column chromatography (SiO2 40% EtOAc:Hexanes) to afford 47b (3.52g, 74%) as 
a pale yellow oil:  
To a solution of 47b (0.184 grams, 0.544 mmol) was dissolved in MeOH (4 mL) and 
treated with potassium carbonate (0.122 grams, 0.87 mmol) and monitored by TLC. Once the 
TLC showed the consumption of starting material the solution was filtered and washed with 
saturated aqueous NaCl, dried (Na2SO4), filtered and concentrated. This residue was purified via 
column chromatography (SiO2, 30% EtOAc:Hexanes), as a colorless oil (0.194g) EtOAc (3 x 
250 mL). The combined organic fractions were washed with saturated aqueous NaCl, dried 
(Na2SO4), filtered, and concentrated. The residue was purified via column chromatography (SiO2 
40% EtOAc:Hexanes) to afford 48 (0.075g, 83%) as a pale yellow oil: 
1
H NMR (500 MHz, 
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Acetone) δ 8.24 (s, 1H), 6.83 (t, J = 8.1 Hz, 1H), 6.35 (dd, J = 8.0, 1.0 Hz, 1H), 6.24 (dd, J = 8.2, 
0.8 Hz, 1H), 4.15 (d, J = 4.7 Hz, 1H), 4.08 (ddd, J = 6.6, 3.8, 1.5 Hz, 1H), 4.04 (ddd, J = 10.4, 
2.9, 1.7 Hz, 1H), 3.75 (ddd, J = 10.4, 7.1, 1.1 Hz, 1H), 2.92 (ddd, J = 16.6, 5.4, 1.5 Hz, 1H), 2.52 
(dd, J = 16.7, 6.7 Hz, 1H); 
13
C NMR (126 MHz, Acetone) δ 157.0, 156.3, 127.6, 109.1, 108.4, 
107.4, 70.4, 63.2;  IR (film) νmax 3338, 2931, 1620, 1595, 1492, 1454, 1381, 1342, 1278, 1147, 
1097, 1012, 961, 827, 733, 698 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C9H10O3Na, 
189.0528; found, 189.0532. 
 
49 
5-(benzyloxy)chroman-3-ol (49). To a solution of 48 (0.0154 grams, 0.093 mmol) was 
dissolved in CH3CN (2 mL) and treated sequentially with benzyl bromide (0.011 mL, 0.095 
mmol) and potassium carbonate (0.013 grams, 0.095 mmol) and allowed to react for 12 hrs. The 
reaction was quenched by the addition of H2O and extracted with EtOAc (3 x 25 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 30% 
EtOAc:Hexanes) to afford 49 (0.016 g, 66%) as a colorless oil: 
1
H NMR (400 MHz, CDCl3) δ 
7.35 (m, 5H), 6.98 (t, J = 8.0, 2.3 Hz, 1H), 6.37-6.34 (d, J = 8.1, 2H), 5.04 (s, 2H), 4.82 (m, 1H), 
3.77 (m, 1H), 3.68 (m, 1H), 3.17 (m, 1H), 2.90 (m, 1H), 1.91 (s, 1H);  
13
C NMR (126 MHz, 
CDCl3) δ 161.3, 157.4, 137.1, 129.5, 128.7 (2x), 127.8, 125.8 (2x), 114.1, 109.5, 103.0, 83.7, 
70.0, 65.1, 29.2; IR (film) νmax 3353(br), 2923, 2871, 1593, 1496, 1471, 1452, 1379, 1340, 
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1265, 1238, 1174, 1108, 1056, 972, 767, 737, 696 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C16H16O3Na, 279.0997; found, 279.0987. 
 
50 
3-((tert-butyldimethylsilyl)oxy)phenol (50): A solution of resorcinol (0.526 grams, 4.78 mmol) 
was dissolved in DMF (8 mL) and treated sequentially with imidazole (0.491 grams, 7.2 mmol) 
and tert-butyl(chloro)dimethylsilane (0.71 grams, 4.78 mmol) and allowed to react for 12 hours. 
The reaction was quenched by the addition of H2O and extracted with EtOAc (3 x 50 mL). The 
combined organic fractions were washed with H2O (3 x 50 mL), saturated aqueous NaCl, dried 
(Na2SO4), filtered and concentrated.  The residue was purified via column chromatography (SiO2 
10% EtOAc:Hexanes) to afford 50 (0.469 g, 44%) as a pale yellow oil: 
1
H NMR (500 MHz, 
CDCl3) δ 7.07 (t, J = 8.1 Hz, 1H), 6.43 (dd, J = 8.1, 2.3 Hz, 2H), 6.35 (t, J = 2.3 Hz, 1H), 4.71 (s, 
1H), 0.98 (s, 9H), 0.20 (s, 6H); 
13
C NMR (126 MHz, CDCl3) δ 157.1, 156.6, 130.1, 112.9, 108.5, 
107.7, 25.8 (3x), 18.3, 4.3 (2x); IR (film) νmax 3429(br), 2956, 2858, 1604, 1593, 1492, 1471, 
1361, 1294, 1257, 1170, 1145, 981, 948, 783 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C12H20O2SiNa, 247.1130; found, 247.1134. 
 
51 
(3-(allyloxy)phenoxy)(tert-butyl)dimethylsilane (51):  A solution of 50 (0.43 grams, 1.9 
mmol) was dissolved in acetone (10 mL)  was treated with potassium carbonate (0.80 grams, 5.7 
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mmol) and allyl bromide (0.5 mL, 5.7 mmol), then the solution was heated to reflux for 12 hours. 
This reaction was cooled to room temperature and quenched by the addition of H2O, extracted 
with EtOAc (3 x 75 mL). The combined organic fractions were washed with saturated aqueous 
NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via column 
chromatography (SiO2 5% EtOAc:Hexanes) to afford 51 (0.462g, 92%) as a pale yellow oil: 
1
H 
NMR (500 MHz, CDCl3) δ 7.11 (t, J = 8.1 Hz, 1H), 6.53 (m, 1H), 6.44 (m, 1H), 6.34 (d, J = 2.3 
Hz, 1H), 6.05 (m, 1H), 5.41 (ddd, J = 17.3, 2.6, 1.6 Hz, 1H), 5.28 (m, 1H), 4.51 (ddt, J = 8.6, 5.3, 
1.5 Hz, 2H), 0.98 (s, 9H), 0.20 (s, 6H); 
13
C NMR (126 MHz, CDCl3) δ 159.8, 156.7, 133.3, 
129.6, 120.8, 117.7, 112.8, 107.0, 68.8, 25.7 (3x), 18.2, 4.4 (2x); IR (film) νmax 2947, 2891, 
1611, 1589, 1514, 1460, 1425, 1359, 1297, 1253, 1172, 1112, 997, 835, 784cm
-1
; HRMS (ESI+) 
m/z: [M + Na]+ calcd for  C15H24O2SiNa, 287.1443; found, 287.1435. 
 
52 
2-allyl-5-((tert-butyldimethylsilyl)oxy)phenol (52): A solution of 51 (0.45 grams, 1.7 mmol) 
was dissolved in DCM (10 mL) and treated dropwise with 1.0M solution of dimethylaluminum 
chloride (1.9 mL, 1.9 mmol) and stirred until TLC revealed complete consumption of starting 
material. The reaction was quenched by the addition of 1.0 N HCl, extracted with EtOAc (3 x 50 
mL). The combined organic fractions were washed with saturated aqueous NaCl, dried 
(Na2SO4), filtered, and concentrated. The residue was purified via column chromatography (SiO2 
5% EtOAc:Hexanes) to afford 52 (0.1604g, 36%) as a colorless oil: 
1
H NMR (500 MHz, CDCl3) 
δ 6.92 (d, J = 8.1 Hz, 1H), 6.38 (dd, J = 8.1, 2.4 Hz, 1H), 6.35 (d, J = 2.4 Hz, 1H), 6.00 (ddd, J = 
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15.8, 12.0, 7.9 Hz, 1H), 5.16 (m, 1H), 5.13 (t, J = 1.6 Hz, 1H), 4.90 (s, 1H), 3.34 (m, 2H), 0.97 
(s, 9H), 0.19 (s, 6H); 
13
C NMR (126 MHz, CDCl3) δ 155.5, 154.8, 136.8, 130.7, 117.9, 116.3, 
112.6, 108.0, 34.7, 25.7 (3x), 18.2, 4.4 (2x); IR (film) νmax 2957, 2929, 2894, 2858, 1614, 1591, 
1514, 1469, 1463, 1425, 1361, 1294, 1255, 1230, 1170, 1112, 997, 867, 833, 781 cm
-1
; HRMS 
(ESI+) m/z: [M + Na]+ calcd for  C15H24O2SiNa, 287.1443; found, 287.1449. 
 
 
53 
3-(4-((tert-butyldimethylsilyl)oxy)-2-hydroxyphenyl)propane-1,2-diol (53): A solution of 52 
(0.132 grams, 0.50 mmol) was dissolved in a (1.5 : 1.0) mixture of THF and H2O (1.65 mL : 0.75 
mL) respectively was treated with 4-methylmorpholine N-oxide (0.090 grams, 0.75 mmol) 
followed by dropwise addition of a 4% Osmium tetraoxide solution in H2O (0.05 mL, 0.01 
mmol). This was allowed to stir for 18 hours before it was diluted with H2O and extracted with 
EtOAc (3 x 50 mL). The combined organic fractions were washed with saturated aqueous NaCl, 
dried (Na2SO4), filtered, and concentrated. The residue was purified via column chromatography 
(SiO2 40% EtOAc:Hexanes) to afford 55 (0.1167g, 78%) as a pale yellow oil: 
1
H NMR (500 
MHz, CDCl3) δ 6.84 (d, J = 8.2 Hz, 1H), 6.42 (d, J = 2.5 Hz, 1H), 6.34 (dd, J = 8.1, 2.4 Hz, 1H), 
4.00 (m, 1H), 3.68 (dd, J = 11.1, 3.3 Hz, 1H), 3.47 (dd, J = 11.1, 7.7 Hz, 1H), 2.79 (dd, J = 14.8, 
3.8 Hz, 1H), 2.72 (dd, J = 14.8, 7.0 Hz, 1H), 0.97 (s, 9H), 0.18 (s, 6H); 
13
C NMR (126 MHz, 
CDCl3) δ 156.0, 155.9, 131.6, 117.2, 112.3, 109.0, 73.6, 65.7, 34.4, 25.7 (3x), 18.2, 4.4 (2x); IR 
(film) νmax 3315(br), 2954, 2929, 2851, 1618, 1579, 1508, 1471, 1425, 1361, 1296, 1255, 1170, 
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1110, 1024, 979, 939, 873, 838, 783 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C15H26O4SiNa, 321.1498; found, 321.1500. 
 
 
56 
7-(benzyloxy)chroman-3-yl acetate (56): A solution of 53 (1.773 grams, 5.95 mmol) was 
dissolved in DCM (25 mL) and cooled to 0°C, treated with pyridine (2.2 mL, 26.8 mmol) and 
allowed to stir for 5 minutes. Finally para-toluenesulfonyl chloride (1.246 grams, 6.5 mmol) was 
added and allowed to warm to room temperature after 1 hour. This was allowed to react for 12 
hours and quenched by the addition of H2O and extracted with EtOAc (3 x 100 mL). The 
combined organic fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, 
and concentrated. The residue was purified via column chromatography (SiO2 20% 
EtOAc:Hexanes) to afford crude phenolic sulfonic ester 53a (2.06g) as a yellow oil. 
 This oil (2.12 grams, 4.69 mmol) was dissolved in MeOH (20 mL) and treated with 
potassium carbonate (1.04 grams, 7.5 mmol) and monitored by TLC. Once the TLC showed the 
consumption of starting material the solution was filtered and washed with EtOAc, dried 
(Na2SO4), filtered and concentrated. This produced an inseparable mixture of compounds 54a-b 
(40% EtOAc:Hexanes), as a colorless oil (0.2042g). 
 This oil (0.469 grams, 2.82 mmol) was dissolved in CH3CN (12 mL) and treated 
sequentially with benzyl bromide (0.33 mL, 2.82 mmol) and potassium carbonate (0.389 grams, 
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0.2.82 mmol) and allowed to react for 12 hrs. The reaction was quenched by the addition of H2O 
and extracted with EtOAc (3 x 50 mL). The combined organic fractions were washed with 
saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via 
column chromatography (SiO2 30% EtOAc:Hexanes) to afford an inseperable mixture of 
compounds 55a-b (0.21 g, 66%) as a colorless oil. 
 The mixture of compounds 55a-b (0.21 grams, 0.82 mmol) was dissolved in DCM (5 
mL) and cooled to 0°C and was treated with diisopropylethyl amine (0.29 mL, 1.64 mmol) and 
stirred for 5 minutes then acetyl chloride (0.06 mL, 0.82 mmol) was added dropwise and allowed 
to warm to room temperature over 12 hours. The reaction was quenched by the addition of H2O 
and extracted with EtOAc (3 x 50 mL). The combined organic fractions were washed with 
saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The residue was purified via 
column chromatography (SiO2 10% EtOAc:Hexanes) to afford 56 (0.1012 g, 41%) as a colorless 
oil: 
1
H NMR (500 MHz, CDCl3) δ 7.38 (m, 5H), 7.06 (m, 1H), 6.51 (dd, J = 7.4, 1.8 Hz, 2H), 
5.03 (m, 3H), 4.35 (dd, J = 11.9, 3.5 Hz, 1H), 4.22 (dd, J = 11.9, 7.2 Hz, 1H), 3.26 (dd, J = 15.3, 
9.4 Hz, 1H), 2.92 (ddd, J = 15.3, 7.4, 0.7 Hz, 1H), 2.13 (s, 3H).
 13
C NMR (126 MHz, CDCl3) δ 
170.9, 160.4, 159.6, 137.0, 128.6 (2x), 127.9, 127.5 (2x), 124.9, 117.9, 107.3, 97.4, 81.0, 70.3, 
66.0, 31.4, 20.9; IR (film) νmax 2933, 2358, 2341, 1735, 1622, 1585, 1506, 1454, 1373, 1238, 
1163, 1132, 1116, 1024, 966, 738, 696 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  
C18H18O4Na, 321.1103; found, 321.1108. 
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7-(benzyloxy)chroman-3-ol (57): A solution of 56 (0.094 grams, 0.315 mmol in a (9:1) mixture 
of MeOH : H2O (1.8 mL : 0.2 mL) was treated with potassium carbonate (0.133 grams, 0.945 
mmol) and allowed to react for 4 hours. The reaction was quenched by the addition of saturated 
aqueous ammonium chloride and extracted with EtOAc (3 x 50 mL). The combined organic 
fractions were washed with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. 
The residue was purified via column chromatography (SiO2 40% EtOAc:Hexanes) to afford 60 
(0.0691g, 86%) as a colorless oil: 
1
H NMR (400 MHz, CDCl3) δ 7.39 (m, 6H), 7.05 (d, J = 8.0 
Hz, 1H), 6.51 (d, J = 2.2 Hz, 1H), 6.48 (dd, J = 3.9, 2.2 Hz, 1H), 5.04 (s, 2H), 4.95 (m, 1H), 3.85 
(m, 1H), 3.75 (dt, J = 12.0, 6.0 Hz, 1H), 3.20 (dd, J = 15.2, 9.4 Hz, 1H), 2.95 (dd, J = 15.1, 7.3 
Hz, 1H), 1.90 (t, J = 6.4 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ 160.6, 159.6, 137.0, 129.4 (2x), 
128.9, 127.9 (2x), 111.2, 107.2, 97.2, 70.3, 70.0, 66.9, 55.4, 29.7; IR (film) νmax 3512, 3438, 
3359, 2923, 1622, 1595, 1494, 1452, 1380, 1344, 1278, 1186, 1147, 1095, 1010, 962, 948, 825, 
736, 696 cm
-1
; HRMS (ESI+) m/z: [M + Na]+ calcd for  C16H16O3Na, 279.0997; found, 
279.0982. 
Anti-proliferation Assay 
 MCF-7 and SKBr3 cells were maintained in a 1:1 mixture of Advanved DMEM/F12 
(Gibco) supplemented with non-essential amino acids, L-glutamine (2 mM), streptomycin (500 
µg/mL), penicillin (100 units/mL), and 10% FBS. Cells were grown to confluence in a 
humidified atmosphere (37°C, 5% CO2), seeded (2000/well, 100 µL) in 96-well plates, and 
allowed to attach overnight. Each compound or GDA at varying concentrations in DMSO (1% 
DMSO final concentration) was added, and cells were returned to the incubator for 72 hours. At 
72 hours, the number of viable cells was determined using an MTS/PMS cell proliferation kit 
(Promega) per the manufacturer’s instructions. Cells incubated in 1% DMSO were used as 100% 
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proliferation, and values were adjusted accordingly. IC50 values were calculated from separate 
experiments performed in triplicate using GraphPad Prism.  
Western Blot Analysis 
MCF-7 cells were cultured as described above and treated with various concentrations of drug, 
GDA in DMSO (1% DMSO final concentration), or vehicle (DMSO) for 24 h. Cells were 
harvested in cold PBS and lysed in RIPA lysis buffer containing 1 mM PMSF, 2 mM sodium 
orthovanadate, and protease inhibitors on ice for 1 h. Lysates were clarified at 14000g for 10 min 
at 4° C. Protein concentrations were determined using the Pierce BCA protein assay kit per the 
manufacturer’s instructions. Equal amounts of protein (20 μg) were electrophoresed under 
reducing conditions, transferred to a nitrocellulose membrane, and immunoblotted with the 
corresponding specific antibodies. Membranes were incubated with an appropriate horseradish 
peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and 
visualized. 
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